Biosynthetic monovalent binding molecules with enhanced effector function - Patents.com
Engineering monovalent antibodies with K248E and T437R mutations and reduced fucose residues addresses the challenge of simultaneously enhancing ADCC, ADCP, and CDC, resulting in more effective cancer treatments.
Patent Information
- Application Number
- JP2024523594
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-20
- Filing Date
- 2022-10-19
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing therapeutic antibodies often face challenges in simultaneously enhancing multiple effector functions such as ADCC, ADCP, and CDC, as strategies to improve one function can interfere with others, limiting their efficacy in cancer treatment.
Engineering monovalent antibodies with K248E and T437R mutations in the Fc region, combined with reduced core fucose residues, to enhance ADCC, ADCP, and CDC activities, allowing for simultaneous improvement of all three functions.
The engineered antibodies demonstrate enhanced ADCC, ADCP, and CDC activities, potentially leading to more potent cancer therapeutics by overcoming functional dysfunctions in cancer patients.
Smart Images

Figure 2024540931000001_ABST
Abstract
Description
[Technical Field]
[0001] (CROSS-REFERENCE TO RELATED APPLICATIONS) This application claims the benefit of priority to U.S. Patent Application No. 63 / 270,023, filed October 20, 2021, the contents of which are incorporated herein by reference in their entirety.
[0002] (Reference to electronically submitted sequence listing) This application contains a computer readable sequence listing submitted herewith in XML file format, the entire contents of which are incorporated herein by reference in their entirety. The sequence listing XML file submitted herewith is entitled "14620-721-228_SEQ_LISTING.xml", was created on October 3, 2022, and is 444,197 bytes in size.
[0003] FIELD OF THE INVENTION In certain aspects, provided herein are monovalent binding molecules with enhanced antibody-dependent cellular cytotoxicity (ADCC), enhanced complement-dependent cytotoxicity (CDC), and / or enhanced antibody-dependent cellular phagocytosis (ADCP). [Background technology]
[0004] Therapeutic antibodies can bind to Fc receptors expressed on immune effector cells such as natural killer (NK) cells and macrophages, resulting in antitumor activity via ADCC and ADCP. Therapeutic antibodies can also activate CDC to achieve antitumor effects. Summary of the Invention
[0005] In one aspect, provided herein is a binding molecule comprising an antigen-binding domain and an Fc region, wherein (i) the antigen-binding domain is monovalent; and (ii) the Fc region comprises K248E and T437R mutations (RE mutations), wherein the numbering of amino acid residues is according to the EU numbering system, and wherein the binding molecule has an increased ability to hexamerize on a cell surface and / or an increased ability to engage C1q.
[0006] In some embodiments, the antigen-binding domain comprises a VH region and / or a VL region, hi some embodiments, the antigen-binding domain comprises a Fab fragment, an scFv, a single VH domain, a single VL domain, or a protein domain specific for the antigen.
[0007] In some embodiments, the oligosaccharide covalently attached to the Fc region via residue N297 does not contain a core fucose residue.
[0008] In some embodiments, the binding molecule is a monovalent antibody or antibody fragment, or an engineered antigen-binding protein.
[0009] In some embodiments, the binding molecule has enhanced ADCC, enhanced CDC, and / or enhanced ADCP.
[0010] In another aspect, provided herein is a population of binding molecules comprising the binding molecules disclosed herein. In some embodiments, each binding molecule of the population of binding molecules comprises an antigen-binding domain and an Fc region, wherein (i) the antigen-binding domain is monovalent, (ii) the Fc region comprises K248E and T437R mutations (RE mutations), wherein amino acid residues are numbered according to the EU numbering system, and (iii) less than 80% of the oligosaccharides covalently attached to the population of binding molecules via residue N297 of the Fc region comprise a core fucose residue.
[0011] In another aspect, provided herein is a population of binding molecules, each binding molecule comprising an antigen-binding domain and an Fc region, wherein the antigen-binding domains of at least 10% of the binding molecules in the population are monovalent, and wherein the Fc region of each binding molecule comprises K248E and T437R mutations (RE mutations), and wherein amino acid residue numbering is according to the EU numbering system, and less than 80% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue in the Fc region comprise a core fucose residue.
[0012] In some embodiments, the antigen-binding domains of at least 20% of the binding molecules in the population are monovalent. In some embodiments, the antigen-binding domains of at least 30% of the binding molecules in the population are monovalent. In some embodiments, the antigen-binding domains of at least 40% of the binding molecules in the population are monovalent. In some embodiments, the antigen-binding domains of at least 50% of the binding molecules in the population are monovalent. In some embodiments, the antigen-binding domains of at least 60% of the binding molecules in the population are monovalent. In some embodiments, the antigen-binding domains of at least 70% of the binding molecules in the population are monovalent. In some embodiments, the antigen-binding domains of at least 80% of the binding molecules in the population are monovalent. In some embodiments, the antigen-binding domains of at least 90% of the binding molecules in the population are monovalent.
[0013] In some embodiments, fewer than 70% of the oligosaccharides covalently attached to a population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue. In some embodiments, fewer than 60% of the oligosaccharides covalently attached to a population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue. In some embodiments, fewer than 50% of the oligosaccharides covalently attached to a population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue. In some embodiments, fewer than 40% of the oligosaccharides covalently attached to a population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue. In some embodiments, fewer than 30% of the oligosaccharides covalently attached to a population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue. In some embodiments, fewer than 20% of the oligosaccharides covalently attached to a population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue. In some embodiments, less than 10% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue.
[0014] In some embodiments, the antigen-binding domain comprises a VH region and / or a VL region, hi some embodiments, the antigen-binding domain comprises a Fab fragment, an scFv, a single VH domain, a single VL domain, or a protein domain specific for the antigen.
[0015] In some embodiments, the binding molecule is a monovalent antibody or antibody fragment, or an engineered antigen-binding protein.
[0016] In some embodiments, the binding molecule is produced by expressing a polynucleotide encoding the binding molecule or a fragment thereof in a host cell that is deficient in adding fucose to oligosaccharides attached to the Fc region of an antibody. In some embodiments, the host cell has reduced GDP-mannose 4,6-dehydratase (GMD) activity or reduced α-1,6 fucosyltransferase activity. In some embodiments, the gene encoding α-1,6 fucosyltransferase is mutated, expressed at lower than normal levels, or knocked out in the host cell. In some embodiments, the gene encoding GDP-mannose 4,6-dehydratase is mutated, expressed at lower than normal levels, or knocked out in the host cell.
[0017] In some embodiments, the population of binding molecules has enhanced ADCC, enhanced CDC, and / or enhanced ADCP.
[0018] In another aspect, provided herein are nucleic acids encoding the binding molecules disclosed herein.
[0019] In another aspect, provided herein is a vector comprising a nucleic acid disclosed herein.
[0020] In a further aspect, provided herein is a pharmaceutical composition comprising a binding molecule and a pharmaceutically acceptable excipient, wherein the binding molecule comprises an antigen-binding domain and an Fc region, wherein (i) the antigen-binding domain is monovalent, (ii) the Fc region comprises K248E and T437R mutations (RE mutations), wherein the numbering of the amino acid residues is according to the EU numbering system, and the binding molecule has an increased ability to hexamerize on the cell surface and / or an increased ability to engage C1q.
[0021] In another aspect, provided herein is a pharmaceutical composition comprising a population of binding molecules and a pharmaceutically acceptable excipient, each binding molecule comprising an antigen-binding domain and an Fc region, wherein (i) the antigen-binding domain is monovalent, (ii) the Fc region comprises K248E and T437R mutations (RE mutations), wherein amino acid residue numbering is according to the EU numbering system, and (iii) less than 80% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue in the Fc region comprise a core fucose residue.
[0022] In another aspect, provided herein is a pharmaceutical composition comprising a population of binding molecules and a pharmaceutically acceptable excipient, wherein each binding molecule comprises an antigen-binding domain and an Fc region, wherein at least 10% of the antigen-binding domains of the binding molecules in the population are monovalent, and wherein the Fc region of each binding molecule comprises K248E and T437R mutations (RE mutations), and wherein amino acid residue numbering is according to the EU numbering system, and less than 80% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue in the Fc region comprise a core fucose residue.
[0023] In yet another aspect, provided herein is a method of making a population of binding molecules, comprising expressing a polynucleotide encoding the binding molecule or a fragment thereof in a host cell that is deficient in the addition of fucose residues to oligosaccharides attached to the antibody via the N297 residue, wherein the population of binding molecules comprises binding molecules comprising an antigen-binding domain and an Fc region, wherein (i) the antigen-binding domain is monovalent, and (ii) the Fc region comprises K248E and T437R mutations (RE mutations), wherein the numbering of the amino acid residues is according to the EU numbering system, and wherein the binding molecules have an increased ability to hexamerize on the cell surface and / or an increased ability to engage C1q.
[0024] In another aspect, provided herein is a method of making a population of binding molecules, comprising expressing a polynucleotide encoding a binding molecule or a fragment thereof in a host cell that is deficient in the addition of fucose residues to oligosaccharides attached to the antibody via the N297 residue, wherein each binding molecule comprises an antigen-binding domain and an Fc region, wherein (i) the antigen-binding domain is monovalent, (ii) the Fc region comprises K248E and T437R mutations (RE mutations), wherein the numbering of amino acid residues is according to the EU numbering system, and (iii) less than 80% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue.
[0025] In another aspect, provided herein is a method of making a population of binding molecules, comprising expressing a polynucleotide encoding a binding molecule or a fragment thereof in a host cell that is deficient in the addition of fucose residues to oligosaccharides attached to the antibody via the N297 residue, wherein each binding molecule comprises an antigen-binding domain and an Fc region, wherein the antigen-binding domains of at least 10% of the binding molecules in the population are monovalent, and wherein the Fc region of each binding molecule comprises K248E and T437R mutations (RE mutations), and wherein amino acid residue numbering is according to the EU numbering system, and wherein less than 80% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue in the Fc region comprise a core fucose residue.
[0026] In yet one aspect, provided herein is a method for enhancing CDC, ADCP and / or ADCC in a system, or a method for modulating immunity in a host, or a method for treating a disease or disorder in a subject, comprising contacting the system with a binding molecule comprising an antigen-binding domain and an Fc region, wherein (i) the antigen-binding domain is monovalent; (ii) the Fc region comprises K248E and T437R mutations (RE mutations), wherein the numbering of the amino acid residues is according to the EU numbering system, and wherein the binding molecule has an increased ability to hexamerize on a cell surface and / or an increased ability to engage C1q.
[0027] In another aspect, provided herein is a method of enhancing CDC, ADCP, and / or ADCC in a system, or modulating immunity in a host, or treating a disease or disorder in a subject, comprising contacting the system with a population of binding molecules, each binding molecule comprising an antigen-binding domain and an Fc region, wherein (i) the antigen-binding domain is monovalent, (ii) the Fc region comprises K248E and T437R mutations (RE mutations), wherein amino acid residue numbering is according to the EU numbering system, and (iii) less than 80% of the oligosaccharides covalently attached to the population of binding molecules via residue N297 of the Fc region comprise a core fucose residue.
[0028] In another aspect, provided herein is a method of enhancing CDC, ADCP, and / or ADCC in a system, or modulating immunity in a host, or treating a disease or disorder in a subject, comprising contacting the system with a population of binding molecules, each binding molecule comprising an antigen-binding domain and an Fc region, wherein at least 10% of the antigen-binding domains of the binding molecules in the population are monovalent, the Fc region of each binding molecule comprises K248E and T437R mutations (RE mutations), and wherein amino acid residue numbering is according to the EU numbering system, and less than 80% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue in the Fc region comprise a core fucose residue.
[0029] In one further aspect, provided herein is a binding molecule comprising a first means for enhancing CDC and a second means for enhancing CDC. In some embodiments, the binding molecule further comprises a third means for enhancing ADCC. In some embodiments, the binding molecule further comprises a fourth means for enhancing ADCP. In some embodiments, the first means increases hexamerization of the binding molecule on the cell surface and / or increases C1q engagement by the binding molecule. In some embodiments, the first means refers to enhancing CDC, ADCP, and / or ADCC.
[0030] In another aspect, provided herein is a method of producing a population of binding molecules, comprising: (i) introducing K248E and T437R mutations (RE mutations) in the Fc region of a binding molecule; and (ii) generating a population of binding molecules having a reduced amount of core fucose in the oligosaccharide attached to the binding molecule via the N297 residue, wherein the binding molecule comprises a monovalent antigen-binding domain. [Brief explanation of the drawings]
[0031] [Figure 1A] Figure 1 shows the CDC activity of different types of anti-CD37 antibodies with hypofucosylation (Figures 1A and 1B), Xencor mutations (Figures 1C and 1D), RE mutations (Figures 1E and 1F), and hypofucosylation and RE mutations (Figures 1G and 1H) on target cells expressing high levels of CD37 (CARNAVAL, Figures 1A, 1C, 1E, and 1G) and low levels of CD37 (JEKO-1, Figures 1B, 1D, 1F, and 1H). Target cells were incubated with titrated concentrations of antibody as indicated for 30 min. Baby rabbit serum was then added to the mixture to a final concentration of 10% to provide a source of complement components. After a 4-hour incubation, cell viability was measured by adding CellTiter-Glo reagent (Promega) and measuring the resulting luminescence, reported in relative luminescence units (RLU). [Figure 1B]Figure 1 shows the CDC activity of different types of anti-CD37 antibodies with hypofucosylation (Figures 1A and 1B), Xencor mutations (Figures 1C and 1D), RE mutations (Figures 1E and 1F), and hypofucosylation and RE mutations (Figures 1G and 1H) on target cells expressing high levels of CD37 (CARNAVAL, Figures 1A, 1C, 1E, and 1G) and low levels of CD37 (JEKO-1, Figures 1B, 1D, 1F, and 1H). Target cells were incubated with titrated concentrations of antibody as indicated for 30 min. Baby rabbit serum was then added to the mixture to a final concentration of 10% to provide a source of complement components. After a 4-hour incubation, cell viability was measured by adding CellTiter-Glo reagent (Promega) and measuring the resulting luminescence, reported in relative luminescence units (RLU). [Figure 1C] Figure 1 shows the CDC activity of different types of anti-CD37 antibodies with hypofucosylation (Figures 1A and 1B), Xencor mutations (Figures 1C and 1D), RE mutations (Figures 1E and 1F), and hypofucosylation and RE mutations (Figures 1G and 1H) on target cells expressing high levels of CD37 (CARNAVAL, Figures 1A, 1C, 1E, and 1G) and low levels of CD37 (JEKO-1, Figures 1B, 1D, 1F, and 1H). Target cells were incubated with titrated concentrations of antibody as indicated for 30 min. Baby rabbit serum was then added to the mixture to a final concentration of 10% to provide a source of complement components. After a 4-hour incubation, cell viability was measured by adding CellTiter-Glo reagent (Promega) and measuring the resulting luminescence, reported in relative luminescence units (RLU). [Figure 1D]Figure 1 shows the CDC activity of different types of anti-CD37 antibodies with hypofucosylation (Figures 1A and 1B), Xencor mutations (Figures 1C and 1D), RE mutations (Figures 1E and 1F), and hypofucosylation and RE mutations (Figures 1G and 1H) on target cells expressing high levels of CD37 (CARNAVAL, Figures 1A, 1C, 1E, and 1G) and low levels of CD37 (JEKO-1, Figures 1B, 1D, 1F, and 1H). Target cells were incubated with titrated concentrations of antibody as indicated for 30 min. Baby rabbit serum was then added to the mixture to a final concentration of 10% to provide a source of complement components. After a 4-hour incubation, cell viability was measured by adding CellTiter-Glo reagent (Promega) and measuring the resulting luminescence, reported in relative luminescence units (RLU). [Figure 1E] Figure 1 shows the CDC activity of different types of anti-CD37 antibodies with hypofucosylation (Figures 1A and 1B), Xencor mutations (Figures 1C and 1D), RE mutations (Figures 1E and 1F), and hypofucosylation and RE mutations (Figures 1G and 1H) on target cells expressing high levels of CD37 (CARNAVAL, Figures 1A, 1C, 1E, and 1G) and low levels of CD37 (JEKO-1, Figures 1B, 1D, 1F, and 1H). Target cells were incubated with titrated concentrations of antibody as indicated for 30 min. Baby rabbit serum was then added to the mixture to a final concentration of 10% to provide a source of complement components. After a 4-hour incubation, cell viability was measured by adding CellTiter-Glo reagent (Promega) and measuring the resulting luminescence, reported in relative luminescence units (RLU). [Figure 1F]Figure 1 shows the CDC activity of different types of anti-CD37 antibodies with hypofucosylation (Figures 1A and 1B), Xencor mutations (Figures 1C and 1D), RE mutations (Figures 1E and 1F), and hypofucosylation and RE mutations (Figures 1G and 1H) on target cells expressing high levels of CD37 (CARNAVAL, Figures 1A, 1C, 1E, and 1G) and low levels of CD37 (JEKO-1, Figures 1B, 1D, 1F, and 1H). Target cells were incubated with titrated concentrations of antibody as indicated for 30 min. Baby rabbit serum was then added to the mixture to a final concentration of 10% to provide a source of complement components. After a 4-hour incubation, cell viability was measured by adding CellTiter-Glo reagent (Promega) and measuring the resulting luminescence, reported in relative luminescence units (RLU). [Figure 1G] Figure 1 shows the CDC activity of different types of anti-CD37 antibodies with hypofucosylation (Figures 1A and 1B), Xencor mutations (Figures 1C and 1D), RE mutations (Figures 1E and 1F), and hypofucosylation and RE mutations (Figures 1G and 1H) on target cells expressing high levels of CD37 (CARNAVAL, Figures 1A, 1C, 1E, and 1G) and low levels of CD37 (JEKO-1, Figures 1B, 1D, 1F, and 1H). Target cells were incubated with titrated concentrations of antibody as indicated for 30 min. Baby rabbit serum was then added to the mixture to a final concentration of 10% to provide a source of complement components. After a 4-hour incubation, cell viability was measured by adding CellTiter-Glo reagent (Promega) and measuring the resulting luminescence, reported in relative luminescence units (RLU). [Figure 1H]Figure 1 shows the CDC activity of different types of anti-CD37 antibodies with hypofucosylation (Figures 1A and 1B), Xencor mutations (Figures 1C and 1D), RE mutations (Figures 1E and 1F), and hypofucosylation and RE mutations (Figures 1G and 1H) on target cells expressing high levels of CD37 (CARNAVAL, Figures 1A, 1C, 1E, and 1G) and low levels of CD37 (JEKO-1, Figures 1B, 1D, 1F, and 1H). Target cells were incubated with titrated concentrations of antibody as indicated for 30 min. Baby rabbit serum was then added to the mixture to a final concentration of 10% to provide a source of complement components. After a 4-hour incubation, cell viability was measured by adding CellTiter-Glo reagent (Promega) and measuring the resulting luminescence, reported in relative luminescence units (RLU). [Figure 2] Figure 1 shows the CDC activity of anti-GPRC5D antibodies with wild-type hypofucosylation and RE mutations on H929 target cells. Target cells were incubated with titrated concentrations of antibody as indicated for 30 minutes. Baby rabbit serum was then added to the mixture to a final concentration of 10% to provide a source of complement components. After a 4-hour incubation, cell viability was measured by adding CellTiter-Glo reagent (Promega) and measuring the resulting luminescence, reported in relative luminescence units (RLU). [Figure 3A]This figure shows the in vitro ADCC kinetics of VCaP cells mediated by KLK2 antibody with PBMCs. Briefly, VCaP cells stably transfected with Nuclight Red (Incucyte®, Essen Bioscience) were seeded at 10,000 cells per well in clear medium (RPMI 1641 + 10% FBS, Thermo Fisher Scientific) in a 384-well plate (Perkin Elmer ViewPlate) and allowed to adhere overnight. The ADCC assay was performed using freshly thawed PBMCs (Hemcare, PB009C-3). The effector to target cell ratio per well was 34:1 with PBMCs as effector cells. KLK2 antibody was tested at final concentrations ranging from 100 nM to 0.01 nM. After adding the effector cells and antibody to the target cells, real-time imaging was performed using an Incucyte® S3 instrument (Essen BioScience). The total intergraded red signal per well was quantified using Incucyte® software. Data analysis was performed using Incucyte® software and Prism (GraphPad Software) based on quadruplicate values. The percentage of cell death was calculated as (1-KLK2mAb / no mAb control) × 100%. [Figure 3B]This figure shows the in vitro ADCC kinetics of VCaP cells mediated by KLK2 antibody with PBMCs. Briefly, VCaP cells stably transfected with Nuclight Red (Incucyte®, Essen Bioscience) were seeded at 10,000 cells per well in clear medium (RPMI 1641 + 10% FBS, Thermo Fisher Scientific) in a 384-well plate (Perkin Elmer ViewPlate) and allowed to adhere overnight. The ADCC assay was performed using freshly thawed PBMCs (Hemcare, PB009C-3). The effector to target cell ratio per well was 34:1 with PBMCs as effector cells. KLK2 antibody was tested at final concentrations ranging from 100 nM to 0.01 nM. After adding the effector cells and antibody to the target cells, real-time imaging was performed using an Incucyte® S3 instrument (Essen BioScience). The total intergraded red signal per well was quantified using Incucyte® software. Data analysis was performed using Incucyte® software and Prism (GraphPad Software) based on quadruplicate values. The percentage of cell death was calculated as (1-KLK2mAb / no mAb control) × 100%. [Figure 3C]This figure shows the in vitro ADCC kinetics of VCaP cells mediated by KLK2 antibody with PBMCs. Briefly, VCaP cells stably transfected with Nuclight Red (Incucyte®, Essen Bioscience) were seeded at 10,000 cells per well in clear medium (RPMI 1641 + 10% FBS, Thermo Fisher Scientific) in a 384-well plate (Perkin Elmer ViewPlate) and allowed to adhere overnight. The ADCC assay was performed using freshly thawed PBMCs (Hemcare, PB009C-3). The effector to target cell ratio per well was 34:1 with PBMCs as effector cells. KLK2 antibody was tested at final concentrations ranging from 100 nM to 0.01 nM. After adding the effector cells and antibody to the target cells, real-time imaging was performed using an Incucyte® S3 instrument (Essen BioScience). The total intergraded red signal per well was quantified using Incucyte® software. Data analysis was performed using Incucyte® software and Prism (GraphPad Software) based on quadruplicate values. The percentage of cell death was calculated as (1-KLK2mAb / no mAb control) × 100%. [Figure 3D]This figure shows the in vitro ADCC kinetics of VCaP cells mediated by KLK2 antibody with PBMCs. Briefly, VCaP cells stably transfected with Nuclight Red (Incucyte®, Essen Bioscience) were seeded at 10,000 cells per well in clear medium (RPMI 1641 + 10% FBS, Thermo Fisher Scientific) in a 384-well plate (Perkin Elmer ViewPlate) and allowed to adhere overnight. The ADCC assay was performed using freshly thawed PBMCs (Hemcare, PB009C-3). The effector to target cell ratio per well was 34:1 with PBMCs as effector cells. KLK2 antibody was tested at final concentrations ranging from 100 nM to 0.01 nM. After adding the effector cells and antibody to the target cells, real-time imaging was performed using an Incucyte® S3 instrument (Essen BioScience). The total intergraded red signal per well was quantified using Incucyte® software. Data analysis was performed using Incucyte® software and Prism (GraphPad Software) based on quadruplicate values. The percentage of cell death was calculated as (1-KLK2mAb / no mAb control) × 100%. [Figure 3E]This figure shows the in vitro ADCC kinetics of VCaP cells mediated by KLK2 antibody with PBMCs. Briefly, VCaP cells stably transfected with Nuclight Red (Incucyte®, Essen Bioscience) were seeded at 10,000 cells per well in clear medium (RPMI 1641 + 10% FBS, Thermo Fisher Scientific) in a 384-well plate (Perkin Elmer ViewPlate) and allowed to adhere overnight. The ADCC assay was performed using freshly thawed PBMCs (Hemcare, PB009C-3). The effector to target cell ratio per well was 34:1 with PBMCs as effector cells. KLK2 antibody was tested at final concentrations ranging from 100 nM to 0.01 nM. After adding the effector cells and antibody to the target cells, real-time imaging was performed using an Incucyte® S3 instrument (Essen BioScience). The total intergraded red signal per well was quantified using Incucyte® software. Data analysis was performed using Incucyte® software and Prism (GraphPad Software) based on quadruplicate values. The percentage of cell death was calculated as (1-KLK2mAb / no mAb control) × 100%. [Figure 4] Figure 1 shows in vitro ADCC dose response killing by KLK2 antibody using PBMC against VCaP at 48 hours. Dose response curves were generated 48 hours after addition of effector cells and antibody to target cells. [Figure 5A] Figure 1 shows the ADCC activity of anti-HLA-G antibodies MHGB732 and MHGB738, and their respective counterparts with hypofucosylation, RE mutation, and hypofucosylation and RE mutation, against JEG-3 and RERF-LC-Ad-1 cells. The percentage of lysis was compared to the maximum lysis of JEG-3 or RERF-LC-Ad-1 cells by Triton-X100 detergent and calculated as (sample value - target only value) / (maximum value - target only value) × 100%. [Figure 5B] Figure 1 shows the ADCC activity of anti-HLA-G antibodies MHGB732 and MHGB738, and their respective counterparts with hypofucosylation, RE mutation, and hypofucosylation and RE mutation, against JEG-3 and RERF-LC-Ad-1 cells. The percentage of lysis was compared to the maximum lysis of JEG-3 or RERF-LC-Ad-1 cells by Triton-X100 detergent and calculated as (sample value - target only value) / (maximum value - target only value) × 100%. [Figure 5C] Figure 1 shows the CDC activity of anti-HLA-G antibodies MHGB732 and MHGB738 and their respective counterparts with hypofucosylation, RE mutation, and hypofucosylation and RE mutation. Target cells were incubated with the indicated antibodies for 30 min at 37°C. 15–20% (stock concentration) rabbit complement and heat-inactivated complement were added to the wells to a volume of 25 μL / well, respectively. The mixtures were incubated at 37°C for 4–12 h. Target cell lysis was measured by adding CellTiter-Glo reagent (Promega) and measuring the resulting luminescence, and is reported in relative luminescence units (RLU). [Figure 5D] Figure 1 shows the CDC activity of anti-HLA-G antibodies MHGB732 and MHGB738 and their respective counterparts with hypofucosylation, RE mutation, and hypofucosylation and RE mutation. Target cells were incubated with the indicated antibodies for 30 min at 37°C. 15–20% (stock concentration) rabbit complement and heat-inactivated complement were added to the wells to a volume of 25 μL / well, respectively. The mixtures were incubated at 37°C for 4–12 h. Target cell lysis was measured by adding CellTiter-Glo reagent (Promega) and measuring the resulting luminescence, and is reported in relative luminescence units (RLU). [Figure 6A]Figure 6 shows the in vitro ADCC dose-response killing of C42B and LNCaP cells mediated by the hypofucosylated and RE-mutated anti-PSMA antibodies PSMB896 and PSMB898. Specifically, Figure 6A shows the in vitro ADCC dose-response killing of C42B cells by PBMCs at 6 hours, Figure 6B shows the in vitro ADCC dose-response killing of LNCaP cells by PBMCs at 6 hours, Figure 6C shows the in vitro ADCC dose-response killing of C42B cells by NK cells at 24 hours, and Figure 6D shows the in vitro ADCC dose-response killing of LNCaP cells by NK cells at 24 hours. Dose-response curves were generated 6 or 24 hours after the addition of effector cells and antibodies to target cells. [Figure 6B] Figure 6 shows the in vitro ADCC dose-response killing of C42B and LNCaP cells mediated by the hypofucosylated and RE-mutated anti-PSMA antibodies PSMB896 and PSMB898. Specifically, Figure 6A shows the in vitro ADCC dose-response killing of C42B cells by PBMCs at 6 hours, Figure 6B shows the in vitro ADCC dose-response killing of LNCaP cells by PBMCs at 6 hours, Figure 6C shows the in vitro ADCC dose-response killing of C42B cells by NK cells at 24 hours, and Figure 6D shows the in vitro ADCC dose-response killing of LNCaP cells by NK cells at 24 hours. Dose-response curves were generated 6 or 24 hours after the addition of effector cells and antibodies to target cells. [Figure 6C]Figure 6 shows the in vitro ADCC dose-response killing of C42B and LNCaP cells mediated by the hypofucosylated and RE-mutated anti-PSMA antibodies PSMB896 and PSMB898. Specifically, Figure 6A shows the in vitro ADCC dose-response killing of C42B cells by PBMCs at 6 hours, Figure 6B shows the in vitro ADCC dose-response killing of LNCaP cells by PBMCs at 6 hours, Figure 6C shows the in vitro ADCC dose-response killing of C42B cells by NK cells at 24 hours, and Figure 6D shows the in vitro ADCC dose-response killing of LNCaP cells by NK cells at 24 hours. Dose-response curves were generated 6 or 24 hours after the addition of effector cells and antibodies to target cells. [Figure 6D] Figure 6 shows the in vitro ADCC dose-response killing of C42B and LNCaP cells mediated by the hypofucosylated and RE-mutated anti-PSMA antibodies PSMB896 and PSMB898. Specifically, Figure 6A shows the in vitro ADCC dose-response killing of C42B cells by PBMCs at 6 hours, Figure 6B shows the in vitro ADCC dose-response killing of LNCaP cells by PBMCs at 6 hours, Figure 6C shows the in vitro ADCC dose-response killing of C42B cells by NK cells at 24 hours, and Figure 6D shows the in vitro ADCC dose-response killing of LNCaP cells by NK cells at 24 hours. Dose-response curves were generated 6 or 24 hours after the addition of effector cells and antibodies to target cells. [Figure 7A]Two exemplary monovalent binding molecules are provided herein. Figure 7A shows one exemplary monovalent binding molecule in which one of the two antigen binding arms of IgG is replaced with a binding arm of unknown specificity, called a "null" arm. The other antigen binding arm binds to the target of interest. Figure 7B shows another exemplary monovalent binding molecule in which one of the two antigen binding arms of IgG is removed. The other antigen binding arm binds to the target of interest. [Figure 7B] Two exemplary monovalent binding molecules are provided herein. Figure 7A shows one exemplary monovalent binding molecule in which one of the two antigen binding arms of IgG is replaced with a binding arm of unknown specificity, called a "null" arm. The other antigen binding arm binds to the target of interest. Figure 7B shows another exemplary monovalent binding molecule in which one of the two antigen binding arms of IgG is removed. The other antigen binding arm binds to the target of interest. [Figure 8A] Figure 1 shows the CDC activity of two anti-CD22 binders with RE mutations formatted as monovalent or bivalent antibodies against Daudi target cells in the presence of 40% normal human serum. [Figure 8B] Pairwise comparison of EC50 values of monovalent and bivalent anti-CD22 antibodies is shown. [Figure 8C] Pairwise comparison of maximum CDC lysis values for monovalent and bivalent anti-CD22 antibodies is shown. [Figure 9A] 1 shows the ADCC activity of the same two anti-CD22 antibodies with RE mutations formatted as monovalent or bivalent antibodies against BATDA-labeled Daudi target cells in the presence of purified NK cells from normal donors. The ADCC activity of an isotype control antibody against Daudi target cells was also tested. [Figure 9B] Pairwise comparison of EC50 values of monovalent and bivalent anti-CD22 antibodies is shown. [Figure 9C] Pairwise comparison of maximum ADCC lysis values of monovalent and bivalent anti-CD22 antibodies is shown. Detailed Description of the Invention
[0032] Antibodies represent an important and growing class of therapeutic biologics for a variety of diseases or disorders, including oncology indications. Their mechanisms of action include blockade of signals that inhibit antitumor immune responses, agonism of signals that enhance antitumor responses, targeted delivery of antitumor drugs by conjugated antibodies, and target-specific depletion of cells expressing tumor-associated antigens via ADCC, ADCP, and CDC. Among these mechanisms of action, ADCC and ADCP are mediated through the interaction of the fragment crystallizable region (Fc) of the antibody with Fcγ receptors on effector cells (natural killer cells, as in ADCC, or macrophages, as in ADCP). CDC is mediated through the interaction between Fc and the complement component C1q. These mechanisms of target cell killing are collectively referred to as antibody effector functions. Many oncology therapeutics utilize these antibody effector functions to specifically deplete or inhibit tumor cell proliferation. Therefore, strategies that can increase Fc-mediated activation of these pathways may result in more potent cancer therapeutics. Strategies that can enhance ADCC or ADCP effector function have been described. However, they are often incompatible with other functions, such as CDC activity. Here, we describe the combined application of several strategies that can enable simultaneous enhancement of multiple antibody effector functions, such as CDC, ADCC, and / or ADCP. Combining improvements in effector function could potentially lead to better therapies that can overcome dysfunction in one of these compartments in cancer patients.
[0033] CDC activity requires activation of the complement cascade, which in turn requires activation of the complement component C1q by a hexamer of Fc regions coplanar with the surface of the target cell. This, in turn, requires the simultaneous binding of five or six antibody molecules in close proximity to the cell surface. Due to the need for Fc-mediated antibody oligomerization, CDC activity requires a relatively high target receptor density. For natural IgG antibodies, the stoichiometry of antibody-receptor binding can vary from 1:2 to 1:1 depending on the antibody concentration, with the former being highly favored due to avidity. To maximize the number of antibodies that can bind to a given number of cell surface receptors, the present disclosure incorporates an engineered monovalent design to enforce a 1:1 antibody-receptor binding stoichiometry. This allows for more Fc regions to be presented on the surface of cells bearing a given number of receptors compared to natural bivalent IgG. Therefore, engineered monovalent antibodies may have stronger CDC activity than their natural bivalent counterparts.
[0034] Another method for increasing CDC activity is to enhance the ability of IgG to hexamerize through mutagenesis. One strategy, called RE mutation, involves incorporating two point mutations (K248E and T437R) in the Fc region. As demonstrated, enhancing CDC activity through RE mutation is compatible with enhanced ADCC and ADCP activity mediated by antibodies produced in low-fucose hosts. Monovalent antibodies featuring RE mutations provided herein are compatible with enhanced ADCC / ADCP via reduced fucose production, among other advanced properties, as shown in Section 7 below.
[0035] The present disclosure is based, in part, on the surprising finding that a population of antibodies has both enhanced ADCC activity and enhanced CDC activity when fewer than 80% of the oligosaccharides covalently attached to the population comprise fucose residues and the Fc regions of the antibodies comprise K248E and T437R mutations (RE mutations). Additionally, as demonstrated in Section 7 below, hypofucosylation does not interfere with the effect of the RE mutations on enhanced CDC, and the RE mutations do not interfere with the enhanced ADCC activity conferred by hypofucosylation. In one aspect, provided herein are antibodies that comprise RE mutations in their Fc regions and that do not contain core fucose residues in the oligosaccharides covalently attached to the Fc region of the antibody. In another aspect, provided herein are antibody populations comprising antibodies that comprise RE mutations in their Fc regions and that do not contain core fucose residues in the oligosaccharides covalently attached to the Fc region of the antibody. In some embodiments, provided herein are populations of antibodies comprising a K248E mutation and a T437R mutation (RE mutation), wherein less than 80% of the oligosaccharides covalently attached to the population of antibodies via their N297 residue comprise a core fucose residue. In some embodiments, less than 70% of the oligosaccharides covalently attached to the population of antibodies via their N297 residue comprise a core fucose residue. In some embodiments, less than 60% of the oligosaccharides covalently attached to the population of antibodies via their N297 residue comprise a core fucose residue. In some embodiments, less than 50% of the oligosaccharides covalently attached to the population of antibodies via their N297 residue comprise a core fucose residue. In some embodiments, less than 40% of the oligosaccharides covalently attached to the population of antibodies via their N297 residue comprise a core fucose residue. In some embodiments, less than 30% of the oligosaccharides covalently attached to the population of antibodies via their N297 residue comprise a core fucose residue. In some embodiments, fewer than 20% of the oligosaccharides covalently attached to a population of antibodies via their N297 residue comprise a core fucose residue. In some embodiments, fewer than 10% of the oligosaccharides covalently attached to a population of antibodies via their N297 residue comprise a core fucose residue. In some embodiments, fewer than 5% of the oligosaccharides covalently attached to a population of antibodies via their N297 residue comprise a core fucose residue.
[0036] The present disclosure is also based, in part, on the surprising finding that, among other advanced properties as demonstrated in Section 7 below, the combination of monovalency with RE mutations provides further enhanced CDC activity through increased hexamerization of such binding molecules and, therefore, increased ability to engage C1q on the cell surface. Accordingly, in another aspect, the present disclosure provides monovalent binding molecules bearing RE mutations in the Fc region. In some embodiments, such binding molecules do not contain core fucose residues in the oligosaccharides covalently attached to the Fc region of the binding molecule. In some embodiments, provided herein are populations of monovalent antibodies, each bearing an RE mutation, wherein fewer than 80% of the oligosaccharides covalently attached to the population of monovalent antibodies via their N297 residues contain core fucose residues. In some embodiments, fewer than 70% of the oligosaccharides covalently attached to the population of monovalent antibodies via their N297 residues contain core fucose residues. In some embodiments, fewer than 60% of the oligosaccharides covalently attached to the population of monovalent antibodies via their N297 residues contain core fucose residues. In some embodiments, fewer than 50% of the oligosaccharides covalently attached to the population of monovalent antibodies through their N297 residue comprise a core fucose residue. In some embodiments, fewer than 40% of the oligosaccharides covalently attached to the population of monovalent antibodies through their N297 residue comprise a core fucose residue. In some embodiments, fewer than 30% of the oligosaccharides covalently attached to the population of monovalent antibodies through their N297 residue comprise a core fucose residue. In some embodiments, fewer than 20% of the oligosaccharides covalently attached to the population of monovalent antibodies through their N297 residue comprise a core fucose residue. In some embodiments, fewer than 10% of the oligosaccharides covalently attached to the population of monovalent antibodies through their N297 residue comprise a core fucose residue. In some embodiments, fewer than 5% of the oligosaccharides covalently attached to the population of monovalent antibodies through their N297 residue comprise a core fucose residue.
[0037] In certain embodiments, any antibody having any antigen-binding structure or targeting any antigen is included in the present disclosure, as long as the antibody has an Fc region. Pharmaceutical compositions comprising the antibodies, methods of making them, and their uses are also included in the present disclosure.
[0038] definition The techniques and procedures described or referenced herein include those generally well understood and / or commonly employed by those skilled in the art using conventional techniques, such as the widely used techniques described in Molecular Cloning: A Laboratory Manual (Sambrook, et al., 3rd ed. 2001), Current Protocols in Molecular Biology (Ausubel, et al. eds., 2003), Therapeutic Monoclonal Antibodies: From Bench to Clinic (An, ed. 2009), Monoclonal Antibodies: Methods and Protocols (Albitar, ed. 2010), and Antibody Engineering Vols 1 and 2 (Kontermann and Dubel, eds., 2nd ed. 2010).
[0039] Unless otherwise defined herein, technical and scientific terms used herein have the meanings that are commonly understood by those skilled in the art. For the purposes of interpreting this specification, the following explanations of terms shall apply, and where appropriate, terms used in the singular shall also include the plural, and vice versa. In the event that any explanation of a term provided herein contradicts any document incorporated herein by reference, the explanation of the term provided below shall prevail.
[0040] The terms "antibody," "immunoglobulin," or "Ig" are used interchangeably herein and are used in the broadest sense, specifically encompassing monoclonal antibodies (including agonist, antagonist, neutralizing, full-length, or intact monoclonal antibodies), antibody compositions with polyepitopic or monoepitopic specificity, polyclonal or monovalent antibodies, multivalent antibodies, and multispecific antibodies (e.g., bispecific antibodies, so long as they exhibit the desired biological activity) formed from at least two intact antibodies, e.g., as described below. Antibodies may be human, humanized, chimeric, and / or affinity matured, as well as antibodies from other species, such as mouse and rabbit. The term "antibody" is intended to include polypeptide products of B cells within the immunoglobulin class of polypeptides, which are capable of binding to a specific molecular antigen and are composed of two identical paired polypeptide chains, each pair having one heavy chain (approximately 50-70 kDa) and one light chain (approximately 25 kDa), with the amino-terminal portion of each chain containing a variable region of about 100 to about 130 or more amino acids, and the carboxy-terminal portion of each chain containing a constant region. See, e.g., Antibody Engineering (Borrebaeck, ed., 2nd ed. 1995) and Kuby, Immunology (3rd ed. 1997). In specific embodiments, specific molecular antigens can be bound by antibodies provided herein, including polypeptides or epitopes. Antibodies also include, but are not limited to, synthetic antibodies, recombinantly produced antibodies, camelized antibodies or humanized variants thereof, intracellular antibodies, and anti-idiotypic (anti-Id) antibodies. As used herein, the term "antibody" also includes any binding molecule having an Fc region and a functional fragment (e.g., an antigen-binding fragment) of any of the above, where a functional fragment refers to a portion of an antibody heavy or light chain polypeptide that retains some or all of the binding activity of the antibody from which the fragment is derived.Non-limiting examples of functional fragments (e.g., antigen-binding fragments) include single-chain Fvs (scFv) (including, e.g., monospecific, bispecific, etc.), Fab fragments, F(ab') fragments, F(ab)2 fragments, F(ab')2 fragments, disulfide-linked Fvs (dsFv), Fd fragments, Fv fragments, diabodies, triabodies, tetrabodies, and minibodies. In particular, antibodies provided herein include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, such as antigen-binding domains or molecules containing an antigen-binding site that binds to an antigen (e.g., one or more CDRs of an antibody). Such antibody fragments can be found, for example, in Harlow and Lane, Antibodies: A Laboratory Manual (1989), Mol. Biology and Biotechnology: A Comprehensive Desk Reference (Myers, ed., 1995), Huston, et al., 1993, Cell Biophysics 22:189-224, Pluckthun and Skerra, 1989, Meth. Enzymol. 178:497-515, and Day, Advanced Immunochemistry (2d ed. 1990). The antibodies provided herein can be of any class (e.g., IgG, IgE, IgM, IgD, and IgA) or any subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) of immunoglobulin molecules. The antibody can be an agonist antibody or an antagonist antibody.
[0041] The term "valent," as used herein, refers to the presence of a particular number of binding sites in an antigen-binding protein (such as an antibody). For example, a natural or full-length antibody has two binding sites and is bivalent. Thus, the terms "monovalent," "trivalent," "tetravalent," "pentavalent," and "hexavalent" refer to the presence of one binding site, two binding sites, three binding sites, four binding sites, five binding sites, and six binding sites, respectively, in an antigen-binding protein (e.g., an antibody).
[0042] An "antigen" is a structure to which an antibody can selectively bind. A target antigen can be a polypeptide, carbohydrate, nucleic acid, lipid, hapten, or other naturally occurring or synthetic compound. In some embodiments, the target antigen is a polypeptide. In certain embodiments, the antigen is associated with a cell, e.g., present on or within a cell.
[0043] An "intact" antibody is one that contains an antigen-binding site as well as a constant domain (CL) and at least heavy chain constant regions CH1, CH2, and CH3. The constant region may include a human constant region or an amino acid sequence variant thereof. In certain embodiments, an intact antibody has one or more effector functions.
[0044] The terms "binding" or "binding" refer to interactions between molecules, including, for example, forming a complex. The interactions can be non-covalent interactions, including, for example, hydrogen bonds, ionic bonds, hydrophobic interactions, and / or van der Waals interactions. A complex can also include the association of two or more molecules held together by covalent or non-covalent bonds, interactions, or forces. The strength of the total non-covalent interactions between a single antigen-binding site of an antibody and a single epitope of a target molecule, such as an antigen, is the affinity of the antibody or functional fragment for that epitope. The dissociation rate (k off ) and association rate (k on ) and the ratio (k off / k on ) is the dissociation constant K D and has an inverse relationship with affinity. D The lower the value, the higher the affinity of the antibody. D The value of k varies for different complexes of antibody and antigen. on and k off The dissociation constant K of the antibodies provided herein depends on both DAffinity can be determined using any of the methods provided herein or any other method known to those skilled in the art. The affinity at one binding site does not necessarily reflect the true strength of the interaction between the antibody and the antigen. When a complex antigen containing multiple repeating antigenic determinants, such as a multivalent antigen, comes into contact with an antibody containing multiple binding sites, the interaction of the antibody with the antigen at one site will increase the probability of reaction at a second site. The strength of multiple interactions between such a multivalent antibody and an antigen is called avidity.
[0045] In reference to the antibodies described herein, terms such as "binds to," "specifically binds to," and similar terms are also used interchangeably herein to refer to an antibody of an antigen-binding domain that specifically binds to an antigen, such as a polypeptide. An antibody or antigen-binding domain that binds to an antigen or specifically binds to an antigen may cross-react with related antigens. In certain embodiments, an antibody or antigen-binding domain that binds to an antigen or specifically binds to an antigen does not cross-react with other antigens. An antibody or antigen-binding domain that binds to an antigen or specifically binds to an antigen can be identified, for example, by immunoassay, Octet®, Biacore®, or other techniques known to those skilled in the art. In some embodiments, an antibody or antigen-binding domain binds to an antigen or specifically binds to an antigen if it binds to the antigen with higher affinity than any cross-reactive antigens as determined using experimental techniques such as radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA). Typically, a specific or selective response is at least twice the background signal or noise and may exceed 10 times the background. For a discussion of binding specificity, see, e.g., Fundamental Immunology 332-36 (Paul, ed., 2d ed. 1989). In certain embodiments, the extent of binding of an antibody or antigen-binding domain to a "non-target" protein is less than about 10% of the binding of the antibody or antigen-binding domain to its specific target antigen, as determined, for example, by fluorescence activated cell sorting (FACS) analysis or RIA. With reference to terms such as "specific binding," "specifically binds to," or "specific for," binding refers to binding that is measurably different from non-specific interactions. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule, which is a molecule of similar structure that generally does not have binding activity. For example, specific binding can be determined by competition with a control molecule similar to the target, e.g., an excess of unlabeled target.In this case, specific binding is indicated if binding of the labeled target to the probe is competitively inhibited by excess unlabeled target. Antibodies or antigen-binding domains that bind to an antigen include those that can bind to the antigen with sufficient affinity so that the antibody is useful, for example, as a diagnostic or therapeutic agent targeted to the antigen. In certain embodiments, antibodies or antigen-binding domains that bind to an antigen have a dissociation constant (K) of 1000 nM, 800 nM, 500 nM, 250 nM, 100 nM, 50 nM, 10 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, or 0.1 nM or less. D In certain embodiments, the antibody or antigen-binding domain binds to an epitope of an antigen that is conserved between antigens from different species (e.g., between human and cynomolgus monkey species).
[0046] "Binding affinity" generally refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., a binding protein such as an antibody) and its binding partner (e.g., an antigen). Unless otherwise specified, as used herein, "binding affinity" refers to the intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a binding molecule X for its binding partner Y is generally determined by the dissociation constant (K D ) Affinity can be measured by common methods known in the art, including those described herein. Low affinity antibodies generally bind antigens slowly and tend to dissociate easily, whereas high affinity antibodies generally bind antigens faster and tend to remain bound for longer. Various methods for measuring binding affinity are known in the art, any of which can be used for the purposes of the present disclosure. Specific exemplary embodiments include the following: In one embodiment, "K D " or "K D The "K value" can be measured by assays known in the art, for example, by binding assays. Dcan be measured, for example, by RIA using the Fab version of the antibody of interest and its antigen (Chen, et al., J. Mol Biol, 1999, 293:865-81). D or K D The value can be measured by using biolayer interferometry (BLI) or surface plasmon resonance (SPR) assays, for example by Octet® using the Octet® Red 96 system, or by Biacore® using, for example, a Biacore® 2000 or Biacore® 3000. Also referred to as "on rate" or "rate of association" or "association rate" or "k on " can be determined using the same biolayer interferometry (BLI) or surface plasmon resonance (SPR) techniques described above, for example, using an Octet® Red 96, Biacore® 2000, or Biacore® 3000 system.
[0047] In certain embodiments, antibodies may comprise "chimeric" sequences in which a portion of the heavy and / or light chain is identical to or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical to or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, so long as they exhibit the desired biological activity (see U.S. Pat. No. 4,816,567, and Morrison, et al., Proc. Natl. Acad. Sci. USA, 1984, 81:6851-55).
[0048] In certain embodiments, antibodies may comprise portions of "humanized" forms of non-human (e.g., murine) antibodies, which are chimeric antibodies comprising a human immunoglobulin (e.g., recipient antibody) in which native CDR residues are replaced by residues from corresponding CDRs of a non-human species (e.g., donor antibody) such as mouse, rat, rabbit, or non-human primate having the desired specificity, affinity, and capacity. In some cases, one or more FR region residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies can comprise residues that are not found in the recipient antibody or the donor antibody. These modifications are made to further refine antibody performance. The heavy or light chains of a humanized antibody can comprise one or more variable regions in which all or substantially all of the CDRs correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of human immunoglobulin sequences. In certain embodiments, a humanized antibody comprises at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones, et al., Nature, 1986, 321:522-25; Riechmann, et al., Nature, 1988, 332:323-29; Presta, Curr. Op. Struct. Biol., 1992, 2:593-96; Carter, et al., Proc. Natl. Acad. Sci. USA, 1992, 89:4285-89; U.S. Patent Nos. 6,800,738, 6,719,971, 6,639,055, 6,407,213, and 6,054,297.
[0049] In certain embodiments, an antibody can comprise a portion of a "fully human antibody" or "human antibody," which terms are used interchangeably herein and refer to an antibody comprising a human variable region and, for example, a human constant region. In specific embodiments, these terms refer to an antibody comprising variable and constant regions of human origin. A "fully human" antibody can also encompass, in certain embodiments, an antibody that binds a polypeptide and is encoded by a nucleic acid sequence that is a naturally occurring somatic variant of a human germline immunoglobulin nucleic acid sequence. The term "fully human antibody" includes antibodies having variable and constant regions that correspond to human germline immunoglobulin sequences as described by Kabat et al. (See Kabat, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDapartment of Health and Human Services, NIH Publication No. 91-3242). A "human antibody" is one that has an amino acid sequence that corresponds to that of an antibody produced by a human and / or has been produced using any of the techniques for producing human antibodies. This definition of a human antibody specifically excludes humanized antibodies that contain non-human antigen-binding residues. Human antibodies can be produced using a variety of techniques known in the art, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., 1991, 227:381; Marks, et al., 1991, J. Mol. Biol., 1991, 222:581) and yeast display libraries (Chao, et al., Nature Protocols, 2006, 1:755-68).In addition, methods described in Cole, et al., Monoclonal Antibodies and Cancer Therapy 77 (1985), Boerner, et al., J. Immunol., 1991, 147(1):86-95, and van Dijk and van de Winkel, Curr. Opin. Pharmacol., 2001, 5:368-74 can also be used to prepare human monoclonal antibodies. Human antibodies can be prepared by administering antigen to transgenic animals, e.g., mice, that have been engineered to produce such antibodies in response to antigen challenge, but whose endogenous gene loci have been disabled (see, e.g., Jakobovits, Curr. Opin. Biotechnol., 1995, 6(5):561-66; Bruggemann and Taussing, Curr. Opin. Biotechnol., 1997, 8(4):455-58, and U.S. Patent Nos. 6,075,181 and 6,150,584 regarding XENO Mouse™ technology). See also, e.g., Li, et al., Proc. Natl. Acad. Sci. USA, 2006, 103:3557-62 (regarding human antibodies generated via human B cell hybridoma technology).
[0050] In certain embodiments, an antibody can comprise a portion of a "recombinant human antibody," which phrase includes human antibodies prepared, expressed, created, or isolated by recombinant means, e.g., antibodies expressed using a recombinant expression vector introduced into a host cell, antibodies isolated from a recombinant combinatorial human antibody library, antibodies isolated from animals (e.g., mice or cows) that are transgenic and / or transchromosomal for human immunoglobulin genes (e.g., Taylor, LD, et al., Nucl. Acids Res., 1992 20:6287-6295), or antibodies prepared, expressed, created, or isolated by any other means involving splicing human immunoglobulin gene sequences into other DNA sequences. Such recombinant human antibodies can have variable and constant regions derived from human germline immunoglobulin sequences (see Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, USDapartment of Health and Human Services, NIH Publication No. 91-3242). However, in certain embodiments, such recombinant human antibodies have been subjected to in vitro mutagenesis (or, when animals transgenic for human Ig sequences are used, in vivo somatic mutagenesis), and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are derived from and related to human germline VH and VL sequences, but are sequences that may not naturally exist within the human antibody germline repertoire in vivo.
[0051] In certain embodiments, an antibody can comprise a portion of a "monoclonal antibody," a term used herein to refer to an antibody obtained from a population of substantially homogeneous antibodies, e.g., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts, and each monoclonal antibody typically recognizes a single epitope on an antigen. In specific embodiments, a "monoclonal antibody," as used herein, is an antibody produced by a single hybridoma or other cell. The term "monoclonal" is not limited to a particular method for making the antibody. For example, monoclonal antibodies useful in the present disclosure can be prepared by the hybridoma method first described by Kohler et al., 1975, Nature 256:495, or can be made using recombinant DNA methods in bacterial or eukaryotic animal or plant cells (see, e.g., U.S. Pat. No. 4,816,567). Monoclonal antibodies can also be isolated from phage antibody libraries using the techniques described, for example, in Clackson, et al., Nature, 1991, 352:624-28 and Marks, et al., J. Mol. Biol., 1991, 222:581-97. Other methods for preparing clonal cell lines and the monoclonal antibodies expressed thereby are well known in the art. See, for example, Short Protocols in Molecular Biology (Ausubel et al. eds., 5th ed. 2002).
[0052] A typical four-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light chains (L) and two identical heavy chains (H). In the case of IgG, the four-chain unit generally has a size of approximately 150,000 daltons. Each L chain is linked to the H chain by one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds depending on the H chain isotype. Each H and L chain also has regularly spaced intrachain disulfide bridges. Each H chain has a variable domain (VH) at its N-terminus followed by three constant domains (CH) for the α and γ chains, and four CH domains for the μ and ε isotypes. Each L chain has a variable domain (VL) at its N-terminus followed by a constant domain (CL) at its other end. The VL is aligned with the VH, and the CL is aligned with the first constant domain (CH1) of the heavy chain. Particular amino acid residues are believed to form an interface between the light-chain and heavy-chain variable domains. The pairing of VH and VL together forms a single antigen-binding site. For the structure and properties of different classes of antibodies, see, for example, Basic and Clinical Immunology 71 (Stites, et al. eds., 8th ed. 1994) and Immunobiology (Janeway, et al. eds., 5th ed. 2001).
[0053] As used herein, "core fucose," "core fucose residue," "fucose," or "fucose residue" refers to the fucose residue in the α1,6-linkage to the first GlcNAc of the Asn297-linked N-oligosaccharide. Ferrara et al., Proc Natl Acad Sci USA, 2011, 108:12669-74. "Core fucose," "core fucose residue," "fucose," and "fucose residue" are used interchangeably in this disclosure.
[0054] The term "Fab" or "Fab region" refers to the region of an antibody that binds to an antigen. Conventional IgGs typically contain two Fab regions, each located in one of the two arms of the Y-shaped IgG structure. Each Fab region typically consists of one variable region and one constant region from each of the heavy and light chains. More specifically, the variable and constant regions of the heavy chain in the Fab region are the VH and CH1 regions, and the variable and constant regions of the light chain in the Fab region are the VL and CL regions. The VH, CH1, VL, and CL regions in the Fab region can be arranged in various ways to confer antigen-binding capability according to the present disclosure. For example, the VH and CH1 regions can be on one polypeptide, while the VL and CL regions can be on separate polypeptides, as in the Fab region of a conventional IgG. Alternatively, the VH, CH1, VL, and CL regions can all be located on the same polypeptide and oriented in different orders, as described in more detail in the following sections.
[0055] The terms "variable region," "variable domain," "V region," or "V domain" refer to a portion of an antibody's light or heavy chain, located generally at the amino terminus of the light or heavy chain, approximately 120-130 amino acids in length for heavy chains and approximately 100-110 amino acids in length for light chains, that is used to determine the binding and specificity of each particular antibody for its particular antigen. The variable region of a heavy chain may be referred to as "VH." The variable region of a light chain may be referred to as "VL." The term "variable" refers to the fact that certain segments of the variable region vary significantly in sequence among antibodies. The V region mediates antigen binding and determines the specificity of a particular antibody for a particular antigen. However, the variability is not uniform across the 110-amino acid span of the variable region. Instead, the V region consists of less variable (e.g., relatively invariant) stretches of approximately 15-30 amino acids called framework regions (FRs), separated by shorter regions of greater variability (e.g., extreme variability) called "hypervariable regions," each approximately 9-12 amino acids in length. The heavy and light chain variable regions each contain four FRs, mostly in a β-sheet structure, connected by three hypervariable regions, which form loops connecting the β-sheet structure and, in some cases, form part of the β-sheet structure. The hypervariable regions within each chain are held in close proximity by the FRs and, together with the hypervariable regions of the other chain, contribute to the formation of the antigen-binding site of antibodies (see, for example, Kabat et al., Sequences of Proteins of Immunological Interest (5th ed. 1991)). The constant regions are not directly involved in binding the antibody to the antigen, but exhibit various effector functions, such as antibody participation in ADCC and CDC. The sequences of the variable regions vary significantly among different antibodies. In a specific embodiment, the variable regions are human variable regions.
[0056] The terms "variable region residue numbering according to Kabat" or "amino acid position numbering as in Kabat," and variations thereof, refer to the numbering system used in the heavy or light chain variable regions of the antibody compilations of Kabat et al. (supra). Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to shortening of, or insertion into, the FRs or CDRs of the variable domain. For example, a heavy chain variable domain may contain a single amino acid insertion after residue 52 (residue 52a according to Kabat) and three inserted residues after residue 82 (e.g., residues 82a, 82b, and 82c according to Kabat). The Kabat numbering of residues can be determined for a given antibody by aligning the antibody sequence with the "standard" Kabat numbering sequence at the region of homology. The Kabat numbering system is generally used when referring to residues of the variable domain (e.g., residues 1-107 for the light chain and residues 1-113 for the heavy chain) (e.g., Kabat et al., supra). The "EU numbering system" or "EU index" is generally used when referring to residues within immunoglobulin heavy chain constant regions (e.g., the EU index reported in Kabat et al., supra). "EU index as in Kabat" refers to the residue numbering of the human IgG1 EU antibody. Other numbering systems have been described, for example, by AbM, Chothia, Contact, IMGT, and AHon.
[0057] The term "heavy chain" when used with respect to antibodies refers to a polypeptide chain of approximately 50 to 70 kDa, the amino-terminal portion of which contains a variable region of approximately 120 to 130 amino acids, and the carboxy-terminal portion of which contains a constant region. The constant region can be one of five distinct types (e.g., isotypes), designated alpha (α), delta (δ), epsilon (ε), gamma (γ), and mu (μ), based on the amino acid sequence of the heavy chain constant region. The distinct heavy chains vary in size, with α, δ, and γ containing approximately 450 amino acids, while μ and ε contain approximately 550 amino acids. When combined with light chains, these distinct types of heavy chains give rise to five well-known classes (e.g., isotypes) of antibodies: IgA, IgD, IgE, IgG, and IgM (including the four subclasses of IgG, i.e., IgG1, IgG2, IgG3, and IgG4).
[0058] The term "light chain" when used in reference to an antibody refers to a polypeptide chain of approximately 25 kDa, which contains a variable region of about 100 to about 110 or more amino acids at its amino terminal end and a constant region at its carboxy terminal end. The approximate length of a light chain is 211 to 217 amino acids. There are two different types, called kappa (κ) or lambda (λ), based on the amino acid sequence of the constant domain.
[0059] As used herein, the terms "hypervariable region," "hypervariable region (HVR)," "complementarity determining region," and "Complementarity Determining Region (CDR)" are used interchangeably. "CDR" refers to one of the three hypervariable regions (H1, H2, or H3) within the non-framework region of an immunoglobulin (Ig or antibody) VH β-sheet framework, or one of the three hypervariable regions (L1, L2, or L3) within the non-framework region of an antibody VL β-sheet framework. Thus, CDRs are variable region sequences interspersed within framework region sequences.
[0060] CDR regions are well known to those skilled in the art and are defined by well-known numbering systems. For example, Kabat complementarity-determining regions (CDRs) are based on sequence variability and are the most commonly used (see, e.g., Kabat et al., supra). Chothia, instead, refers to the position of the structural loop (see, e.g., Chothia and Lesk, J. Mol. Biol., 1987, 196:901-17). When numbered using the Kabat numbering system, the end of the Chothia CDR-H1 loop varies from H32 to H34 depending on the length of the loop (this is because the Kabat numbering scheme places insertions at H35A and H35B; if neither 35A nor 35B is present, the loop ends at 32; if only 35A is present, the loop ends at 33; and if both 35A and 35B are present, the loop ends at 34). AbM hypervariable regions represent a compromise between Kabat CDRs and Chothia structural loops and are used by Oxford Molecular's AbM antibody modeling software (see, e.g., Antibody Engineering Vol. 2 (Kontermann and Dubel, eds., 2nd ed. 2010)). The "contact" hypervariable regions are based on an analysis of available complex crystal structures. Another universal numbering system that has been developed and widely adopted is the ImMunoGeneTics (IMGT) Information System® (Lafranc, et al., Dev. Comp. Immunol., 2003, 27(1):55-77). IMGT is an integrated information system dedicated to immunoglobulins (IGs), T cell receptors (TCRs), and major histocompatibility complexes (MHCs) of humans and other vertebrates. CDRs are referred to herein in terms of both amino acid sequence and location within a light or heavy chain.Because the "location" of CDRs within the structure of immunoglobulin variable domains is conserved among species and resides in structures called loops, CDR and framework residues are readily identified by using a numbering system that aligns variable domain sequences according to structural features. This information can be used to graft and substitute CDR residues from one species of immunoglobulin into an acceptor framework, typically from a human antibody. An additional numbering system (AHon) has been developed by Honegger and Pluckthun, J. Mol. Biol., 2001, 309:657-70. For example, the correspondence between numbering systems, including the Kaba numbering and the IMGT specific numbering system, is well known to those skilled in the art (see, e.g., Kabat, supra; Chothia and Lesk, supra; Martin, supra; Lefranc et al., supra). Residues from each of these hypervariable regions or CDRs are shown below.
[0061] [Table 1]
[0062] The boundaries of a given CDR may vary depending on the scheme used for identification. Thus, unless otherwise specified, the terms "CDR" and "complementarity determining region" of a given antibody or region thereof, such as a variable region, and individual CDRs of an antibody or region thereof (e.g., "CDR-H1, CDR-H2"), should be understood to encompass the complementarity determining regions defined by any of the known schemes described hereinabove. In some cases, a scheme for identifying a particular CDR or CDRs is specified, such as CDRs defined by the Kabat, Chothia, or Contact methods. In other cases, the specific amino acid sequences of the CDRs are provided.
[0063] The hypervariable regions may include "extended hypervariable regions" such as: 24-36 or 24-34 (L1), 46-56 or 50-56 (L2), and 89-97 or 89-96 (L3) in VL, and 26-35 or 26-35A (H1), 50-65 or 49-65 (H2), and 93-102, 94-102, or 95-102 (H3) in VH.
[0064] The term "constant region" or "constant domain" refers to the carboxy-terminal portions of the light and heavy chains that are not directly involved in binding the antibody to an antigen, but which exhibit various effector functions, such as interaction with Fc receptors. This term refers to the portion of an immunoglobulin molecule that has a more conserved amino acid sequence compared to the other portion of the immunoglobulin, the variable region, which contains the antigen-binding site. The constant region can include the CH1, CH2, and CH3 regions of the heavy chain and the CL region of the light chain.
[0065] The term "framework" or "FR" refers to the variable region residues adjacent to the CDRs. FR residues are present, for example, in chimeric antibodies, humanized antibodies, human antibodies, domain antibodies, diabodies, linear antibodies, and bispecific antibodies. FR residues are variable domain residues other than hypervariable region or CDR residues. Typically, there are four FR regions in each of the VH and VL regions. The FR regions in VH are VH FR1, VH FR2, VH FR3, and VH FR4 (or FR H1, FR H2, FR H3, and FR H4). The FR regions in VL are VL FR1, VL FR2, VL FR3, and VL FR4 (or FR L1, FR L2, FR L3, and FR L4).
[0066] As used herein, the term "Fc region" is used to define the C-terminal region of an immunoglobulin heavy chain, including, for example, native-sequence Fc regions, recombinant Fc regions, and variant Fc regions. While the boundaries of the Fc region of an immunoglobulin heavy chain can vary, the Fc region of a human IgG heavy chain is often defined to stretch from the amino acid residue at position Cys226, or from the amino acid residue at position Pro230, to the carboxyl terminus. The C-terminal lysine of the Fc region (residue 447 according to the EU numbering system) can be removed, for example, during antibody production or purification, or by recombinantly engineering the nucleic acid encoding the antibody heavy chain. Thus, an intact antibody composition can include an antibody population in which all K447 residues have been removed, an antibody population in which the K447 residue has not been removed, and an antibody population having a mixture of antibodies with and without the K447 residue. A "functional Fc region" possesses the "effector functions" of a native-sequence Fc region. Exemplary "effector functions" include C1q binding, CDC, Fc receptor binding, ADCC, phagocytosis, down-regulation of cell surface receptors (e.g., B cell receptors), and the like. Such effector functions generally require that the Fc region be combined with a binding region or domain (e.g., an antibody variable region or domain) and can be assessed using a variety of assays known to those of skill in the art. A "variant Fc region" comprises an amino acid sequence that differs from that of a native-sequence Fc region by at least one amino acid modification (e.g., substitution, addition, or deletion). In certain embodiments, the variant Fc region comprises at least one amino acid substitution compared to a native-sequence Fc region or the Fc region of a parent polypeptide, e.g., from about 1 to about 10 amino acid substitutions, or from about 1 to about 5 amino acid substitutions in the native-sequence Fc region or the Fc region of a parent polypeptide. The variant Fc region herein may have at least about 80% homology to a native sequence Fc region and / or the Fc region of a parent polypeptide, or at least about 90% homology thereto, for example, at least about 95% homology thereto.
[0067] The term "variant," when used with respect to an antigen or antibody, can refer to a peptide or polypeptide that contains one or more (e.g., about 1 to about 25, about 1 to about 20, about 1 to about 15, about 1 to about 10, or about 1 to about 5) amino acid sequence substitutions, deletions, and / or additions compared to the native or unmodified sequence. For example, a CD37 variant can result from one or more (e.g., about 1 to about 25, about 1 to about 20, about 1 to about 15, about 1 to about 10, or about 1 to about 5) modifications to the amino acid sequence of native CD37. Also, by way of example, a variant of an anti-CD37 antibody can result from one or more (e.g., about 1 to about 25, about 1 to about 20, about 1 to about 15, about 1 to about 10, or about 1 to about 5) modifications to the amino acid sequence of a native or previously unmodified anti-CD37 antibody. Variants can be naturally occurring, such as allelic variants or splice variants, or can be artificially constructed. Polypeptide variants can be prepared from corresponding nucleic acid molecules encoding the variants. In specific embodiments, CD37 variants or anti-CD37 antibody variants retain at least the functional activity of CD37 or anti-CD37 antibody, respectively. In specific embodiments, anti-CD37 antibody variants bind to CD37 and / or are antagonistic to CD37 activity. In certain embodiments, variants are encoded by single nucleotide polymorphism (SNP) variants of a nucleic acid molecule encoding a CD37 or anti-CD37 antibody VH or VL region or subregion, e.g., one or more CDRs.
[0068] The term "identity" refers to the relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by aligning and comparing the sequences. "Percent (%) amino acid sequence identity" to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to those in the reference polypeptide sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, without considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved by a variety of methods within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or MEGALIGN (DNAStar, Inc.) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximum alignment over the entire length of the sequences being compared.
[0069] An "alteration" of an amino acid residue / position refers to a change in the primary amino acid sequence compared to the starting amino acid sequence, where the alteration results from a sequence change involving that amino acid residue / position. For example, typical alterations include substitution of the residue with another amino acid (e.g., a conservative or non-conservative substitution), insertion of one or more (e.g., generally less than 5, 4, or 3) amino acids adjacent to that residue / position, and / or deletion of that residue / position.
[0070] As used herein, "epitope" is a term of art that refers to a localized region of an antigen to which an antibody can specifically bind. An epitope can be a linear or conformational epitope, a non-linear epitope, or a discontinuous epitope. In the case of a polypeptide antigen, for example, an epitope can be consecutive amino acids of the polypeptide (a "linear" epitope), or it can include amino acids from two or more non-contiguous regions of the polypeptide (a "conformational," "non-linear," or "discontinuous" epitope). In general, it will be understood by those skilled in the art that a linear epitope may or may not depend on secondary, tertiary, or quaternary structure. For example, in some embodiments, an antibody binds to a group of amino acids regardless of whether the amino acids are folded into the native three-dimensional protein structure. In other embodiments, antibodies require that the amino acid residues comprising the epitope exhibit a particular conformation (eg, a bend, twist, turn, or fold) in order to recognize and bind to the epitope.
[0071] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, may comprise modified amino acids, and may be interrupted by non-amino acids. The term also refers to amino acid polymers that are naturally modified or modified by intervention, such as disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification. The definition also includes polypeptides containing one or more analogs of an amino acid, including, but not limited to, unnatural amino acids, as well as other modifications known in the art. Because the polypeptides of the present disclosure may be based on antibodies or other members of the immunoglobulin superfamily, it is understood that in certain embodiments, a "polypeptide" can occur as a single chain or as two or more related chains.
[0072] The term "vector" refers to a substance used to carry or contain a nucleic acid sequence, such as a nucleic acid sequence encoding an antibody described herein, for introducing the nucleic acid sequence into a host cell. Vectors applicable for use include, for example, expression vectors, plasmids, phage vectors, viral vectors, episomes, and artificial chromosomes, which may contain an operable selection sequence or marker capable of stable integration into a host cell chromosome. In addition, a vector may contain one or more selectable marker genes and appropriate expression control sequences. Selectable marker genes that may be included provide, for example, resistance to antibiotics or toxins, complement deficiencies in auxiliary auxotrophies, or supply critical nutrients absent from the culture medium. Expression control sequences may include constitutive and inducible promoters, transcription enhancers, transcription terminators, and the like, as are well known in the art. When two or more nucleic acid molecules are coexpressed (e.g., both the heavy and light chains of an antibody, or antibody VH and VL), both nucleic acid molecules may be inserted, for example, into a single expression vector or into separate expression vectors. For expression in a single vector, the encoding nucleic acids can be operably linked to a common expression control sequence or to different expression control sequences, such as one inducible promoter and one constitutive promoter. Introduction of nucleic acid molecules into host cells can be confirmed using methods well known in the art. Such methods include, for example, nucleic acid analysis, such as Northern blot or amplification of mRNA by polymerase chain reaction (PCR), immunoblotting for expression of gene products, or other suitable analytical methods for testing expression of the introduced nucleic acid sequence or its corresponding gene product. Those skilled in the art will understand that nucleic acid molecules will be expressed in amounts sufficient to produce the desired product, and will further understand that expression levels can be optimized to obtain sufficient expression using methods well known to those skilled in the art.
[0073] As used herein, the term "host" refers to an animal, such as a mammal (e.g., a human).
[0074] As used herein, the term "host cell" refers to a particular subject cell into which a nucleic acid molecule can be transfected, and to the progeny or potential progeny of such a cell. The progeny of such a cell may not be identical to the parent cell transfected with the nucleic acid molecule due to mutations or environmental influences that may occur during the subsequent generation or integration of the nucleic acid molecule into the host cell genome.
[0075] An "isolated nucleic acid" is a nucleic acid, e.g., RNA, DNA, or mixed nucleic acid, that is substantially separated from other genomic DNA sequences and proteins or complexes, such as ribosomes and polymerases, that are naturally associated with the native sequence. An "isolated" nucleic acid molecule is one that is separated from other nucleic acid molecules that are present in the natural source of the nucleic acid molecule. Furthermore, an "isolated" nucleic acid molecule, such as a cDNA molecule, may be substantially free of other cellular material or culture medium if produced by recombinant techniques, or substantially free of chemical precursors or other chemicals if chemically synthesized. In certain embodiments, one or more nucleic acid molecules encoding an antibody described herein are isolated or purified. This term encompasses nucleic acid sequences that have been removed from their naturally occurring environment, and includes recombinant or cloned DNA isolates, as well as chemically synthesized analogs or heterologous biologically synthesized analogs. A substantially pure molecule can include isolated forms of the molecule.
[0076] "Polynucleotide," "nucleotide," or "nucleic acid," as used interchangeably herein, refer to a polymer of nucleotides of any length, including DNA and RNA. Nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and / or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase or by a synthetic reaction. Polynucleotides can include modified nucleotides, such as methylated nucleotides and their analogs. As used herein, "oligonucleotide" refers to a short, generally single-stranded, synthetic polynucleotide, generally, but not necessarily, less than about 200 nucleotides in length. The terms "oligonucleotide" and "polynucleotide" are not mutually exclusive. The above description of polynucleotides is equally fully applicable to oligonucleotides. Cells producing antibodies of the present disclosure can include parent hybridoma cells, as well as bacterial and eukaryotic host cells into which nucleic acid encoding the antibody has been introduced. Unless otherwise specified, the left-hand end of any single-stranded polynucleotide sequence disclosed herein is the 5' end. The left-hand direction of a double-stranded polynucleotide sequence is referred to as the 5' direction. The direction of 5' to 3' addition of the nascent RNA transcript is referred to as the transcription direction. The region of the DNA strand with the same sequence as the RNA transcript at the 5' to 5' end of the RNA transcript is referred to as the "upstream sequence," and the region of the DNA strand with the same sequence as the RNA transcript at the 3' to 3' end of the RNA transcript is referred to as the "downstream sequence."
[0077] As used herein, the term "pharmaceutically acceptable" means approved by a federal or state regulatory agency for use in animals, and more particularly for use in humans, or listed in the United States Pharmacopoeia, the European Pharmacopoeia, or other generally recognized pharmacopoeias.
[0078] The term "excipient" refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, encapsulating material, etc. Excipients include, for example, encapsulating materials or additives such as absorption enhancers, antioxidants, binders, buffers, carriers, coating agents, colorants, diluents, disintegrants, emulsifiers, extenders, fillers, flavorings, wetting agents, lubricants, fragrances, preservatives, propellants, release agents, bactericides, sweeteners, solubilizers, wetting agents, and mixtures thereof. The term "excipient" can also refer to a diluent, adjuvant (e.g., Freund's adjuvant (complete or incomplete)), or vehicle.
[0079] In some embodiments, the excipient is a pharmaceutically acceptable excipient. Examples of pharmaceutically acceptable excipients include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; proteins such as low molecular weight (e.g., less than about 10 amino acid residues) polypeptides, serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or nonionic surfactants such as TWEEN™, polyethylene glycol (PEG), and PLURONICS™. Other examples of pharmaceutically acceptable excipients are described in Remington and Gennaro, Remington's Pharmaceutical Sciences (18th ed. 1990).
[0080] In one embodiment, each component is "pharmaceutically acceptable" in the sense of being compatible with the other components of the pharmaceutical formulation and suitable for use in contact with the tissues or organs of humans and animals without undue toxicity, irritation, allergic response, immunogenicity, or other problem or complication, commensurate with a reasonable benefit / risk ratio. See, e.g., Lippincott Williams & Wilkins: Philadelphia, PA, 2005; Handbook of Pharmaceutical Excipients, 6th ed., Rowe et al., Eds., The Pharmaceutical Press and the American Pharmaceutical Association: 2009; Handbook of Pharmaceutical Additives, 3rd ed., Ash and Ash Eds., Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, 2nd ed., Gibson Ed., CRC Press LLC: Boca Raton, FL, 2009. In some embodiments, a pharmaceutically acceptable excipient is nontoxic to cells or mammals exposed thereto at the dosages and concentrations employed. In some embodiments, the pharmaceutically acceptable excipient is an aqueous pH buffered solution.
[0081] In some embodiments, the excipient may be a sterile liquid, such as water or oil, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, or sesame oil. Water is an exemplary excipient when the composition (e.g., pharmaceutical composition) is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions may also be employed as liquid excipients, particularly for injectable solutions. Excipients may also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, dried skim milk, glycerin, propylene, glycol, water, ethanol, or the like. If desired, the composition may further contain minor amounts of wetting or emulsifying agents, or pH buffering agents. The composition may take the form of a solution, suspension, emulsion, tablet, pill, capsule, powder, sustained-release formulation, or the like. Oral composition containing formulations can include standard excipients such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, etc.
[0082] A composition containing a pharmaceutical compound can include, for example, an antibody in isolated or purified form, together with a suitable amount of excipients.
[0083] As used herein, the term "effective amount" or "therapeutically effective amount" refers to an amount of an antibody or pharmaceutical composition provided herein that is sufficient to effect a desired result.
[0084] The terms "subject" and "patient" can be used interchangeably herein. As used herein, in certain embodiments, a subject is a mammal, such as a non-primate (e.g., cows, pigs, horses, cats, dogs, rats, etc.) or a primate (e.g., monkeys and humans). In specific embodiments, a subject is a human. In one embodiment, a subject is a mammal, e.g., a human, diagnosed with a condition or disorder. In another embodiment, a subject is a mammal, e.g., a human, at risk of developing a condition or disorder.
[0085] "Administering" or "administration" refers to the act of injecting or otherwise physically delivering a substance present outside the body to a patient, such as by mucosal, intradermal, intravenous, intramuscular, subcutaneous delivery, and / or any other physical delivery method described herein or known in the art.
[0086] As used herein, the terms "treatment" and "treatment / treating" refer to the reduction or amelioration of the progression, severity, and / or duration of a disease or condition resulting from the administration of one or more therapies. Treatment may be determined by assessing whether there has been a reduction, alleviation, and / or alleviation of one or more symptoms associated with the underlying disease, such that an improvement is observed in the patient, even though the patient may still be suffering from the underlying disease. The term "treating" includes both disease management and remission. The terms "manage," "managing," and "management" refer to the beneficial effects a subject derives from treatment, which does not necessarily result in a cure of the disease.
[0087] The terms "prevent," "preventing," and "prevention" refer to reducing the likelihood of the onset (or recurrence) of a disease, disorder, condition, or associated symptom.
[0088] The terms "about" and "approximately" refer to within 20%, within 15%, within 10%, within 9%, within 8%, within 7%, within 6%, within 5%, within 4%, within 3%, within 2%, within 1%, or less of a given value or range.
[0089] As used in this disclosure and the claims, the singular forms "a," "an," and "the" include the plural forms unless the context clearly dictates otherwise.
[0090] Whenever an embodiment is described herein with the term "comprising," it is understood that other similar embodiments otherwise described in terms of "consisting of" and / or "consisting essentially of" are also provided. Whenever an embodiment is described herein with the phrase "consisting essentially of," it is also understood that similar embodiments otherwise described in terms of "consisting of" are also provided.
[0091] The term "between" when used in phrases such as "between A and B" or "between A and B" refers to a range that includes both A and B.
[0092] The term "and / or" used herein in phrases such as "A and / or B" is intended to include both A and B, A or B, A alone, and B alone. Similarly, the term "and / or" used in phrases such as "A, B, and / or C" is intended to include each of the following embodiments: A, B, and C, A, B, or C, A or C, A or B, B or C, A and C, A and B, B and C, A alone, B alone, and C alone.
[0093] Fc mutations with enhanced effector function The binding molecules (e.g., monovalent antibodies) provided herein have mutations at lysine at position 248 (K248) (EU numbering) and threonine at position 437 (T437) (EU numbering) in the Fc region.
[0094] Lysine at position 248 (K248) (EU numbering) and threonine at position 437 (T437) (EU numbering) are both conserved residues in the Fc region among different IgG subtypes (Zhang, D., et al., supra). Fc mutations T437R and K248E (EU numbering) have been shown to promote oligomerization of antibodies upon antigen binding on the cell surface and to have enhanced effector function (Zhang, D., et al., supra). The T437R and K248E double mutation ("RE mutation") has been shown to confer CDC activity to wild-type IgG1 antibodies that did not possess CDC activity in a dose-dependent manner (Zhang, D., et al., supra).
[0095] "EU numbering" or "EU index" is generally used when referring to residues in immunoglobulin heavy chain constant regions. It refers to the residue numbering of the human IgG1 EU antibody. It is calculated by aligning the antibody sequence with the sequence of the Eu antibody (Edelman, GM, et al., Proc Natl Acad Sci USA, 1969, 63(1):78-85; Kabat, et al., supra), and therefore each residue that is homologous to a residue in the Eu antibody will have the same residue number as the Eu residue.
[0096] Antibodies containing other Fc region mutations, such as S239D / I332E and S239D / I332E / A330L (EU numbering), have also been shown to exhibit significantly enhanced ADCC through enhanced binding to FcγR (Lazar, GA et al., Proc Natl Acad Sci USA, 2006, 103(11):4005-10).
[0097] Monovalent antibodies In one aspect, provided herein are monovalent binding molecules (such as monovalent antibodies) with RE mutations in the Fc region of the monovalent binding molecule. As demonstrated below, the combination of monovalency with RE mutations further enhances CDC activity compared to RE mutations alone, among other advantages.
[0098] CDC activity requires activation of the complement cascade, which requires activation of the complement component C1q by a hexamer of Fc regions coplanar with the surface of the target cell. This, in turn, requires the simultaneous binding of five or six antibody molecules in close proximity to the cell surface. Due to the need for Fc-mediated antibody oligomerization, CDC activity requires a relatively high target receptor density. For natural IgG antibodies, the stoichiometry of antibody-receptor binding can vary from 1:2 to 1:1 depending on the antibody concentration, with the former being highly favored due to avidity.
[0099] To maximize the number of antibodies that can bind to a given number of cell surface receptors, the antibodies provided herein are formatted as monovalent antibodies that enforce a 1:1 antibody-receptor binding stoichiometry. This allows more Fc regions to be presented on the surface of cells bearing a given number of receptors compared to natural bivalent IgG. The monovalent antibodies provided herein have stronger CDC activity than their natural bivalent counterparts.
[0100] For example, antibodies can be formatted as monovalent antibodies using standard techniques known to those of skill in the art, including in vitro expression of recombinant protein.
[0101] Any monovalent antibody format can be applied to the present constructs, as long as it confers further enhanced CDC activity through increased oligomerization (e.g., hexamerization) of the binding molecule at the cell surface and / or increased C1q engagement.
[0102] In some embodiments, a monovalent antibody comprises one antigen-binding arm of unknown specificity and another antigen-binding arm that is specific for a target of interest.
[0103] In some embodiments, a monovalent antibody comprises an antigen-binding arm specific for a target of interest, one antigen-binding arm of unknown specificity, or one remaining binding arm without any binding arm.
[0104] In some embodiments, the antigen-binding domain of a monovalent antibody comprises a VH region and / or a VL region. In some embodiments, the antigen-binding domain of a monovalent antibody comprises a Fab fragment. In some embodiments, the antigen-binding domain of a monovalent antibody comprises an scFv. In some embodiments, the antigen-binding domain of a monovalent antibody comprises a single VH domain. In some embodiments, the antigen-binding domain of a monovalent antibody comprises a single VL domain. In some embodiments, the antigen-binding domain of a monovalent antibody comprises a protein domain specific for an antigen.
[0105] In some embodiments, the monovalent antibody comprises a Fab domain and an Fc domain, wherein the monovalent antibody comprises a heavy chain, a light chain and a polypeptide, wherein the heavy chain and light chain form a Fab, and the heavy chain and polypeptide form the Fc domain.
[0106] In some embodiments, a monovalent antibody comprises an scFv and an Fc domain, wherein the monovalent antibody comprises two polypeptides, a first polypeptide comprising an scFv at its N-terminus and a domain at its C-terminus that forms an Fc domain together with the second polypeptide.
[0107] In some embodiments, a monovalent antibody comprises a single VH domain and an Fc domain, wherein the monovalent antibody comprises two polypeptides, a first polypeptide comprising at its N-terminus a single VH domain and at its C-terminus a domain which, together with the second polypeptide, forms an Fc domain.
[0108] In some embodiments, a monovalent antibody comprises a single VL domain and an Fc domain, wherein the monovalent antibody comprises two polypeptides, a first polypeptide comprising at its N-terminus a single VL domain and at its C-terminus a domain which, together with the second polypeptide, forms an Fc domain.
[0109] In some embodiments, a monovalent antibody comprises an antigen-specific protein domain and an Fc domain, wherein the monovalent antibody comprises two polypeptides, a first polypeptide comprising at its N-terminus the antigen-specific protein domain and at its C-terminus a domain that, together with the second polypeptide, forms an Fc domain.
[0110] Hypofucosylation In another embodiment, the monovalent binding molecules provided herein do not comprise fucose in the oligosaccharides covalently attached to the Fc region of the binding molecule. In another embodiment, a population of monovalent binding molecules is provided herein, wherein less than 80% of the oligosaccharides covalently attached to the Fc region of the binding molecule comprise fucose.
[0111] Antibody glycosylation is a type of post-translational modification that can occur through the addition of oligosaccharides to antibodies via two types of covalent bonds: attachment to asparagine residues (N-oligosaccharides) or attachment to serine / threonine residues (O-oligosaccharides) (Alter, G., et al., Semin Immunol., 2018, 39:102-10), and has a profound impact on the therapeutic function of antibodies (Walsh, G. and Jefferis, R., Nat. Biotechnol., 2006, 24:1241-52; Jefferis, R., Nat. Rev. Drug Discov., 2009, 8(3):226-34; Dalziel, M., et al., Science, 2014, 343(6166):1235-681). In particular, all IgG antibodies are glycosylated at the conserved Asn-297 residue in their Fc region (Alter G., et al., supra).
[0112] The Asn-297-linked N-oligosaccharides consist of a conserved biantennary core structure (Liu, L., J Pharm Sci., 2015, 104(6):1866-84), which consists of two covalently linked N-acetylglucosamine (GlcNAc) residues, further linked to a mannose, which is linked to two other mannose residues in a 1,3- and 1,6-branched manner (Alter, G., et al., supra). Additional monosaccharides, including two galactoses, fucose, a bisecting GlcNAc, and two sialic acids (Alter, G., et al., supra), may extend the core structure, resulting in considerable structural and functional heterogeneity (Jefferis, R., Biochem J., 1990, 268(3):529-37; Rudd, P. M., Science, 2001, 291(5512):2370-6; Liu, L., supra). At least 30 structures (glycoforms) of the Asn-297-linked N-oligosaccharide of IgG have been reported (Alter, G., et al., supra).
[0113] Antibodies expressed in mammalian cells are typically greater than 80% fucosylated (Kamoda, S., et al., J. Chromatogr. A., 2004, 1050(2):211-6; Shinkawa, T., et al., J. Biol. Chem., 2003, 278(5):3466-73). For example, normal Chinese Hamster Ovary (CHO) cells and HEK293 cells add fucose to 80-98% of the Asn-297-linked N-oligosaccharides of IgG antibodies (Shields, R., et al., J. Biol. Chem., 2002, 277(30):26733-40).
[0114] In one aspect, provided herein is an antibody that does not have fucose in the oligosaccharides attached to its Fc region and that has RE mutations in the Fc region. In another aspect, provided herein is a population of antibodies comprising antibodies that do not have fucose in the oligosaccharides attached to their Fc region and that have RE mutations in the Fc region. In yet another aspect, provided herein is a population of antibodies, wherein less than 80% of the oligosaccharides covalently attached to the population of antibodies comprise fucose residues, and the Fc regions of these antibodies comprise K248E and T437R mutations (RE mutations).
[0115] In some embodiments, fewer than 70% of the oligosaccharides covalently attached to the population of antibodies comprise a fucose residue. In some embodiments, fewer than 60% of the oligosaccharides covalently attached to the population of antibodies comprise a fucose residue. In some embodiments, fewer than 50% of the oligosaccharides covalently attached to the population of antibodies comprise a fucose residue. In some embodiments, fewer than 40% of the oligosaccharides covalently attached to the population of antibodies comprise a fucose residue. In still other embodiments, fewer than 30% of the oligosaccharides covalently attached to the population of antibodies comprise a fucose residue. In still other embodiments, fewer than 20% of the oligosaccharides covalently attached to the population of antibodies comprise a fucose residue. In still other embodiments, fewer than 10% of the oligosaccharides covalently attached to the population of antibodies comprise a fucose residue.
[0116] Standard techniques known to those skilled in the art, such as mass spectrometry, can be used to characterize the Asn297-linked N-oligosaccharides on antibodies (Pereira, N.A., et al., supra; Shields, R.L. et al., supra). For example, for matrix-assisted laser desorption / ionization time-of-flight mass spectrometry (MALDI-TOF-MS) analysis, 50 mg of IgG antibody was immobilized on a polyvinylidene difluoride membrane in a MultiScreen 96-well IP plate (Millipore). The protein was then reduced using 50 mL of a 0.1 M solution of DTT in RCM buffer (pH 8.6, 3.2 mM EDTA, 360 mM Tris, and 8 M urea). To carboxymethylate the free sulfhydryl groups resulting from the reduction step, the antibody was then incubated in the dark at 25°C for 30 minutes in RCM buffer containing 0.1 M iodoacetic acid. The membrane-bound proteins were then incubated in a 1% aqueous solution of polyvinylpyrrolidone 360 (Sigma) for 1 hour at 25°C, and their oligosaccharides were cleaved from the proteins by a three-step process: incubation in pH 8.4 acetate-Tris buffer (25 mL) containing 32 units of peptide:N-glycosidase F (New England Biolabs, Beverly, MA) for 3 hours at 37°C, addition of 1.5 M acetic acid (2.5 mL) to lower the pH, and incubation at 25°C for 3 hours (Shields, R. Let al., J. Biol. Chem., 2001, 276(9):6591-604).
[0117] In some embodiments, the antibodies provided herein are produced by expressing a polynucleotide encoding the antibody or fragment thereof in a host cell that is deficient in adding fucose to the oligosaccharides attached to the antibody.
[0118] In mammalian cells, FUT8 encodes the sole enzyme, α-1,6 fucosyltransferase, that catalyzes core fucosylation (the transfer of a GDP-fucose residue to the innermost GlcNAc via an α-1,6-linkage) (Imai-Nishiya, H., et al., BMC Biotechnol., 2007, 7:84). Oligosaccharide fucosylation requires intracellular GDP-fucose as a substrate, which is synthesized in the cytoplasm via de novo or salvage pathways. In the de novo pathway, GDP-mannose 4,6-dehydratase (GMD) mediates the synthesis of GDP-4-keto-6-deoxymannose (GKDM) from GDP-mannose, followed by GDP-keto-6-deoxymannose 3,5-epimerase, 4-reductase (FX) to produce GDP-fucose (Imai-Nishiya, H., et al., supra). Accordingly, cell lines lacking the GMD enzyme, such as CHO Lec13 cells, or reduced α-1,6 fucosyltransferase activity due to mutations in the FUT8 gene, have been shown to produce afucosylated antibodies (Pereira, N.A., et al., Mabs, 2018, 10(5):693-711). For example, antibodies with about 10% fucosylation (Shields, RR et al., supra) or less can be consistently produced in Lec13 cells (Shields, RR et al., supra; Kanda Y., Biotechnol Bioeng., 2006, 94(4):680-8), although increased fucosylation can occur when cells are cultured to confluence in static flasks (Pereira, NA, et al., supra).
[0119] Addition of a bisecting GlcNAc to the oligosaccharide core structure sterically hampers fucosylation (Alter, G., et al., supra). Accordingly, overexpression of β-1,4-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase (GnT-III), which catalyzes the addition of a bisecting GlcNAc to the innermost mannose, has been shown to significantly reduce Fc fucosylation (Pereira, N.A., et al., supra).
[0120] Furthermore, an inactivated Golgi GDP-fucose transporter (GFT) gene (Slc35c1) has been shown to produce afucosylated antibodies, for example, in CHO-gmt3 cells (Pereira, NA, et al., supra). Afucosylated antibodies can also be generated by using biochemical inhibitors of fucosylation, such as fucose analogs such as 2-fluorofucose and 5-alkynylfucose (Pereira, NA, et al., supra). GKDM, an intermediate in the fucose de novo synthesis pathway in mammalian cells, can be reduced to GDP-rhamnose by bacterial GDP-4-keto-6-deoxymannose reductase (RMD), thus bypassing the fucose biosynthetic pathway. Afucosylated antibodies can also be produced in cells in which bacterial RMD is heterologously expressed in the cytosol (Pereira, NA, et al., supra).
[0121] In some embodiments, the antibodies provided herein are produced by expressing the antibody in a host cell that is deficient in any of the above enzymes. In some embodiments, the host cell has reduced GDP-mannose 4,6-dehydratase (GMD) activity. In some embodiments, the host cell has reduced α-1,6 fucosyltransferase activity.
[0122] ADCC, CDC, and ADCP effector functions The antibodies or populations of antibodies provided herein have enhanced ADCC activity, enhanced CDC activity, and / or enhanced ADCP activity.
[0123] Therapeutic antibodies bind to Fc receptors on the cell surface of effector cells such as NK cells, macrophages, monocytes, neutrophils, and eosinophils (Saunder, KO, Front Immunol., 2019, 10:1296), resulting in important antibody-dependent effector functions such as ADCC and ADCP. The family of receptors in the Fc region of IgG is called Fcγ receptors (FcγR) (Cohen-Solal, JF, Immunol Lett., 2004, 92(3):199-205), and consists of FcγRI; FcγRII, which includes the isoforms FcγRIIa, FcγRIIb, and FcγRIIc; and FcγRIII, which includes the isoforms FcγRIIIa and FcγRIIIb (Jefferis, R. and Lund, J., Immunol Lett., 2002, 82(1-2):57-65).
[0124] Among various effector functions, ADCC and ADCP have been shown to have clinically significant antitumor effects. For example, ADCC has been shown to be a key mechanism of trastuzumab's antitumor efficacy in vitro, as evidenced by the ability of NK cells to kill trastuzumab-coated tumor cells via an FcγRIII receptor (CD16)-mediated ADCC mechanism (Cooley, S., et al., Exp Hematol., 1999;27(10):1533-41; Carson, W. E., et al., Eur J Immunol., 2001,31(10):3016-3025; Kubo, M., et al., Anticancer Res., 2003,23(6a):4443-9), and in vivo, as evidenced by increased numbers of NK cells in tumor infiltrates after trastuzumab treatment (Clynes, R. A., et al., Nat Med., 2000,6(4):443-6; Arnould, L., et al., Br J Cancer, 2006, 94(2):259-67). In addition, macrophage-mediated ADCP has been shown to be important in the antitumor effect of trastuzumab (Shi, Y., et al., J Immunol., 2015, 194(9):4379-86).
[0125] Non- or hypofucosylated antibodies showed dramatically enhanced ADCC activity due to their enhanced binding ability to FcγRIIIa without detectable changes in CDC or antigen binding ability (Okazaki, A., et al., J Mol Biol., 2004, 336(5):1239-49; Kanda, Y., et al., Glycobiology, 2007, 17(1):104-18). N-oligosaccharides in the antibody Fc region are essential for binding to FcγR, which is involved in the effector function of antibodies (Yamane-Ohnuki, N. and Satoh, M., Mabs, 2009, 1(3):230-6).
[0126] The absence of fucose on the N-oligosaccharides of antibody Fc regions has been shown to dramatically enhance the binding ability of antibodies to the FcγRIIIa receptor present on immune effector cells such as NK cells and macrophages, resulting in antitumor therapeutic effects (Pereira, N.A., et al., supra). The FcγRIIIa receptor binds to the Fc region through interactions with the hinge region and CH2 domain of Fc (Radaev, S., et al., J. Biol. Chem., 2001, 276:16469-77; Sondermann, P., et al., Nature, 2000, 406:267-73). Therefore, the absence of fucose eliminates steric hindrance, enhancing Fc-FcγRIIIa interaction and enhancing effector function (Pereira, N.A., et al., supra).
[0127] CDC is another important antibody effector function. In the antibody-dependent classical complement activation pathway, binding between the complement C1q heterohexameric headpiece and oligomeric antibody complexes initiates the complement cascade of proteins (Wang, G. et al., Mol Cell, 2016, 63:135-45; Diebolder, CA et al., Science, 2014, 343:1260-3), which leads to opsonization of target cells with C3-derived opsonins (e.g., C3b) and the generation of potent inflammatory mediators (C3a and C5a), ultimately resulting in the formation of the membrane attack complex (MAC) (C5b-C9) on the target cell membrane (Reis, ES, et al., Nat Rev Immunol., 2018, 18:5-18). CDC has also been shown to have clinically significant antitumor effects in the anti-CD20 mAb rituximab and the anti-CD38 mAb daratumumab (de Weers, M., et al., J Immunol., 2011, 186:1840-8; Lokhorst, HM, et al., N Engl J Med., 2015, 373:1207-19; Taylor, RP and Lindorfer, MA, Semin Immunol., 2016, 28:309-16).
[0128] Mutations in the Fc region that promote antibody oligomerization, such as the RE mutation and E345R (EU numbering), have been demonstrated to significantly enhance the CDC activity of antibodies (Diebolder, CA et al., supra; Zhang, D., et al., supra).
[0129] Monovalent antibodies allow more Fc regions to be presented to the surface of a cell with a given number of receptors compared to natural bivalent IgG, and therefore engineered monovalent antibodies have stronger CDC activity than their natural bivalent counterparts.
[0130] In some embodiments, the ADCC activity of the antibody is 10% higher than that of an antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is 20% higher than that of an antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is 30% higher than that of an antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is 40% higher than that of an antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is 50% higher than that of an antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is 60% higher than that of an antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is 70% higher than that of an antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is 80% higher than that of an antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is 90% higher than that of an antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is more than twice that of an antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is more than three-fold greater than that of an antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is more than four-fold greater than that of an antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is more than five-fold greater than that of an antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is more than six-fold greater than that of an antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is more than seven-fold greater than that of an antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is more than eight-fold greater than that of an antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is more than nine-fold greater than that of an antibody with normal fucosylation. In some embodiments, the ADCC activity of the antibody is more than ten-fold greater than that of an antibody with normal fucosylation.
[0131] In some embodiments, the above antibodies also have higher CDC activity. In some embodiments, the CDC activity of the antibody is 10% higher than that of an antibody without a RE mutation. In some embodiments, the CDC activity of the antibody is 20% higher than that of an antibody without a RE mutation. In some embodiments, the CDC activity of the antibody is 30% higher than that of an antibody without a RE mutation. In some embodiments, the CDC activity of the antibody is 40% higher than that of an antibody without a RE mutation. In some embodiments, the CDC activity of the antibody is 50% higher than that of an antibody without a RE mutation. In some embodiments, the CDC activity of the antibody is 60% higher than that of an antibody without a RE mutation. In some embodiments, the CDC activity of the antibody is 70% higher than that of an antibody without a RE mutation. In some embodiments, the CDC activity of the antibody is 80% higher than that of an antibody without a RE mutation. In some embodiments, the CDC activity of the antibody is 90% higher than that of an antibody without a RE mutation. In some embodiments, the CDC activity of the antibody is more than twice that of an antibody without a RE mutation. In some embodiments, the CDC activity of the antibody is more than three-fold greater than that of an antibody without a RE mutation. In some embodiments, the CDC activity of the antibody is more than four-fold greater than that of an antibody without a RE mutation. In some embodiments, the CDC activity of the antibody is more than five-fold greater than that of an antibody without a RE mutation. In some embodiments, the CDC activity of the antibody is more than six-fold greater than that of an antibody without a RE mutation. In some embodiments, the CDC activity of the antibody is more than seven-fold greater than that of an antibody without a RE mutation. In some embodiments, the CDC activity of the antibody is more than eight-fold greater than that of an antibody without a RE mutation. In some embodiments, the CDC activity of the antibody is more than nine-fold greater than that of an antibody without a RE mutation. In some embodiments, the CDC activity of the antibody is more than ten-fold greater than that of an antibody without a RE mutation.
[0132] In some embodiments, the antibodies also have higher CDC activity. In some embodiments, the CDC activity of the antibody is 10% higher than the antibody without a monovalent format. In some embodiments, the CDC activity of the antibody is 20% higher than the antibody without a monovalent format. In some embodiments, the CDC activity of the antibody is 30% higher than the antibody without a monovalent format. In some embodiments, the CDC activity of the antibody is 40% higher than the antibody without a monovalent format. In some embodiments, the CDC activity of the antibody is 50% higher than the antibody without a monovalent format. In some embodiments, the CDC activity of the antibody is 60% higher than the antibody without a monovalent format. In some embodiments, the CDC activity of the antibody is 70% higher than the antibody without a monovalent format. In some embodiments, the CDC activity of the antibody is 80% higher than the antibody without a monovalent format. In some embodiments, the CDC activity of the antibody is 90% higher than the antibody without a monovalent format. In some embodiments, the CDC activity of the antibody is more than twice the CDC activity of the antibody without a monovalent format. In some embodiments, the CDC activity of the antibody is more than three-fold greater than the CDC activity of the antibody without monovalent formatting. In some embodiments, the CDC activity of the antibody is more than four-fold greater than the CDC activity of the antibody without monovalent formatting. In some embodiments, the CDC activity of the antibody is more than five-fold greater than the CDC activity of the antibody without monovalent formatting. In some embodiments, the CDC activity of the antibody is more than six-fold greater than the CDC activity of the antibody without monovalent formatting. In some embodiments, the CDC activity of the antibody is more than seven-fold greater than the CDC activity of the antibody without monovalent formatting. In some embodiments, the CDC activity of the antibody is more than eight-fold greater than the CDC activity of the antibody without monovalent formatting. In some embodiments, the CDC activity of the antibody is more than nine-fold greater than the CDC activity of the antibody without monovalent formatting. In some embodiments, the CDC activity of the antibody is more than ten-fold greater than the CDC activity of the antibody without monovalent formatting.
[0133] Exemplary Monovalent Antibodies In one aspect, provided herein are monovalent antibodies derived from traditional bivalent antibodies.
[0134] In yet another aspect, provided herein are monovalent antibodies that compete with one of the known monovalent antibodies. Such monovalent antibodies may bind to the same epitope as one of the known monovalent antibodies, or to an overlapping epitope. Antibodies that compete with or bind to the same epitope are expected to exhibit similar functional properties.
[0135] In certain embodiments, the monovalent antibodies described herein comprise an amino acid sequence having a particular percent identity to one of the known monovalent antibodies or exemplary monovalent antibodies described in Section 7 below.
[0136] The determination of percent identity between two sequences (e.g., amino acid sequences or nucleic acid sequences) can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for comparing two sequences is the algorithm of Karlin and Altschul, Proc. Natl. Acad. Sci. USA, 1990, 87:2264-8, modified as in Karlin and Altschul, Proc. Natl. Acad. Sci. USA, 1993, 90:5873-7. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al., J. Mol. Biol., 1990, 215:403. BLAST nucleotide searches can be performed with the NBLAST nucleotide program parameters set, for example, to score=100 and word length=12 to obtain nucleotide sequences homologous to the nucleic acid molecules described herein. BLAST protein searches can be performed with the XBLAST program parameters set, for example, to score 50 and word length = 3, to obtain amino acid sequences homologous to the protein molecules described herein. To obtain gapped alignments for comparison purposes, GappedBLAST can be utilized as described in Altschul et al., Nucleic Acids Res., 1997, 25:3389-402. Alternatively, PSI BLAST can be used to perform an iterated search that detects distant relationships between molecules (ibid.). When utilizing BLAST, Gapped BLAST, and PSI Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used (see, e.g., the National Center for Biotechnology Information (NCBI) on the World Wide Web at ncbi.nlm.nih.gov). Another preferred, non-limiting example of a mathematical algorithm utilized for sequence comparison is the algorithm of Myers and Miller, 1988, CABIOS 4:11 17.Such an algorithm is incorporated into the ALIGN program (version 2.0), which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.
[0137] The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, typically only exact matches are counted.
[0138] In certain embodiments, provided herein are monovalent antibodies comprising an Fc region having RE mutations but no fucose residues.
[0139] Standard techniques known to those skilled in the art can be used to introduce mutations into the nucleotide sequences encoding the monovalents provided herein, including, for example, site-directed mutagenesis and PCR-mediated mutagenesis resulting in amino acid substitutions.
[0140] In some embodiments, a glutamic acid is substituted for lysine at position 248 of the Fc region of a monovalent antibody provided herein (K248E) (EU numbering). In some embodiments, a glutamic acid is substituted for alanine at position 338 of the Fc region of a monovalent antibody provided herein (K338A) (EU numbering). In some embodiments, an arginine is substituted for threonine at position 437 of the Fc region of a monovalent antibody provided herein (T437R) (EU numbering). In some embodiments, a glutamic acid is substituted for lysine at position 248 and an arginine is substituted for threonine at position 437 of the Fc region of a monovalent antibody provided herein (K248E / T437R) (EU numbering). In some embodiments, the Fc region of the monovalent antibody provided herein has a glutamic acid to alanine substitution at position 338 and an arginine to threonine substitution at position 437 (K248E / T437R) (EU numbering).
[0141] In some embodiments, the monovalent antibodies provided herein comprise a heavy chain comprising a T437R mutation. In some embodiments, the monovalent antibodies provided herein comprise a heavy chain comprising a K248E mutation. In some embodiments, the monovalent antibodies provided herein comprise a heavy chain comprising a K338A mutation. In some embodiments, the monovalent antibodies provided herein comprise a heavy chain comprising a K248E / T437R mutation. In some embodiments, the monovalent antibodies provided herein comprise a heavy chain comprising a K338A / T437R mutation.
[0142] Standard techniques known to those of skill in the art can be used to generate monovalent antibodies provided herein having heavy chains that do not contain a fucose residue in their Asn-297 linked N-oligosaccharide. For example, mammalian cell lines that are deficient in GMD enzymes (e.g., CHO Lec13 cells), have reduced α-1,6 fucosyltransferase activity due to a mutated FUT8 gene, overexpress β-1,4-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase (GnT-III), have an inactivated Golgi GDP-fucose transporter (GFT) gene Slc35c1 (e.g., CHO-gmt3 cells), heterologously express bacterial RMDs, or use biochemical inhibitors of fucosylation (e.g., fucose analogs such as 2-fluorofucose and 5-alkynylfucose) have been shown to produce antibodies that lack a fucose residue in the Asn-297-linked N-oligosaccharide on the heavy chain (Pereira, N.A., et al., supra; Shields, R.L. et al., supra; Kanda Y., supra).
[0143] In some embodiments, the monovalent antibody comprises a heavy chain that does not contain a fucose residue on its Asn-297 linked N-oligosaccharide.
[0144] For example, antibodies can be formatted as monovalent antibodies using standard techniques known to those of skill in the art, including in vitro expression of recombinant protein.
[0145] In some embodiments, a monovalent antibody comprises one antigen-binding arm of unknown specificity and another antigen-binding arm that is specific for a target of interest.
[0146] In some embodiments, the antigen-binding domain of a monovalent antibody comprises a VH region and / or a VL region. In some embodiments, the antigen-binding domain of a monovalent antibody comprises a Fab fragment. In some embodiments, the antigen-binding domain of a monovalent antibody comprises an scFv. In some embodiments, the antigen-binding domain of a monovalent antibody comprises a single VH domain. In some embodiments, the antigen-binding domain of a monovalent antibody comprises a single VL domain. In some embodiments, the antigen-binding domain of a monovalent antibody comprises a protein domain specific for an antigen.
[0147] In some embodiments, the monovalent antibody comprises a Fab domain and an Fc domain, wherein the monovalent antibody comprises a heavy chain, a light chain and a polypeptide, wherein the heavy chain and light chain form a Fab, and the heavy chain and polypeptide form the Fc domain.
[0148] In some embodiments, a monovalent antibody comprises an scFv and an Fc domain, wherein the monovalent antibody comprises two polypeptides, a first polypeptide comprising an scFv at its N-terminus and a domain at its C-terminus that forms an Fc domain together with the second polypeptide.
[0149] In some embodiments, a monovalent antibody comprises a single VH domain and an Fc domain, wherein the monovalent antibody comprises two polypeptides, a first polypeptide comprising at its N-terminus a single VH domain and at its C-terminus a domain which, together with the second polypeptide, forms an Fc domain.
[0150] In some embodiments, a monovalent antibody comprises a single VL domain and an Fc domain, wherein the monovalent antibody comprises two polypeptides, a first polypeptide comprising at its N-terminus a single VL domain and at its C-terminus a domain which, together with the second polypeptide, forms an Fc domain.
[0151] In some embodiments, a monovalent antibody comprises an antigen-specific protein domain and an Fc domain, wherein the monovalent antibody comprises two polypeptides, a first polypeptide comprising at its N-terminus the antigen-specific protein domain and at its C-terminus a domain that, together with the second polypeptide, forms an Fc domain.
[0152] In some embodiments, one antigen bound by a monovalent antibody is an antigen on the surface of a target cell, such as a cancer cell, hi some embodiments, the antigen is a tumor-specific antigen, a tumor-associated antigen, or a neoantigen.
[0153] In some embodiments, the cancer cells are cells of adrenal gland cancer, anal cancer, appendix cancer, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gallbladder cancer, gestational trophoblastic, head and neck cancer, Hodgkin's lymphoma, intestinal cancer, kidney cancer, leukemia, liver cancer, lung cancer, melanoma, mesothelioma, multiple myeloma, neuroendocrine tumors, non-Hodgkin's lymphoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, sinus cancer, skin cancer, soft tissue sarcoma spinal cancer, stomach cancer, testicular cancer, pharyngeal cancer, thyroid cancer, uterine cancer, endometrial cancer, vaginal cancer, or vulvar cancer. In some embodiments, the cancer is adrenal gland cancer, anal cancer, appendix cancer, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gallbladder cancer, gestational trophoblastic cancer, head and neck cancer, Hodgkin's lymphoma, intestinal cancer, kidney cancer, leukemia, liver cancer, lung cancer, melanoma, mesothelioma, multiple myeloma, neuroendocrine tumors, non-Hodgkin's lymphoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, sinus cancer, skin cancer, soft tissue sarcoma, spinal cancer, stomach cancer, testicular cancer, pharyngeal cancer, thyroid cancer, uterine cancer, endometrial cancer, vaginal cancer, or vulvar cancer. In some embodiments, the cancer is adrenal gland cancer. In some embodiments, the cancer is anal cancer. In some embodiments, the cancer is appendix cancer. In some embodiments, the cancer is bile duct cancer. In some embodiments, the cancer is bladder cancer. In some embodiments, the cancer is bone cancer. In some embodiments, the cancer is brain cancer. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is cervical cancer. In some embodiments, the cancer is colorectal cancer. In some embodiments, the cancer is esophageal cancer. In some embodiments, the cancer is gallbladder cancer. In some embodiments, the cancer is gestational trophoblastic cancer. In some embodiments, the cancer is head and neck cancer. In some embodiments, the cancer is Hodgkin's lymphoma. In some embodiments, the cancer is intestinal cancer. In some embodiments, the cancer is kidney cancer. In some embodiments, the cancer is leukemia. In some embodiments, the cancer is liver cancer. In some embodiments, the cancer is lung cancer. In some embodiments, the cancer is melanoma. In some embodiments, the cancer is mesothelioma. In some embodiments, the cancer is multiple myeloma. In some embodiments, the cancer is a neuroendocrine tumor. In some embodiments, the cancer is non-Hodgkin's lymphoma.In some embodiments, the cancer is oral cancer. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is sinus cancer. In some embodiments, the cancer is skin cancer. In some embodiments, the cancer is soft tissue sarcoma, spinal cancer. In some embodiments, the cancer is gastric cancer. In some embodiments, the cancer is testicular cancer. In some embodiments, the cancer is pharyngeal cancer. In some embodiments, the cancer is thyroid cancer. In some embodiments, the cancer is uterine cancer, endometrial cancer. In some embodiments, the cancer is vaginal cancer. In some embodiments, the cancer is vulvar cancer.
[0154] In some embodiments, the adrenal cancer is adrenocortical carcinoma (ACC), adrenocortical carcinoma, pheochromocytoma, or neuroblastoma. In some embodiments, the anal cancer is squamous cell carcinoma, cloacal carcinoma, adenocarcinoma, basal cell carcinoma, or melanoma. In some embodiments, the appendix cancer is neuroendocrine tumor (NET), mucinous adenocarcinoma, goblet cell carcinoid, intestinal adenocarcinoma, or signet ring cell adenocarcinoma. In some embodiments, the cholangiocarcinoma is extrahepatic cholangiocarcinoma, adenocarcinoma, perihilar cholangiocarcinoma, perihilar cholangiocarcinoma, distal cholangiocarcinoma, or intrahepatic cholangiocarcinoma. In some embodiments, the bladder cancer is transitional cell carcinoma (TCC), papillary carcinoma, squamous carcinoma, squamous cell carcinoma, adenocarcinoma, small cell carcinoma, or sarcoma. In some embodiments, the bone cancer is primary bone cancer, sarcoma, osteosarcoma, chondrosarcoma, sarcoma, fibrosarcoma, malignant fibrous histiocytoma, giant cell tumor of bone, chordoma, or metastatic bone cancer. In some embodiments, the brain cancer is astrocytoma, brain stem glioma, glioblastoma, meningioma, ependymoma, oligodendroglioma, mixed glioma, pituitary carcinoma, pituitary adenoma, craniopharyngioma, germ cell tumor, pineal region tumor, medulloblastoma, or primary CNS lymphoma. In some embodiments, the breast cancer is breast adenocarcinoma, invasive breast cancer, non-invasive breast cancer, breast sarcoma, metaplastic carcinoma, adenocystic carcinoma, phyllodes tumor, angiosarcoma, HER2-positive breast cancer, triple-negative breast cancer, or inflammatory breast cancer. In some embodiments, the cervical cancer is squamous cell carcinoma or adenocarcinoma. In some embodiments, the colorectal cancer is colorectal adenocarcinoma, primary colorectal lymphoma, gastrointestinal stromal tumor, leiomyosarcoma, carcinoid tumor, mucinous adenocarcinoma, signet ring cell adenocarcinoma, gastrointestinal carcinoid tumor, or melanoma. In some embodiments, the esophageal cancer is an adenocarcinoma or squamous cell carcinoma. In some embodiments, the gallbladder cancer is an adenocarcinoma, papillary adenocarcinoma, adenosquamous carcinoma, squamous cell carcinoma, small cell carcinoma, or sarcoma. In some embodiments, the gestational trophoblastic disease (GTD) is hydatidiform mole, gestational trophoblastic neoplasm (GTN), choriocarcinoma, placental site trophoblastic tumor (PSTT), or epithelioid trophoblastic tumor (ETT). In some embodiments, the head and neck cancer is laryngeal cancer, nasopharyngeal cancer, hypopharyngeal cancer, nasal cavity cancer, paranasal sinus cancer, salivary gland cancer, oral cavity cancer, oropharynx cancer, or tonsil cancer.In some embodiments, the Hodgkin's lymphoma is classical Hodgkin's lymphoma, nodular sclerosing, mixed cytology, lymphocyte-rich, lymphocyte-reduced, or nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL). In some embodiments, the intestinal cancer is small intestine cancer, small bowel cancer, adenocarcinoma, sarcoma, gastrointestinal stromal tumor, carcinoid tumor, or lymphoma. In some embodiments, the kidney cancer is renal cell carcinoma (RCC), clear cell RCC, papillary RCC, chromophobe RCC, collecting duct RCC, unclassified RCC, transitional cell carcinoma, urothelial carcinoma, renal pelvic carcinoma, or renal sarcoma. In some embodiments, the leukemia is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), hairy cell leukemia (HCL), or myelodysplastic syndrome (MDS). In particular embodiments, the leukemia is AML. In some embodiments, the liver cancer is hepatocellular carcinoma (HCC), fibrolamellar HCC, cholangiocarcinoma, angiosarcoma, or liver metastasis. In some embodiments, the lung cancer is small cell lung cancer, small cell carcinoma, hybrid small cell carcinoma, non-small cell lung cancer, lung adenocarcinoma, squamous cell lung carcinoma, large cell undifferentiated carcinoma, lung nodule, metastatic lung cancer, adenosquamous carcinoma, large cell neuroendocrine carcinoma, salivary gland lung carcinoma, lung carcinoid, mesothelioma, sarcomatoid carcinoma of the lung, or malignant granular cell lung tumor. In some embodiments, the melanoma is superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, lentigo maligna melanoma, amelanotic melanoma, desmoplastic melanoma, ocular melanoma, or metastatic melanoma. In some embodiments, the mesothelioma is pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma, or testicular mesothelioma. In some embodiments, the multiple myeloma is active or smoldering multiple myeloma. In some embodiments, the neuroendocrine tumor is a gastrointestinal neuroendocrine tumor, a pancreatic neuroendocrine tumor, or a pulmonary neuroendocrine tumor.In some embodiments, the non-Hodgkin's lymphoma is selected from the group consisting of anaplastic large cell lymphoma, lymphoblastic lymphoma, peripheral T-cell lymphoma, follicular lymphoma, cutaneous T-cell lymphoma, lymphoplasmacytic lymphoma, marginal zone B-cell lymphoma, MALT lymphoma, small cell lymphocytic lymphoma, Burkitt's lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), precursor T-lymphoblastic leukemia / lymphoma, acute lymphocytic leukemia (ALL), adult T-cell lymphoma / leukemia (ATLL), hairy cell leukemia, B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, primary central nervous system leukemia, and / or primary thyroid cancer. Central nervous system (CNS) lymphoma, mantle cell lymphoma (MCL), marginal zone lymphoma, mucosa-associated lymphoid tissue (MALT) lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma, lymphoplasmacytic lymphoma, B-cell non-Hodgkin's lymphoma, T-cell non-Hodgkin's lymphoma, natural killer cell lymphoma, cutaneous T-cell lymphoma, Alibert-Bazin syndrome, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), systemic ALCL, enteropathic T-cell lymphoma (EATL), or hepatosplenic gamma / delta T-cell lymphoma. In some embodiments, the oral cancer is squamous cell carcinoma, verrucous carcinoma, minor salivary gland carcinoma, lymphoma, benign oral tumor, eosinophilic granuloma, fibroma, granular cell tumor, keratoacanthoma, leiomyoma, osteochondroma, lipoma, schwannoma, neurofibroma, papilloma, condyloma acuminata, verrucous xanthomas, pyogenic granuloma, rhabdomyoma, odontogenic tumor, leukoplakia, erythroplakia, squamous cell lip carcinoma, basal cell lip carcinoma, mouth cancer, gum cancer, or tongue cancer. In some embodiments, the ovarian cancer is ovarian epithelial cancer, mucinous epithelial ovarian cancer, endometrioid epithelial ovarian cancer, clear cell epithelial ovarian cancer, undifferentiated epithelial ovarian cancer, ovarian low malignant potential tumor, primary peritoneal carcinoma, fallopian tube carcinoma, germ cell tumor, teratoma, undifferentiated ovarian germ cell carcinoma, endodermal sinus tumor, sex cord-stromal tumor, sex cord-gonadal stromal tumor, ovarian stromal tumor, granulosa cell tumor, granulosa theca tumor, Sertoli-Leydig tumor, ovarian sarcoma, ovarian carcinosarcoma, ovarian adenosarcoma, ovarian leiomyosarcoma, ovarian fibrosarcoma, Krukenberg tumor, or ovarian cyst.In some embodiments, the pancreatic cancer is exocrine pancreatic cancer, endocrine pancreatic cancer, or pancreatic adenocarcinoma, islet cell tumor, or neuroendocrine tumor. In some embodiments, the prostate cancer is prostate adenocarcinoma, prostatic sarcoma, transitional cell carcinoma, small cell carcinoma, or neuroendocrine tumor. In some embodiments, the sinus cancer is squamous cell carcinoma, mucosal cell carcinoma, adenoid cystic cell carcinoma, acinar cell carcinoma, undifferentiated carcinoma of the paranasal sinus, nasal cavity carcinoma, paranasal sinus carcinoma, maxillary sinus carcinoma, ethmoid sinus carcinoma, or nasopharyngeal carcinoma. In some embodiments, the skin cancer is basal cell carcinoma, squamous cell carcinoma, melanoma, Merkel cell carcinoma, Kaposi's sarcoma (KS), actinic keratosis, cutaneous lymphoma, or keratoacanthoma. In some embodiments, the soft tissue cancer is angiosarcoma, dermatofibrosarcoma, epithelial sarcoma, Ewing's sarcoma, fibrosarcoma, gastrointestinal stromal tumor (GIST), Kaposi's sarcoma, leiomyosarcoma, liposarcoma, dedifferentiated liposarcoma (DL), myxoid / round cell liposarcoma (MRCL), well-differentiated liposarcoma (WDL), malignant fibrous histiocytoma, neurofibrosarcoma, rhabdomyosarcoma (RMS), or synovial sarcoma. In some embodiments, the spinal cancer is a spinal metastatic tumor. In some embodiments, the gastric cancer is gastric adenocarcinoma, gastric lymphoma, gastrointestinal stromal tumor, carcinoid tumor, gastric carcinoid tumor, type I ECL-cell carcinoid, type II ECL-cell carcinoid, or type III ECL-cell carcinoid. In some embodiments, the testicular cancer is seminoma, nonseminoma, embryonal carcinoma, yolk sac carcinoma, choriocarcinoma, teratoma, gonadal stromal tumor, Leydig cell tumor, or Sertoli cell tumor. In some embodiments, the pharyngeal cancer is squamous cell carcinoma, adenocarcinoma, sarcoma, laryngeal carcinoma, pharyngeal carcinoma, nasopharyngeal carcinoma, oropharyngeal carcinoma, hypopharyngeal carcinoma, laryngeal squamous cell carcinoma, laryngeal adenocarcinoma, lymphoepithelioma, spindle cell carcinoma, verrucous carcinoma, undifferentiated carcinoma, or lymph node carcinoma. In some embodiments, the thyroid cancer is papillary carcinoma, follicular carcinoma, Hurthle cell carcinoma, medullary thyroid carcinoma, or undifferentiated carcinoma. In some embodiments, the uterine cancer is endometrial carcinoma, endometrial adenocarcinoma, endometrioid carcinoma, serous adenocarcinoma, adenosquamous carcinoma, uterine carcinosarcoma, uterine sarcoma, uterine leiomyosarcoma, endometrial stromal sarcoma, or undifferentiated sarcoma. In some embodiments, the vaginal cancer is squamous cell carcinoma, adenocarcinoma, melanoma, or sarcoma. In some embodiments, the vulvar cancer is squamous cell carcinoma or adenocarcinoma.
[0155] In some embodiments, one antigen bound by the monovalent antibody is a cancer antigen. In some embodiments, the cancer antigen is angiopoietin, BCMA, CD19, CD20, CD22, CD25 (IL2-R), CD30, CD33, CD37, CD38, CD52, CD56, CD123 (IL-3R), cMET, DLL / Notch, EGFR, EpCAM, FGF, FGF-R, GD2, HER2, mesothelin, nectin-4, PDGFRα, RANKL, SLAMF7, TROP2, VEGF, or VEGF-R. In some embodiments, the cancer antigen is angiopoietin. In some embodiments, the cancer antigen is BCMA. In some embodiments, the cancer antigen is CD19. In some embodiments, the cancer antigen is CD20. In some embodiments, the cancer antigen is CD22. In some embodiments, the cancer antigen is CD25 (IL2-R). In some embodiments, the cancer antigen is CD30. In some embodiments, the cancer antigen is CD33. In some embodiments, the cancer antigen is CD37. In some embodiments, the cancer antigen is CD38. In some embodiments, the cancer antigen is CD52. In some embodiments, the cancer antigen is CD56. In some embodiments, the cancer antigen is CD123 (IL-3R). In some embodiments, the cancer antigen is cMET. In some embodiments, the cancer antigen is DLL / Notch. In some embodiments, the cancer antigen is EGFR. In some embodiments, the cancer antigen is EpCAM. In some embodiments, the cancer antigen is FGF. In some embodiments, the cancer antigen is FGF-R. In some embodiments, the cancer antigen is GD2. In some embodiments, the cancer antigen is HER2. In some embodiments, the cancer antigen is mesothelin. In some embodiments, the cancer antigen is nectin-4. In some embodiments, the cancer antigen is PDGFRα. In some embodiments, the cancer antigen is RANKL. In some embodiments, the cancer antigen is SLAMF7. In some embodiments, the cancer antigen is TROP2. In some embodiments, the cancer antigen is VEGF. In some embodiments, the cancer antigen is VEGF-R.
[0156] In some embodiments, the cancer antigen is CEA, immature laminin receptor, TAG-72, HPV E6, HPV E7, BING-4, calcium-activated chloride channel 2, cyclin-B1, 9D7, EpCAM, EphA3, Her2 / neu, telomerase, mesothelin, SAP-1, survivin, BAGE family antigens, CAGE family antigens, GAGE family antigens, MAGE family antigens, SAGE family antigens, XAGE family antigens, NY-ESO-1 / LAGE-1, PRAME, SSX-2, Melan-A, MART-1, Gp100, pmel17, tyrosinase, TRP-1, TRP-2, P polypeptide, MC1R, prostate-specific antigen, β-catenin, BRCA1, BRCA2, CDK4, CML66, fibronectin, MART-2, p53, Ras, TGF-βRII, or MUC1. In some embodiments, the cancer antigen is CEA. In some embodiments, the cancer antigen is immature laminin receptor. In some embodiments, the cancer antigen is TAG-72. In some embodiments, the cancer antigen is HPV E6. In some embodiments, the cancer antigen is HPV E7. In some embodiments, the cancer antigen is BING-4. In some embodiments, the cancer antigen is calcium-activated chloride channel 2. In some embodiments, the cancer antigen is cyclin-B1. In some embodiments, the cancer antigen is 9D7. In some embodiments, the cancer antigen is EpCAM. In some embodiments, the cancer antigen is EphA3. In some embodiments, the cancer antigen is Her2 / neu. In some embodiments, the cancer antigen is telomerase. In some embodiments, the cancer antigen is mesothelin. In some embodiments, the cancer antigen is SAP-1. In some embodiments, the cancer antigen is survivin. In some embodiments, the cancer antigen is a BAGE family antigen. In some embodiments, the cancer antigen is a CAGE family antigen. In some embodiments, the cancer antigen is a GAGE family antigen. In some embodiments, the cancer antigen is a MAGE family antigen. In some embodiments, the cancer antigen is a SAGE family antigen.In some embodiments, the cancer antigen is an XAGE family antigen. In some embodiments, the cancer antigen is NY-ESO-1 / LAGE-1. In some embodiments, the cancer antigen is PRAME. In some embodiments, the cancer antigen is SSX-2. In some embodiments, the cancer antigen is Melan-A. In some embodiments, the cancer antigen is MART-1. In some embodiments, the cancer antigen is Gp100. In some embodiments, the cancer antigen is pmel17. In some embodiments, the cancer antigen is tyrosinase. In some embodiments, the cancer antigen is TRP-1. In some embodiments, the cancer antigen is TRP-2. In some embodiments, the cancer antigen is P. polypeptide. In some embodiments, the cancer antigen is MC1R. In some embodiments, the cancer antigen is prostate-specific antigen. In some embodiments, the cancer antigen is β-catenin. In some embodiments, the cancer antigen is BRCA1. In some embodiments, the cancer antigen is BRCA2. In some embodiments, the cancer antigen is CDK4. In some embodiments, the cancer antigen is CML66. In some embodiments, the cancer antigen is fibronectin. In some embodiments, the cancer antigen is MART-2. In some embodiments, the cancer antigen is p53. In some embodiments, the cancer antigen is Ras. In some embodiments, the cancer antigen is TGF-βRII. In some embodiments, the cancer antigen is MUC1.
[0157] In some embodiments, the monovalent antibody binds to a B cell antigen. In some embodiments, the B cell antigen is CD1a, CD1b, CD1c, CD1d, CD2, CD5, CD6, CD9, CD11a, CD11b, CD11c, CD17, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD29, CD30, CD31, CD32a, CD32b, CD35, CD37, CD38, CD39, CD40, CD45, CD45RA, CD45RB ... D45RC, CD45RO, CD46, CD47, CD48, CD49b, CD49c, CD49d, CD50, CD52, CD53, CD54, CD55, CD58, CD60a, CD62L, CD63, CD68, CD 69, CD70, CD72, CD73, CD74, CD75, CD75S, CD77, CD79a, CD79b, CD80, CD81, CD82, CD83, CD84, CD85E, CD85I, CD85J, CD86, CD 92, CD95, CD97, CD98, CD99, CD100, CD102, CD108, CD119, CD120a, CD120b, CD121b, CD122, CD124, CD125, CD126, CD130, CD 132, CD137, CD138, CD139, CD147, CD148, CD150, CD152, CD162, CD164, CD166, CD167a, CD170, CD171, CD175, CD175s, CD180 , CD184, CD185, CD192, CD196, CD197, CD200, CD205, CD201a, CDw210b, CD212, CD213a1, CD213a2, CD215, CD217, CD218a, C D218b, CD220, CD221, CD222, CD224, CD225, CD226, CD227, CD229, CD230, CD232, CD252, CD252, CD254, CD255, CD256, CD257 CD258, CD259, CD260, CD261, CD262, CD263, CD264, CD267, CD268, CD269, CD270, CD272, CD274, CD27 5, CD277, CD279, CD283, CD289, CD290, CD295, CD298, CD300, CD300c, CD305, CD306, CD307a, CD307b,In some embodiments, the B cell antigen is a CD307c, CD307d, CD307e, CD314, CD215, CD316, CD317, CD319, CD321, CD327, CD328, CD329, CD338, CD351, CD352, CD353, CD354, CD355, CD356, CD357, CD358, CD360, CD361, CD362, or CD363 antigen. In some embodiments, the B cell antigen is a CD1a antigen. In some embodiments, the B cell antigen is a CD1b antigen. In some embodiments, the B cell antigen is a CD1c antigen. In some embodiments, the B cell antigen is a CD1d antigen. In some embodiments, the B cell antigen is a CD2 antigen. In some embodiments, the B cell antigen is a CD5 antigen. In some embodiments, the B cell antigen is a CD6 antigen. In some embodiments, the B cell antigen is a CD9 antigen. In some embodiments, the B cell antigen is a CD11a antigen. In some embodiments, the B cell antigen is a CD11b antigen. In some embodiments, the B cell antigen is a CD11c antigen. In some embodiments, the B cell antigen is a CD17 antigen. In some embodiments, the B cell antigen is a CD18 antigen. In some embodiments, the B cell antigen is a CD19 antigen. In some embodiments, the B cell antigen is a CD20 antigen. In some embodiments, the B cell antigen is a CD21 antigen. In some embodiments, the B cell antigen is a CD22 antigen. In some embodiments, the B cell antigen is a CD23 antigen. In some embodiments, the B cell antigen is a CD24 antigen. In some embodiments, the B cell antigen is a CD25 antigen. In some embodiments, the B cell antigen is a CD26 antigen. In some embodiments, the B cell antigen is a CD27 antigen. In some embodiments, the B cell antigen is a CD29 antigen. In some embodiments, the B cell antigen is a CD30 antigen. In some embodiments, the B cell antigen is a CD31 antigen. In some embodiments, the B cell antigen is CD32a antigen. In some embodiments, the B cell antigen is CD32b antigen. In some embodiments, the B cell antigen is CD35 antigen. In some embodiments, the B cell antigen isThe B cell antigen is a CD37 antigen. In some embodiments, the B cell antigen is a CD38 antigen. In some embodiments, the B cell antigen is a CD39 antigen. In some embodiments, the B cell antigen is a CD40 antigen. In some embodiments, the B cell antigen is a CD45 antigen. In some embodiments, the B cell antigen is a CD45RA antigen. In some embodiments, the B cell antigen is a CD45RB antigen. In some embodiments, the B cell antigen is a CD45RC antigen. In some embodiments, the B cell antigen is a CD45RO antigen. In some embodiments, the B cell antigen is a CD46 antigen. In some embodiments, the B cell antigen is a CD47 antigen. In some embodiments, the B cell antigen is a CD48 antigen. In some embodiments, the B cell antigen is a CD49b antigen. In some embodiments, the B cell antigen is a CD49c antigen. In some embodiments, the B cell antigen is a CD49d antigen. In some embodiments, the B cell antigen is a CD50 antigen. In some embodiments, the B cell antigen is a CD52 antigen. In some embodiments, the B cell antigen is a CD53 antigen. In some embodiments, the B cell antigen is a CD54 antigen. In some embodiments, the B cell antigen is a CD55 antigen. In some embodiments, the B cell antigen is a CD58 antigen. In some embodiments, the B cell antigen is a CD60a antigen. In some embodiments, the B cell antigen is a CD62L antigen. In some embodiments, the B cell antigen is a CD63 antigen. In some embodiments, the B cell antigen is a CD68 antigen. In some embodiments, the B cell antigen is a CD69 antigen. In some embodiments, the B cell antigen is a CD70 antigen. In some embodiments, the B cell antigen is a CD72 antigen. In some embodiments, the B cell antigen is a CD73 antigen. In some embodiments, the B cell antigen is a CD74 antigen. In some embodiments, the B cell antigen is a CD75 antigen. In some embodiments, the B cell antigen is a CD75S antigen. In some embodiments, the B cell antigen is a CD77 antigen. In some embodiments, the B cell antigen is a CD79a antigen. In some embodiments, the B cell antigen isIn some embodiments, the B cell antigen is a CD79b antigen. In some embodiments, the B cell antigen is a CD80 antigen. In some embodiments, the B cell antigen is a CD81 antigen. In some embodiments, the B cell antigen is a CD82 antigen. In some embodiments, the B cell antigen is a CD83 antigen. In some embodiments, the B cell antigen is a CD84 antigen. In some embodiments, the B cell antigen is a CD85E antigen. In some embodiments, the B cell antigen is a CD85I antigen. In some embodiments, the B cell antigen is a CD85J antigen. In some embodiments, the B cell antigen is a CD86 antigen. In some embodiments, the B cell antigen is a CD92 antigen. In some embodiments, the B cell antigen is a CD95 antigen. In some embodiments, the B cell antigen is a CD97 antigen. In some embodiments, the B cell antigen is a CD98 antigen. In some embodiments, the B cell antigen is a CD99 antigen. In some embodiments, the B cell antigen is a CD100 antigen. In some embodiments, the B cell antigen is a CD102 antigen. In some embodiments, the B cell antigen is a CD108 antigen. In some embodiments, the B cell antigen is a CD119 antigen. In some embodiments, the B cell antigen is a CD120a antigen. In some embodiments, the B cell antigen is a CD120b antigen. In some embodiments, the B cell antigen is a CD121b antigen. In some embodiments, the B cell antigen is a CD122 antigen. In some embodiments, the B cell antigen is a CD124 antigen. In some embodiments, the B cell antigen is a CD125 antigen. In some embodiments, the B cell antigen is a CD126 antigen. In some embodiments, the B cell antigen is a CD130 antigen. In some embodiments, the B cell antigen is a CD132 antigen. In some embodiments, the B cell antigen is a CD137 antigen. In some embodiments, the B cell antigen is a CD138 antigen. In some embodiments, the B cell antigen is a CD139 antigen. In some embodiments, the B cell antigen is a CD147 antigen. In some embodiments, the B cell antigen is a CD148 antigen. In some embodiments, the B cell antigen isThe B cell antigen is a CD150 antigen. In some embodiments, the B cell antigen is a CD152 antigen. In some embodiments, the B cell antigen is a CD162 antigen. In some embodiments, the B cell antigen is a CD164 antigen. In some embodiments, the B cell antigen is a CD166 antigen. In some embodiments, the B cell antigen is a CD167a antigen. In some embodiments, the B cell antigen is a CD170 antigen. In some embodiments, the B cell antigen is a CD171 antigen. In some embodiments, the B cell antigen is a CD175 antigen. In some embodiments, the B cell antigen is a CD175s antigen. In some embodiments, the B cell antigen is a CD180 antigen. In some embodiments, the B cell antigen is a CD184 antigen. In some embodiments, the B cell antigen is a CD185 antigen. In some embodiments, the B cell antigen is a CD192 antigen. In some embodiments, the B cell antigen is a CD196 antigen. In some embodiments, the B cell antigen is a CD197 antigen. In some embodiments, the B cell antigen is a CD200 antigen. In some embodiments, the B cell antigen is a CD205 antigen. In some embodiments, the B cell antigen is a CD201a antigen. In some embodiments, the B cell antigen is a CDw210b antigen. In some embodiments, the B cell antigen is a CD212 antigen. In some embodiments, the B cell antigen is a CD213a1 antigen. In some embodiments, the B cell antigen is a CD213a2 antigen. In some embodiments, the B cell antigen is a CD215 antigen. In some embodiments, the B cell antigen is a CD217 antigen. In some embodiments, the B cell antigen is a CD218a antigen. In some embodiments, the B cell antigen is a CD218b antigen. In some embodiments, the B cell antigen is a CD220 antigen. In some embodiments, the B cell antigen is a CD221 antigen. In some embodiments, the B cell antigen is a CD222 antigen. In some embodiments, the B cell antigen is a CD224 antigen. In some embodiments, the B cell antigen is the CD225 antigen. In some embodiments, the B cell antigen is the CD226 antigen. In some embodiments, the B cell antigen isIn some embodiments, the B cell antigen is a CD227 antigen. In some embodiments, the B cell antigen is a CD229 antigen. In some embodiments, the B cell antigen is a CD230 antigen. In some embodiments, the B cell antigen is a CD232 antigen. In some embodiments, the B cell antigen is a CD252 antigen. In some embodiments, the B cell antigen is a The B cell antigen is a CD252 antigen. In some embodiments, the B cell antigen is a CD254 antigen. In some embodiments, the B cell antigen is a CD255 antigen. In some embodiments, the B cell antigen is a CD256 antigen. In some embodiments, the B cell antigen is a CD257 or CD258 antigen. In some embodiments, the B cell antigen is a CD259 antigen. In some embodiments, the B cell antigen is a CD260 antigen. In some embodiments, the B cell antigen is a CD261 antigen. In some embodiments, the B cell antigen is a CD262 antigen. In some embodiments, the B cell antigen is a CD263 antigen. In some embodiments, the B cell antigen is a CD264 antigen. In some embodiments, the B cell antigen is a CD267 antigen. In some embodiments, the B cell antigen is a CD268 antigen. In some embodiments, the B cell antigen is a CD269 antigen. In some embodiments, the B cell antigen is a CD270 antigen. In some embodiments, the B cell antigen is a CD272 antigen. In some embodiments, the B cell antigen is a CD274 antigen. In some embodiments, the B cell antigen is a CD275 antigen. In some embodiments, the B cell antigen is a CD277 antigen. In some embodiments, the B cell antigen is a CD279 antigen. In some embodiments, the B cell antigen is a CD283 antigen. In some embodiments, the B cell antigen is a CD289 antigen. In some embodiments, the B cell antigen is a CD290 antigen. In some embodiments, the B cell antigen is a CD295 antigen. In some embodiments, the B cell antigen is a CD298 antigen. In some embodiments, the B cell antigen is a CD300 antigen. In some embodiments, the B cell antigen is a CD300c antigen. In some embodiments, the B cell antigen is a CD305 antigen. In some embodiments, the B cell antigen is a CD306 antigen. In some embodiments, the B cell antigen is a CD307a antigen. In some embodiments, the B cell antigen is a CD307b antigen. In some embodiments, the B cell antigen is a CD307c antigen. In some embodiments, the B cell antigen is the CD307d antigen.In some embodiments, the B cell antigen is a CD307e antigen. In some embodiments, the B cell antigen is a CD314 antigen. In some embodiments, the B cell antigen is a CD215 antigen. In some embodiments, the B cell antigen is a CD316 antigen. In some embodiments, the B cell antigen is a CD317 antigen. In some embodiments, the B cell antigen is a CD319 antigen. In some embodiments, the B cell antigen is a CD321 antigen. In some embodiments, the B cell antigen is a CD327 antigen. In some embodiments, the B cell antigen is a CD328 antigen. In some embodiments, the B cell antigen is a CD329 antigen. In some embodiments, the B cell antigen is a CD338 antigen. In some embodiments, the B cell antigen is a CD351 antigen. In some embodiments, the B cell antigen is a CD352 antigen. In some embodiments, the B cell antigen is a CD353 antigen. In some embodiments, the B cell antigen is a CD354 antigen. In some embodiments, the B cell antigen is a CD355 antigen. In some embodiments, the B cell antigen is the CD356 antigen. In some embodiments, the B cell antigen is the CD357 antigen. In some embodiments, the B cell antigen is the CD358 antigen. In some embodiments, the B cell antigen is the CD360 antigen. In some embodiments, the B cell antigen is the CD361 antigen. In some embodiments, the B cell antigen is the CD362 antigen. In some embodiments, the B cell antigen is the CD363 antigen.
[0158] In one embodiment, the monovalent antibody binds to a pathogen. In some embodiments, the pathogen is acute flaccid myelitis (AFM), anaplasmosis, anthrax, babesiosis, botulism, brucellosis, campylobacteriosis, carbapenem-resistant infections, chancroid, chikungunya virus infection, chlamydia, ciguatera, C. difficile infection, C. perfringens, coccidioidomycosis fungal infection, coronavirus infection, Covid-19 (SARS-CoV-2), Creutzfeldt-Jakob disease / transmissible spongiform encephalopathy, cryptosporidiosis (Cr ypto), Cyclosporiasis, Dengue 1, 2, 3, or 4, Diphtheria, Escherichia coli infection / Shiga toxin-producing (STEC), Eastern equine encephalitis, Hemorrhagic fever (Ebola), Ehrlichiosis, Encephalitis, Arbovirus or parainfectious encephalitis, Non-polio enterovirus, D68 enterovirus (EV-D68), Giardiasis, Glanders, Gonococcal infection, Granuloma inguinale, Haemophilus influenzae infection type B (Hib or H-flu), Hantavirus pulmonary syndrome (HPS), Hemolytic uremic syndrome (HUS), Hepatitis A (Hep A), Hepatitis B (Hep B), Hepatitis C (Hep C), Hepatitis D (Hep D), Hepatitis E (Hep E), herpes, herpes zoster (shingles), histoplasmosis, human immunodeficiency virus / AIDS (HIV / AIDS), human papillomavirus (HPV), influenza (Flu), legionnaires' disease, leprosy (hansen's disease), leptospirosis, listeriosis (listeria), Lyme disease, lymphogranuloma venereum infection (LGV), malaria, measles, melioidosis, meningitis (viral), meningococcal disease (meningitis (bacterial)), Middle East respiratory syndrome coronavirus (MERS-CoV), mumps, norovirus Virus, Pediculosis, Pelvic Infection (PID), Pertussis (whooping cough), Plague (glandular, septicemic, pneumonic), Pneumococcal disease (pneumonia), Poliovirus infection (polio), Powassan, Psittacosis, Pituitary lice (pubic lice), Impetigo (smallpox, monkeypox, cowpox), Q fever, Rabies, Rickettsiosis (Rocky Mountain spotted fever), Rubella (German measles), Salmonellosis (Salmonella), Scabies, Scombroid, Septicemia, Severe Acute Respiratory Syndrome (SARS), Shigella (Shigella), SmallpoxMethicillin-resistant Staphylococcal Infections (MRSA), Staphylococcal Food Poisoning Enterotoxin B Poisoning (Staphylococcal Food Poisoning), Vancomycin-Intermediate Staphylococcal Infections (VISA), Vancomycin-Resistant Staphylococcal Infections (VRSA), Group A Streptococcal Infections (Invasive) (Strep A (Invasive)), Group B Streptococcal Infections (Strep-B), Streptococcal Toxic Shock Syndrome (STSS), Syphilis (Primary, Secondary, Early Latent, Late Latent, Congenital), Tetanus Infection, Trichomoniasis, Trichonoccosis Infection, Tuberculosis (TB), Latent Tuberculosis (LTBI), Tularemia, Typhoid Group D, Vaginosis, Varicella (Chickenpox), Vibrio cholerae (Cholera), Vibriosis (Vibrio), Ebola Virus Hemorrhagic Fever, Lassa Virus Hemorrhagic Fever, Marburg Virus Hemorrhagic Fever, West Nile Virus, Yellow In some embodiments, the infection is selected from the group consisting of fever, yersenia, and Zika virus infection. In some embodiments, the infection is acute flaccid myelitis (AFM). In some embodiments, the infection is anaplasmosis. In some embodiments, the infection is anthrax. In some embodiments, the infection is babesiosis. In some embodiments, the infection is botulism. In some embodiments, the infection is brucellosis. In some embodiments, the infection is erythrombocytopenia. In some embodiments, the infection is campylobacteriosis. In some embodiments, the infection is a carbapenem-resistant infection. In some embodiments, the infection is chancroid. In some embodiments, the infection is chikungunya virus infection. In some embodiments, the infection is chlamydia. In some embodiments, the infection is ciguatera poisoning. In some embodiments, the infection is a Bacillus difficile infection. In some embodiments, the infection is B. perfringens. In some embodiments, the infection is a coccidioidomycosis fungal infection. In some embodiments, the infection is a coronavirus. In some embodiments, the infection is Covid-19 (SARS-CoV-2). In some embodiments, the infection is Creutzfeldt-Jakob disease / transmissible spongiform encephalopathy. In some embodiments, the infection is cryptosporidiosis. In some embodiments, the infection isIn some embodiments, the infection is cyclosporia. In some embodiments, the infection is dengue 1, 2, 3, or 4. In some embodiments, the infection is diphtheria. In some embodiments, the infection is Escherichia coli infection / Shiga toxin-producing (STEC). In some embodiments, the infection is eastern equine encephalitis. In some embodiments, the infection is hemorrhagic fever (Ebola). In some embodiments, the infection is ehrlichiosis. In some embodiments, the infection is encephalitis. In some embodiments, the infection is an arbovirus or parainfectious. In some embodiments, the infection is a non-polio enterovirus. In some embodiments, the infection is D68 enterovirus (EV-D68). In some embodiments, the infection is giardiasis. In some embodiments, the infection is glanders. In some embodiments, the infection is gonorrhea. In some embodiments, the infection is granuloma venereum. In some embodiments, the infection is Haemophilus influenzae infection type B (Hib or H-flu). In some embodiments, the infection is Hantavirus Pulmonary Syndrome (HPS). In some embodiments, the infection is Hemolytic Uremic Syndrome (HUS). In some embodiments, the infection is Hepatitis A (Hep A). In some embodiments, the infection is Hepatitis B (Hep B). In some embodiments, the infection is Hepatitis C (Hep C). In some embodiments, the infection is Hepatitis D (Hep D). In some embodiments, the infection is Hepatitis E (Hep E). In some embodiments, the infection is Herpes. In some embodiments, the infection is Herpes Zoster (Shingles). In some embodiments, the infection is Histoplasmosis. In some embodiments, the infection is Human Immunodeficiency Virus / AIDS (HIV / AIDS). In some embodiments, the infection is Human Papillomavirus (HPV). In some embodiments, the infection is Influenza (Flu). In some embodiments, the infection is Legionnaires' Disease. In some embodiments, the infectious disease is leprosy. In some embodiments, the infectious disease isIn some embodiments, the infection is leptospirosis. In some embodiments, the infection is listeriosis (Listeria). In some embodiments, the infection is Lyme disease. In some embodiments, the infection is lymphogranuloma venereum infection (LGV). In some embodiments, the infection is malaria. In some embodiments, the infection is measles. In some embodiments, the infection is melioidosis. In some embodiments, the infection is meningitis (viral). In some embodiments, the infection is meningococcal disease (meningitis (bacterial)). In some embodiments, the infection is Middle East Respiratory Syndrome Coronavirus (MERS-CoV). In some embodiments, the infection is mumps. In some embodiments, the infection is norovirus. In some embodiments, the infection is pediculosis. In some embodiments, the infection is pelvic infection (PID). In some embodiments, the infection is pertussis (whooping cough). In some embodiments, the infection is plague (bubonic. In some embodiments, the infection is septicemic. In some embodiments, the infection is pneumonic). In some embodiments, the infection is pneumococcal disease (pneumonia). In some embodiments, the infection is poliovirus infection (polio). In some embodiments, the infection is Powassan. In some embodiments, the infection is psittacosis. In some embodiments, the infection is pediculosis (pubic lice). In some embodiments, the infection is pustular disease (smallpox). In some embodiments, the infection is monkeypox. In some embodiments, the infection is cowpox). In some embodiments, the infection is Q fever. In some embodiments, the infection is rabies. In some embodiments, the infection is rickettsiosis (Rocky Mountain spotted fever). In some embodiments, the infection is rubella (German measles). In some embodiments, the infection is salmonellosis gastroenteritis (Salmonella). In some embodiments, the infection is scabies. In some embodiments, the infection is scombroid. In some embodiments, the infection is sepsis. In some embodiments,In some embodiments, the infection is Severe Acute Respiratory Syndrome (SARS). In some embodiments, the infection is Shigella gastroenteritis (Shigella). In some embodiments, the infection is smallpox. In some embodiments, the infection is methicillin-resistant staphylococcal infections (MRSA). In some embodiments, the infection is Staphylococcal food poisoning enterotoxin B poisoning (Staphylococcal food poisoning). In some embodiments, the infection is vancomycin intermediate staphylococcal infections (VISA). In some embodiments, the infection is vancomycin-resistant staphylococcal infections (VRSA). In some embodiments, the infection is Group A Streptococcal infections (invasive) (Strep In some embodiments, the infection is Group A (invasive). In some embodiments, the infection is a streptococcal infection. In some embodiments, the infection is Group B (Strep-B). In some embodiments, the infection is Streptococcal Toxic Shock Syndrome (STSS). In some embodiments, the infection is syphilis (primary stage. In some embodiments, the infection is secondary stage. In some embodiments, the infection is early latent. In some embodiments, the infection is late latent. In some embodiments, the infection is congenital). In some embodiments, the infection is a tetanus infection. In some embodiments, the infection is trichomoniasis. In some embodiments, the infection is a trichomoniasis infection. In some embodiments, In some embodiments, the infection is tuberculosis (TB). In some embodiments, the infection is latent tuberculosis (LTBI). In some embodiments, the infection is tularemia. In some embodiments, the infection is typhoid group D. In some embodiments, the infection is chickenpox (varicella), Vibrio cholerae (cholera). In some embodiments, the infection is vibriosis (vibrio). In some embodiments, the infection is Ebola virus hemorrhagic fever. In some embodiments, the infection is Lassa virus hemorrhagic fever. In some embodiments, the infection is Marburg virus hemorrhagic fever. In some embodiments, the infection is West Nile virus. In some embodiments, the infection is yellow fever. In some embodiments, the infection isIn some embodiments, the infection is Yersinia and Zika virus infection.
[0159] In some embodiments, the pathogen is a virus. In some embodiments, the virus is an Adenoviridae, Arenaviridae, Astroviridae, Bunyaviridae, Caliciviridae, Coronaviridae, Filoviridae, Flaviviridae, Hepadnaviridae, Hepeviridae, Orthomyxoviridae, Papillomaviridae, Paramyxoviridae, Parvoviridae, Picornaviridae, Polyomaviridae, Poxviridae, Reoviridae, Retroviridae, Rhabdoviridae, or Togaviridae virus. In some embodiments, the virus is an Adenoviridae virus. In some embodiments, the virus is an Arenaviridae virus. In some embodiments, the virus is an Astroviridae virus. In some embodiments, the virus is a Bunyaviridae virus. In some embodiments, the virus is a Caliciviridae virus. In some embodiments, the virus is a Coronaviridae virus. In some embodiments, the virus is a Filoviridae virus. In some embodiments, the virus is a Flaviviridae virus. In some embodiments, the virus is a Hepadnaviridae virus. In some embodiments, the virus is a Hepeviridae virus. In some embodiments, the virus is an Orthomyxoviridae virus. In some embodiments, the virus is a Papillomaviridae virus. In some embodiments, the virus is a Paramyxoviridae virus. In some embodiments, the virus is a Parvoviridae virus. In some embodiments, the virus is a Picornaviridae virus. In some embodiments, the virus is a Polyomaviridae virus. In some embodiments, the virus is a Poxviridae virus. In some embodiments, the virus is a Reoviridae virus. In some embodiments, the virus is a Retroviridae virus. In some embodiments, the virus is a Rhabdoviridae virus. In some embodiments, the virus is a Togaviridae virus.
[0160] In some embodiments, the virus is an adenovirus, a coronavirus, a coxsackievirus, an Epstein-Barr virus, a hepatitis A virus, a hepatitis B virus, a hepatitis C virus, a herpes simplex virus type 2, a cytomegalovirus, a human herpes virus type 8, a human immunodeficiency virus, an influenza virus, a measles virus, a mumps virus, a human papillomavirus, a parainfluenza virus, a poliovirus, a rabies virus, a respiratory syncytial virus, a rubella virus, or a varicella-zoster virus. In some embodiments, the virus is an adenovirus. In some embodiments, the virus is a coronavirus. In some embodiments, the coronavirus virus is Covid-19 (SARS-CoV-2). In some embodiments, the virus is a coxsackievirus. In some embodiments, the virus is an Epstein-Barr virus. In some embodiments, the virus is a hepatitis A virus. In some embodiments, the virus is a hepatitis B virus. In some embodiments, the virus is a hepatitis C virus. In some embodiments, the virus is herpes simplex virus type 2. In some embodiments, the virus is cytomegalovirus. In some embodiments, the virus is human herpesvirus type 8. In some embodiments, the virus is human immunodeficiency virus. In some embodiments, the virus is influenza virus. In some embodiments, the virus is measles virus. In some embodiments, the virus is mumps virus. In some embodiments, the virus is human papillomavirus. In some embodiments, the virus is parainfluenza virus. In some embodiments, the virus is poliovirus. In some embodiments, the virus is rabies virus. In some embodiments, the virus is respiratory syncytial virus. In some embodiments, the virus is rubella virus. In some embodiments, the virus is varicella-zoster virus.
[0161] In some embodiments, the pathogen is a bacterium. In some embodiments, the bacterium is a bacterium of the genus Bacillus, Bartonella, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia, Chlamydophila, Clostridium, Corynebacterium, Enterococcus, Escherichia, Francisella, Haemophilus, Helicobacter, Legionella, Leptospira, Listeria, Mycobacteria, Mycoplasma, Neisseria, Pseudomonas, Rickettsia, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema, Ureaplasma, Vibrio, or Yersinia. In some embodiments, the bacterium is a bacterium of the genus Bacillus. In some embodiments, the bacterium is a bacterium of the genus Bartonella. In some embodiments, the bacterium is a bacterium of the genus Bordetella. In some embodiments, the bacterium is a bacterium of the genus Borrelia. In some embodiments, the bacterium is a bacterium of the genus Brucella. In some embodiments, the bacterium is a bacterium of the genus Campylobacter. In some embodiments, the bacterium is a bacterium of the genus Chlamydia. In some embodiments, the bacterium is a bacterium of the genus Chlamydophila. In some embodiments, the bacterium is a bacterium of the genus Clostridium. In some embodiments, the bacterium is a bacterium of the genus Corynebacterium. In some embodiments, the bacterium is a bacterium of the genus Enterococcus. In some embodiments, the bacterium is a bacterium of the genus Escherichia. In some embodiments, the bacterium is a bacterium of the genus Francisella. In some embodiments, the bacterium is a bacterium of the genus Haemophilus. In some embodiments, the bacterium is a bacterium of the genus Helicobacter. In some embodiments, the bacterium is a bacterium of the genus Legionella. In some embodiments, the bacterium is a bacterium of the genus Leptospira. In some embodiments, the bacterium is a bacterium of the genus Listeria. In some embodiments, the bacterium is a bacterium of the genus Mycobacteria. In some embodiments, the bacterium is a bacterium of the genus Mycoplasma. In some embodiments, the bacterium is a bacterium of the genus Neisseria. In some embodiments, the bacterium is a bacterium of the genus Pseudomonas. In some embodiments, the bacterium is a bacterium of the genus Rickettsia. In some embodiments, the bacterium is a bacterium of the genus Salmonella.In some embodiments, the bacterium is a bacterium of the Shigella genus. In some embodiments, the bacterium is a bacterium of the Staphylococcus genus. In some embodiments, the bacterium is a bacterium of the Streptococcus genus. In some embodiments, the bacterium is a bacterium of the Treponema genus. In some embodiments, the bacterium is a bacterium of the Ureaplasma genus. In some embodiments, the bacterium is a bacterium of the Vibrio genus. In some embodiments, the bacterium is a bacterium of the Yersinia genus.
[0162] In some embodiments, the pathogen is a parasite. In some embodiments, the parasite is a protozoan, a helminth, or an ectoparasite. In some embodiments, the protozoan is an Entamoeba, Giardia, Leishmania, Balantidium, Plasmodium, or Cryptosporidium. In some embodiments, the helminth is a trematode, a cestode, an anchocephalan, or an ascarid. In some embodiments, the ectoparasite is an arthropod.
[0163] In some specific embodiments, the monovalent antibodies provided herein bind to CD22. In some specific embodiments, the monovalent antibodies provided herein bind to CD37. In some specific embodiments, the monovalent antibodies provided herein bind to GPRC5D. In some specific embodiments, the monovalent antibodies provided herein bind to KLK2. In some specific embodiments, the monovalent antibodies provided herein bind to HLA-G. In some specific embodiments, the monovalent antibodies provided herein bind to PSMA. In some specific embodiments, the monovalent antibodies provided herein bind to BCMA.
[0164] Other Exemplary Binding Molecules In some embodiments, the monovalent antibodies provided herein are derived from specific known antibodies comprising an Fc region with RE mutations and, optionally, without fucosylation. Exemplary known antibodies include, but are not limited to, ReoPro (abciximab), Humira (adalimumab), Hyrimoz (adalimumab-adaz), Cyltezo (adalimumab-adbm), Abrilada (adalimumab-afzb), Amjevita (adalimumab-atto), Hadlima (adalimumab-bwwd), Campath, Lemtrada (alemtuzumab), Praluent (alirocumab), Tecentri q (atezolizumab), Bavencio (avelumab), Simulect (basiliximab), Benlysta (belimumab), Benlysta (belimumab), Fasenra (benralizumab), Avastin (bevacizumab), Mvasi (bevacizumab-awwb), Zirabev (bevacizumab-bvzr), Zinplava (bezlotoxumab), Blincyto (blinatumomab), Siliq (brodalumab), Beovu (brolucizumab-dbll), Crysvita (burosumab-twza), Ilaris (canakinumab), Cablivi (caplacizumab-yhdp), Libtayo (cemiplimab-rwlc), Erbitux (cetuximab), Adakveo (crizanlizumab-tmca), Zenapax (daclizumab), Zinbryta (daclizumab), Darzalex (daratumumab), Prolia, Xgeva (denosumab), Unituxin (dinutuximab), Dupixent (dupilumab) ), Imfinzi (durvalumab), Soliris (eculizumab), Empliciti (elotuzumab), Gamifant (emapalumab-lzsg), Hemlibra (emicizumab-kxwh), Vyepti (eptinezumab-jjmr), Aimovig (erenumab-aooe), Repatha (evolocumab), Ajovy (freemansumab-vfrm), Emgality (galcanezumab-gnlm), Simponi (golimumab), Simponi Aria (golimumab), Tremfya (guselkumab),Trogarzo (ibalizumab-uiyk), Praxbind (idarucizumab), Remicade (infliximab), Renflexis (infliximab-abda), Avsola (infliximab-axxq), Inflectra (infliximab-dyyb), Ixifi (infliximab-qbtx), Yervoy (ipilimumab), Sarclisa (isatuximab-irfc), Taltz (ixekizumab), Takhzyro (lanadelumab-flyo), Nucala (mepolizumab), Nuc ala (mepolizumab), Poteligeo (mogamulizumab-kpkc), Tysabri (natalizumab), Portrazza (necitumumab), Opdivo (nivolumab), Anthim (obiltoxaximab), Gazyva (obinutuzumab), Ocrevus (ocrelizumab), Arzerra (ofatumumab), Lartruvo (olaratumab), Xolair (omalizumab), Synagis (palivizumab), Vectibix (panitumumab), Keytruda (pembrolizumab), Perjeta ( pertuzumab), Cyramza (ramucirumab), Lucentis (ranibizumab), Ultomiris (ravulizumab-cwvz), raxibacumab (raxibacumab), Cinqair (reslizumab), Skyrizi (risankizumab-rzaa), Rituxan (rituximab), Truxima (rituximab-abbs), Ruxience (rituximab-pvvr), Evenity (romosozumab-aqqg), Kevzara (sarilumab), Cosentyx (secukinumab), Sylvant (siltuximab) b), Tepezza (teprotumumab-trbw), Ilumya (tildrakizumab-asmn), Actemra (tocilizumab), Actemra (tocilizumab), Herceptin (trastuzumab), Kanjinti (trastuzumab-anns), Ogivri (trastuzumab-dkst), Ontruzant (trastuzumab-dttb), Herzuma (trastuzumab-pkrb), Trazimera (trastuzumab-qyyp), Stelara (ustekinumab), Stelara (ustekinumab),and Entyvio (vedolizumab). Methods for introducing RE mutations and reducing fucosylation are described in more detail in other sections provided herein and are well known in the art.
[0165] In some embodiments, the monovalent binding molecule is a fragment of an antibody, hi some embodiments, the monovalent binding molecule is an engineered antigen binding protein.
[0166] Polynucleotides In certain embodiments, the present disclosure encompasses polynucleotides that encode the antibodies described herein. The term "polynucleotide encoding a polypeptide" encompasses polynucleotides that contain only the coding sequence for a polypeptide, as well as polynucleotides that contain additional coding and / or non-coding sequences. Polynucleotides of the present disclosure may be in the form of RNA or in the form of DNA. DNA includes cDNA, genomic DNA, and synthetic DNA, which may be double-stranded or single-stranded, and, if single-stranded, may be the coding strand or the non-coding (antisense) strand.
[0167] In certain embodiments, a polynucleotide comprises a coding sequence for a polypeptide, e.g., fused in frame with a polynucleotide that aids in the expression and secretion of the polypeptide from a host cell (e.g., a leader sequence that functions as a secretory sequence to control transport of the polypeptide). The polypeptide can have a leader sequence that is cleaved by the host cell to form a "mature" form of the polypeptide.
[0168] In certain embodiments, the polynucleotide comprises the coding sequence for the polypeptide fused in-frame to a marker or tag sequence. For example, in some embodiments, in the case of a bacterial host, the marker sequence is a hexahistidine tag provided by the vector, which allows for efficient purification of the polypeptide fused to the marker. In some embodiments, the marker is used in conjunction with other affinity tags.
[0169] The present disclosure further relates to variants of the polynucleotides described herein, where variants encode, for example, fragments, analogs, and / or derivatives of the polynucleotides. In certain embodiments, the present disclosure provides polynucleotides, including polynucleotides having a nucleotide sequence at least about 80% identical, at least about 85% identical, at least about 90% identical, at least about 95% identical, and in some embodiments, at least about 96%, 97%, 98%, or 99% identical to a polynucleotide encoding a polypeptide comprising an antibody described herein.
[0170] As used herein, the phrase "a polynucleotide having a nucleotide sequence at least, e.g., 95% "identical" to a reference nucleotide sequence" is intended to mean that the nucleotide sequence of the polynucleotide is identical to the reference sequence, except that the polynucleotide sequence may contain up to 5 point mutations for every 100 nucleotides of the reference nucleotide sequence. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides of the reference sequence may be deleted or replaced with alternative nucleotides, or up to 5% of the total number of nucleotides of the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence, or anywhere between these terminal positions, and may be interspersed individually among the nucleotides of the reference sequence or in one or more contiguous groups within the reference sequence.
[0171] Polynucleotide variants can contain alterations in coding regions, non-coding regions, or both. In some embodiments, polynucleotide variants contain alterations that result in silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. In some embodiments, polynucleotide variants contain silent substitutions that do not result in changes to the amino acid sequence of a polypeptide (due to the degeneracy of the genetic code). Polynucleotide variants can be generated for a variety of reasons, such as to optimize codon expression for a particular host (i.e., changing codons in human mRNA to those preferred by a bacterial host, such as E. coli). In some embodiments, polynucleotide variants contain at least one silent mutation in a non-coding or coding region of the sequence.
[0172] In some embodiments, polynucleotide variants are produced to modulate or alter expression (or expression levels) of an encoded polypeptide. In some embodiments, polynucleotide variants are produced to increase expression of an encoded polypeptide. In some embodiments, polynucleotide variants are produced to decrease expression of an encoded polypeptide. In some embodiments, polynucleotide variants increase expression of an encoded polypeptide compared to the parent polynucleotide sequence. In some embodiments, polynucleotide variants decrease expression of an encoded polypeptide compared to the parent polynucleotide sequence.
[0173] In certain embodiments, the polynucleotide is isolated. In certain embodiments, the polynucleotide is substantially pure.
[0174] Also provided are vectors and cells comprising the polynucleotides described herein. In some embodiments, an expression vector comprises the polynucleotide molecule. In some embodiments, an expression vector comprises the polynucleotide molecule. In some embodiments, a host cell comprises one or more expression vectors comprising the polynucleotide molecule. In some embodiments, a host cell comprises the polynucleotide molecule. In some embodiments, a host cell comprises one or more polynucleotide molecules. Construction of vectors provided herein is exemplified in Section 7, below.
[0175] Polyclonal and monoclonal antibodies In some embodiments, the antibody populations provided herein comprise polyclonal antibodies. Methods for preparing polyclonal antibodies are known to those skilled in the art. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and / or adjuvant are injected into the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may comprise a polypeptide (such as HLA-G, CD37, GPRC5D, KLK2, PSMA, or BCMA or a fragment thereof) or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized and immunize the mammal with the protein and one or more adjuvants. Examples of such immunogenic proteins include, but are not limited to, keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants that can be employed include Ribi, CpG, Poly(I:C), Freund's complete adjuvant, and MPL-TDM adjuvant (monophosphoryl lipid, synthetic trehalose dicorynomycolate). Immunization protocols can be selected by one of ordinary skill in the art without undue experimentation. The mammal is then bled, and the serum can be assayed for, for example, anti-HLA-G, anti-CD37, anti-GPRC5D, anti-KLK2 antibody, anti-PSMA, or anti-BCMA titer. If desired, the mammal can be boosted until the antibody titer increases or plateaus. Additionally or alternatively, lymphocytes can be obtained from the immunized animal for fusion and preparation of monoclonal antibodies from hybridomas.
[0176] In some embodiments, the antibodies provided herein comprise monoclonal antibodies, which may be made using the hybridoma method first described by Kohler, et al., Nature, 1975, 256:495-7, or may be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567).
[0177] In the hybridoma method, a mouse, or other suitable host animal, such as a hamster, is immunized as described above to elicit lymphocytes that produce, or are capable of producing, antibodies that specifically bind to the protein used for immunization. Alternatively, lymphocytes can be immunized in vitro. After immunization, the lymphocytes are isolated and then fused with a myeloma cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice 59-103 (1986)).
[0178] The hybridoma cells thus prepared are seeded and grown in a suitable culture medium that, in certain embodiments, contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells (also referred to as the fusion partner). For example, if the parental myeloma cells lack the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT or HPRT), then the selective culture medium for the hybridomas typically contains hypoxanthine, aminopterin, and thymidine (HAT medium), which prevents the growth of HGPRT-deficient cells.
[0179] Exemplary fusion partner myeloma cells are those that fuse efficiently, support stable high-level antibody production by the selected antibody-producing cells, and are sensitive to selective media that select against the unfused parent cells. Exemplary myeloma cell lines are mouse myeloma lines such as SP-2 cells and derivatives, e.g., X63-Ag8-653 cells, available from the American Type Culture Collection (Manassas, VA), and mouse myeloma lines derived from the MOPC-21 and MPC-11 mouse tumors, available from the Salk Institute Cell Distribution Center (San Diego, CA). Human myeloma cell lines and mouse-human heteromyeloma cell lines for producing human monoclonal antibodies have also been described (Kozbor, Immunol., 1984, 133:3001-05; and Brodeur, et al., Monoclonal Antibody Production Techniques and Applications, 1987, 51-63).
[0180] The culture medium in which the hybridoma cells grow is assayed for the production of monoclonal antibodies against the antigen. The binding specificity of the monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or an in vitro binding assay, such as RIA or ELISA. The binding affinity of the monoclonal antibody can be determined, for example, by Scatchard analysis as described in Munson et al., Anal. Biochem., 1980, 107:220-39.
[0181] Once hybridoma cells that produce antibodies with the desired specificity, affinity, and / or activity are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods (Goding, supra). Suitable culture media for this purpose include, for example, DMEM medium or RPMI-1640 medium. Additionally, hybridoma cells can be grown in vivo as ascites tumors in animals, for example, by i.p. injection of the cells into mice.
[0182] The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional antibody purification procedures such as, for example, affinity chromatography (using, for example, protein A-Sepharose or protein G-Sepharose), ion-exchange chromatography, hydroxylapatite chromatography, gel electrophoresis, dialysis, or the like.
[0183] DNA encoding monoclonal antibodies can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). Hybridoma cells can be used as a source of such DNA. Once isolated, the DNA can be placed into an expression vector, which can then be transfected into host cells that do not normally produce antibody protein, such as Escherichia coli (E. coli) cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. Review articles on recombinant expression of antibody-encoding DNA in bacteria include Skerra, et al., Curr. Opinion in Immunol., 1993, 5:256-62 and Pluckthun, Immunol. Revs., 1992, 130:151-88.
[0184] In some embodiments, antibodies that bind to an epitope (e.g., of HLA-G, CD37, GPRC5D, KLK2, PSMA, or BCMA) can be isolated by (1) hybridization under stringent conditions (e.g., hybridization in which the bound DNA is filtered in 6x sodium chloride / sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2x SSC / 0.1% SDS at about 50-65°C), or (2) hybridization under high stringency conditions (e.g., hybridization in which the bound nucleic acid is filtered in 6x SSC at about 45°C, followed by one or more washes in 0.2x SSC / 0.1% SDS at about 50-65°C). The hybridization conditions include the amino acid sequence of a VH domain and / or the amino acid sequence of a VL domain encoded by a nucleotide sequence that hybridizes to the complement of a nucleotide sequence encoding any one of the VH domains and / or VL domains described herein under (hybridization through a 0.1x SSC / 0.2% SDS at about 68°C followed by one or more washes), or other stringent hybridization conditions known to those of skill in the art (see, for example, Current Protocols in Molecular Biology Vol. I, 6.3.1-6.3.6 and 2.10.3 (Ausubel et al. eds., 1989)).
[0185] In a further embodiment, the monoclonal antibodies can be isolated from antibody phage libraries generated using, for example, the techniques described in Antibody Phage Display: Methods and Protocols (O'Brien and Aitken, eds., 2002), in which functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. Examples of phage display methods that can be used to generate the antibodies described herein are described in Brinkman, et al., J. Immunol. Methods, 1995, 182:41-50; Ames, et al., J. Immunol. Methods, 1995, 184:177-86; Kettleborough, et al., Eur. J. Immunol., 1994, 24:952-8; Persic, et al., Gene, 1997, 187:9-18; Burton et al., Advances in Immunology, 1994, 57:191-280; PCT Application No. GB91 / 01134, WO 90 / 02809, WO 91 / 10737, WO 92 / 01047, WO 92 / 18619, WO 93 / 11236, WO 95 / 15982, WO 95 / 20401, and WO 97 / 13844, and U.S. Pat. Nos. 5,698,426 and 5,223,409, These include the phage display methods disclosed in US Pat. Nos. 5,403,484, 5,580,717, 5,427,908, 5,750,753, 5,821,047, 5,571,698, 5,427,908, 5,516,637, 5,780,225, 5,658,727, 5,733,743 and 5,969,108.
[0186] In principle, synthetic antibody clones are selected by screening phage libraries containing phage displaying diverse fragments of antibody variable regions (Fv) fused to phage coat proteins. Such phage libraries are screened against a desired antigen. Clones expressing Fv fragments capable of binding to the desired antigen are adsorbed to the antigen and thus separated from non-binding clones in the library. Binding clones can then be eluted from the antigen and further enriched by additional cycles of antigen adsorption / elution.
[0187] The variable domains are each fused to a constant domain and interact non-covalently, as described, for example, in Winter et al., 1994, Ann. Rev. Immunol. 12:433-55.
[0188] Repertoires of VH and VL genes can be individually cloned by PCR and randomly recombined into phage libraries, as described in Winter et al., supra, and then screened for antigen-binding clones. Libraries from immunized sources provide high-affinity antibodies to immunogens without the need to construct hybridomas. Alternatively, naive repertoires can be cloned to provide a single source of human antibodies to a broad range of non-self antigens, as well as to self-antigens without immunization, as described by Griffiths et al., EMBO J, 1993, 12:725-34. Finally, naive libraries can also be generated synthetically by cloning unrearranged V gene segments derived from stem cells and using PCR primers containing random sequences to encode highly variable CDR3 regions and achieve in vitro rearrangement, as described, for example, by Hoogenboom and Winter, J. Mol. Biol., 1992, 227:381-88.
[0189] Screening of libraries can be accomplished by a variety of techniques known in the art. For example, HLA-G, CD37, GPRC5D, KLK2, PSMA, or BCMA (e.g., an HLA-G, CD37, GPRC5D, KLK2, PSMA, or BCMA polypeptide, fragment, or epitope) can be used to coat the wells of an adsorption plate, expressed on host cells immobilized to an adsorption plate, used in cell sorting, conjugated to biotin for capture by streptavidin-coated beads, or used in any other method for panning display libraries. Selection of antibodies with slow dissociation kinetics (e.g., good binding affinity) can be facilitated by the use of extended washes and monovalent phage display, as described in Bass, et al., Proteins, 1990, 8:309-14 and WO 92 / 09690, and by the use of low coating densities of antigen, as described in Marks et al., Biotechnol., 1992, 10:779-83.
[0190] Antibodies can be obtained by designing the construction of full-length antibody clones using VH and / or VL sequences (e.g., Fv sequences) derived from the phage clone of interest and suitable constant region (e.g., Fc) sequences, or various CDR sequences derived from the VH and VL sequences, including the K248E, T437R, or K248E / T437R mutations, as described in Kabat, et al. (supra), followed by a suitable antigen screening procedure to select the phage clone of interest.
[0191] The antibodies described herein may also include, for example, chimeric antibodies. Chimeric antibodies are molecules in which different portions of the antibody are derived from different immunoglobulin molecules. For example, a chimeric antibody may contain the variable region of a mouse or rat monoclonal antibody fused to the constant region of a human antibody. Methods for producing chimeric antibodies are known in the art. See, for example, Morrison, Science, 1985, 229:1202; Oi et al., 1986, BioTechniques 4:214; Gillies et al., 1989, J. Immunol. Methods 125:191-202; and U.S. Patent Nos. 5,807,715, 4,816,567, 4,816,397, and 6,331,415.
[0192] Antibodies produced using techniques such as those described herein can be isolated using well-known standard techniques. For example, antibodies can be suitably separated from, for example, culture medium, ascites fluid, serum, cell lysates, synthesis reaction materials, etc., by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. As used herein, an "isolated" or "purified" antibody is substantially free of cellular material or other proteins from the cell or tissue source from which it is derived, or, if chemically synthesized, substantially free of chemical precursors or other chemicals.
[0193] In certain specific embodiments, monoclonal antibodies are generated using the methods exemplified in Section 7.
[0194] humanized antibodies In some embodiments, the antibodies provided herein may be humanized antibodies. Humanized antibodies may comprise human framework regions and human constant region sequences. For example, humanized antibodies may comprise human constant region sequences. In certain embodiments, humanized antibodies may be selected from any immunoglobulin class, including IgM, IgG, IgD, IgA, and IgE, and any isotype, including IgG1, IgG2, IgG3, and IgG4 (e.g., IgG4 mutants and IgG4 nullbodies). In certain embodiments, humanized antibodies may comprise kappa or lambda light chain constant sequences.
[0195] Humanized antibodies can be produced by a variety of techniques, including CDR grafting (EP 239,400; WO 91 / 09967; U.S. Pat. Nos. 5,225,539, 5,530,101, and 5,585,089), veneering, or resurfacing (EP 592,106; U.S. Pat. Nos. 519,596; Padlan, Molecular Immunology, 1991, 28(4 / 5):489-498; Studnicka, et al., Protein Engineering, 1994, 7(6):805-814; and Roguska, et al. al., Proc. Natl. Acad. Sci. USA, 1994, 91:969-73), chain shuffling (US Pat. No. 5,565,332), and, for example, US Pat. No. 6,407,213, US Pat. al.,J.Immunol.,2002,169:1119-25;Caldas,et al.,Protein Eng.,2000,13(5):353-60;Morea et al.,Methods,2000,20(3):267-79,Baca,et al., J. Biol. Chem., 1997, 272(16):10678-84; Roguska, et al., Protein Eng., 1996,9(10):895-904; Couto, et al., Cancer Res., 1995,55(23 Supp):5973s-5977s; Couto, et al., Cancer Res., 1995,55(8):1717-22; Sandhu, JS, Gene, 1994,150(2):409-10 and Pedersen, et al., J. Mol. Biol., 1994,235(3):959-73. See also U.S. Patent Application Publication No. 2005 / 0042664(A1) (February 24, 2005), each of which is incorporated herein by reference in its entirety.
[0196] Various methods for humanizing non-human antibodies are known in the art. For example, a humanized antibody can have one or more amino acid residues introduced into it from a non-human source. These non-human amino acid residues are often referred to as "import" residues and are typically taken from an "import" variable domain. Humanization can be performed, for example, by substituting hypervariable region sequences for the corresponding sequences of a human antibody, according to the methods of Jones, et al., 1986, Nature 321:522-5; Riechmann, et al., Nature, 1988, 332:323-7; and Verhoeyen, et al., Science, 1988, 239:1534-6.
[0197] In some cases, humanized antibodies are constructed by CDR grafting, which involves grafting the amino acid sequences of the six CDRs of a parent non-human antibody (e.g., a rodent) onto a human antibody framework. For example, Padlan et al. determined that only about one-third of the residues in the CDRs actually contact the antigen, and named these "specificity-determining residues" or SDRs (Padlan, et al., FASEB J., 1995, 9:133-9). In the SDR grafting technique, only the SDR residues are grafted onto a human antibody framework (see, for example, Kashmiri, et al., Methods, 2005, 36:25-34).
[0198] The selection of human variable domains, both light and heavy, used to create a humanized antibody can be important to reduce antigenicity. For example, according to the so-called "best-fit" method, the sequence of the variable domain of a non-human (e.g., rodent) antibody is screened against the entire library of known human variable domain sequences. The human sequence that is closest to the rodent sequence can be selected as the human framework for the humanized antibody (Sims et al., J. Immunol., 1993, 151:2296-308; and Chothia et al., J. Mol. Biol., 1987, 196:901-17). Another method uses a specific framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework can be used for several different humanized antibodies (Carter et al., Proc. Natl. Acad. Sci. USA, 1992, 89:4285-89; and Presta et al., J. Immunol., 1993, 151:2623-32). In some cases, the framework is derived from the consensus sequences of the most abundant human subclasses, VL6 subgroup I (VL6I) and VH subgroup III (VHIII). In other methods, human germline genes are used as the source of the framework regions.
[0199] In an alternative paradigm based on CDR comparison, called superhumanization, the homology of FRs is irrelevant. This method involves comparing non-human sequences with functional human germline gene repertoires. Then, genes encoding canonical structures identical to or closely related to the mouse sequence are selected. Next, among the genes that share canonical structures with non-human antibodies, the genes with the highest homology within the CDRs are selected as FR donors. Finally, non-human CDRs are grafted onto these FRs (see, for example, Tan et al., J. Immunol., 2002, 169:1119-25).
[0200] Furthermore, it is generally desirable for antibodies to be humanized with retention of affinity for the antigen and other favorable biological properties. To achieve this goal, according to one method, humanized antibodies are prepared by a process of analyzing the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are well known to those skilled in the art. Computer programs are available that illustrate and display probable three-dimensional conformations of selected candidate immunoglobulin sequences. These include, for example, WAM (Whitelegg and Rees, Protein Eng., 2000, 13:819-24), Modeller (Sali and Blundell, J. Mol. Biol., 1993, 234:779-815), and Swiss PDB Viewer (Guex and Peitsch, Electrophoresis, 1997, 18:2714-23). Inspection of these displays permits analysis of the likely role of the residues in the function of the candidate immunoglobulin sequence, for example, analysis of residues that influence the ability of the candidate immunoglobulin to bind to its antigen. In this way, FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen, is achieved. In general, the hypervariable region residues are directly and most substantially involved in antigen binding.
[0201] Another method for antibody humanization is based on a measure of antibody humanity called Human String Content (HSC). This method compares the mouse sequence with the human germline gene repertoire and scores the differences as HSC. The target sequence is then humanized by maximizing its HSC, rather than using an overall identity measure to generate diverse humanized variants (Lazar et al., Mol. Immunol., 2007, 44:1986-98).
[0202] In addition to the methods described above, empirical methods can be used to generate and select humanized antibodies. These methods involve generating large libraries of humanized variants and selecting the best clones using enrichment or high-throughput screening techniques. Antibody variants can also be isolated from phage, ribosomal, and yeast display libraries, as well as by screening bacterial colonies (see, e.g., Hoogenboom, Nat. Biotechnol., 2005, 23:1105-16; Dufner, et al., Trends Biotechnol., 2006, 24:523-9; Feldhaus, et al., Nat. Biotechnol., 2003, 21:163-70; and Schlapschy et al., Protein Eng. Des. Sel., 2004, 17:847-60).
[0203] In the FR library approach, multiple residue variants are introduced at specific positions in the FR, and the library is then screened to select the FR that best supports the grafted CDR. The substituted residues may include some or all of the "vernier" residues identified as potentially contributing to CDR structure (see, e.g., Foote and Winter, J. Mol. Biol., 1992, 224:487-99), or may be from a more limited set of target residues identified by Baca, et al., J. Biol. Chem., 1997, 272:10678-84.
[0204] In FR shuffling, entire FRs are combined with non-human CDRs rather than creating a combinatorial library of selected residue variants (see, e.g., Dall'Acqua et al., Methods, 2005, 36:43-60). The library can be screened for binding in a two-step process, first humanizing the VL, followed by humanizing the VH. Alternatively, a one-step FR shuffling process can be used. Such a process has been shown to be more efficient than two-step screening, as the resulting antibodies exhibit improved biochemical and physicochemical properties, including enhanced expression, increased affinity, and thermal stability (see, e.g., Damschroder, et al., Mol. Immunol., 2007, 44:3049-60).
[0205] The "humaneering" method is based on the experimental identification of essential minimum specificity determinants (MSDs) and involves sequentially substituting nonhuman fragments into a human FR library and evaluating binding. Humaneering begins with the CDR3 regions of the nonhuman VH and VL chains, and then gradually replaces other regions of the nonhuman antibody, including CDR1 and CDR2 of both VH and VL, with human FRs. This approach typically identifies multiple subclasses of antibodies that retain the epitope but have distinct CDRs in the human V segments. Humaneering allows the isolation of antibodies that are 91-96% homologous to human germline antibodies (see, e.g., Alfenito, Cambridge Healthtech Institute's Third Annual PEGS, The Protein Engineering Summit, 2007).
[0206] "Human engineering" methods involve modifying non-human antibodies or antibody fragments, such as murine or chimeric antibodies or antibody fragments, by making specific changes to the antibody's amino acid sequence to generate modified antibodies that reduce immunogenicity in humans while retaining the desired binding characteristics of the original non-human antibody. Generally, the techniques involve classifying amino acid residues in non-human (e.g., murine) antibodies as "low risk," "moderate risk," or "high risk" residues. Classification is performed using a global risk / benefit calculation that assesses the predicted benefit of making a particular substitution (e.g., for immunogenicity in humans) against the risk that the substitution will affect the folding of the resulting antibody. Specific human amino acid residues to be substituted at a given position (e.g., low risk or moderate risk) in a non-human (e.g., murine) antibody sequence can be selected by aligning amino acid sequences from the variable regions of the non-human antibody with the corresponding regions of specific or consensus human antibody sequences. Amino acid residues at low or moderate risk positions in the non-human sequence can be substituted with the corresponding residues in the human antibody sequence depending on the alignment. Techniques for producing human engineered proteins are described in detail in Studnicka et al., Protein Engineering, 1994, 7:805-14; U.S. Patent Nos. 5,766,886, 5,770,196, 5,821,123, and 5,869,619, and WO 93 / 11794.
[0207] Composite human antibodies can be produced, for example, using Composite Human Antibody™ technology (Antitope Ltd., Cambridge, United Kingdom). To produce a composite human antibody, fragments of multiple human antibody variable region sequences are engineered to minimize the immunogenicity of the resulting antibody by avoiding T-cell epitopes. Such antibodies may contain human constant region sequences, such as a human light chain constant region and / or a human heavy chain constant region.
[0208] A deimmunized antibody is an antibody from which T cell epitopes have been removed. Methods for producing deimmunized antibodies have been described (see, for example, Jones, et al., Methods Mol Biol., 2009, 525:405-23; and De Groot, et al., Cell. Immunol., 2006, 244:148-153). A deimmunized antibody comprises a T cell epitope-depleted variable region and a human constant region. Briefly, the VH and VL of an antibody are cloned, and then T cell epitopes are identified by examining overlapping peptides derived from the VH and VL of the antibody in a T cell proliferation assay. T cell epitopes are identified by an in silico method to identify peptides that bind to human MHC class II. Mutations are introduced into the VH and VL to abolish binding to human MHC class II. The VH and VL are then used to generate a deimmunized antibody.
[0209] Antibody variants In some embodiments, modification(s) of the amino acid sequence of the antibodies provided herein are contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antibody, including, but not limited to, specificity, thermal stability, expression level, effector function, glycosylation (e.g., fucosylation), reduced immunogenicity, or solubility. Thus, in addition to the antibodies described herein, it is contemplated that antibody variants may also be prepared. For example, antibody variants can be prepared by introducing appropriate nucleotide changes into the encoding DNA and / or by synthesizing the desired antibody or polypeptide. Those skilled in the art will understand that amino acid changes may alter post-translational processes of the antibody, such as changing the number or position of glycosylation sites or altering membrane anchoring properties.
[0210] In some embodiments, the antibodies provided herein are chemically modified, for example, by covalently attaching any type of molecule to the antibody. Antibody derivatives can include antibodies that have been chemically altered by, for example, glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, linkage to cellular ligands or other proteins, and the like. Any of a number of chemical modifications can be performed by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formulation, metabolic synthesis of tunicamycin, and the like. Additionally, the antibody can contain one or more non-classical amino acids.
[0211] Mutations can be substitutions, deletions, or insertions of one or more codons encoding the antibody or polypeptide, resulting in a change in the amino acid sequence compared to the native sequence antibody or polypeptide. Amino acid substitutions can be the result of substituting one amino acid for another with similar structural and / or chemical properties, such as the substitution of a serine for a leucine, e.g., a conservative amino acid substitution. Standard techniques known to those of skill in the art can be used to introduce mutations into the nucleotide sequences encoding the molecules provided herein, including, for example, site-directed mutagenesis and PCR-mediated mutagenesis resulting in amino acid substitutions. Insertions or deletions can optionally range from about 1 to 5 amino acids. In certain embodiments, substitutions, deletions, or insertions comprise fewer than 25 amino acid substitutions, fewer than 20 amino acid substitutions, fewer than 15 amino acid substitutions, fewer than 10 amino acid substitutions, fewer than 5 amino acid substitutions, fewer than 4 amino acid substitutions, fewer than 3 amino acid substitutions, or fewer than 2 amino acid substitutions compared to the original molecule. In certain embodiments, substitutions are conservative amino acid substitutions made at one or more predicted non-essential amino acid residues. Permissible variations can be determined by systematically making amino acid insertions, deletions, or substitutions in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence.
[0212] Amino acid sequence insertions include amino- and / or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing 100 or more residues, as well as intrasequence insertions of single or multiple amino acid residues. An example of a terminal insertion is an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g., antibody-directed enzyme prodrug therapy) or a polypeptide which increases the serum half-life of the antibody.
[0213] A "conservative amino acid substitution" is one in which an amino acid residue is replaced with an amino acid residue having a side chain with a similar charge. Families of amino acid residues with similarly charged side chains have been defined. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Alternatively, mutations can be introduced randomly along all or part of a coding sequence, such as by saturation mutagenesis, and the resulting mutants screened for biological activity to identify mutants that retain activity. Following mutagenesis, the encoded protein can be expressed and the activity of the protein determined.
[0214] Substantial modifications in the biological properties of antibodies can be achieved by selecting substitutions that differ significantly in their effect on maintaining (a) the structural backbone of the polypeptide in the area of substitution, e.g., sheet or helix conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chains. Alternatively, conservative substitutions (e.g., within a group of amino acids with similar properties and / or side chains) can be made that maintain or do not significantly change the properties. Amino acids can be grouped according to the similarity of their side chain properties (see, e.g., Lehninger, Biochemistry 73-75 (2d ed. 1975)): (1) nonpolar: Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M); (2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q); (3) acidic: Asp (D), Glu (E); and (4) basic: Lys (K), Arg (R), His (H)).
[0215] Alternatively, naturally occurring residues can be divided into groups based on common side chain properties: (1) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe.
[0216] Non-conservative substitutions involve exchanging a member of one of these classes for a member of another class. Such substituted residues also may be introduced into the conservative substitution sites or into the remaining (non-conserved) sites.
[0217] Thus, in one embodiment, an antibody that binds to a CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of an antibody described herein, e.g., an antibody described in Section 7, below.
[0218] In one embodiment, an antibody that binds to a CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 35% identical to the amino acid sequence of an antibody described herein. In one embodiment, an antibody that binds to a CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 40% identical to the amino acid sequence of an antibody described herein. In one embodiment, an antibody that binds to a CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 45% identical to the amino acid sequence of an antibody described herein. In one embodiment, an antibody that binds to a CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 50% identical to the amino acid sequence of an antibody described herein. In one embodiment, an antibody that binds to a CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 55% identical to the amino acid sequence of an antibody described herein. In one embodiment, an antibody that binds to a CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 60% identical to the amino acid sequence of an antibody described herein. In one embodiment, an antibody that binds to a CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 65% identical to the amino acid sequence of an antibody described herein. In one embodiment, an antibody that binds to a CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 70% identical to the amino acid sequence of an antibody described herein. In one embodiment, an antibody that binds to a CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of an antibody described herein. In one embodiment, an antibody that binds to a CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 80% identical to the amino acid sequence of an antibody described herein. In one embodiment, the antibody that binds to a CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of an antibody described herein.In one embodiment, an antibody that binds to a CD22, GPRC5D, PSMA, or BCMA epitope comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of an antibody described herein, hi one embodiment, an antibody that binds to CD22, GPRC5D, PSMA, or BCMA comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of an antibody described herein.
[0219] How to generate antibodies In yet another aspect, provided herein are methods for producing the various antibodies provided herein.
[0220] In some embodiments, recombinant expression of an antibody provided herein (e.g., a full-length antibody provided herein, a heavy and / or light chain of the antibody, or a mutant thereof) that binds to an antigen (e.g., CD22, GPRC5D, PSMA, or BCMA) requires construction of an expression vector containing a polynucleotide encoding the antibody. Once a polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody provided herein is obtained, variants of such polynucleotides, including K248E, T437R, or K248E / T437R mutations in the full-length antibody or its heavy chain, can be generated by gene synthesis (e.g., Zhang, D., et al., supra) and / or site-directed mutagenesis (Clynes, R.A., et al., Nature Medicine, 2000, 6(4):443-6).
[0221] Vectors for the production of antibody molecules can be produced by recombinant DNA technology using techniques well known in the art. Accordingly, methods for preparing a protein by expressing a polynucleotide containing an antibody-encoding nucleotide sequence are described herein. Methods well known to those skilled in the art can be used to construct expression vectors containing antibody-coding sequences and appropriate transcriptional and translational control signals. In some embodiments, these methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. In some embodiments, these expression vectors are replicable vectors containing a nucleotide sequence encoding an antibody molecule provided herein, or the heavy or light chain of the antibody, operably linked to a promoter. In some embodiments, these vectors can contain nucleotide sequences encoding the constant region of the antibody molecule (see, e.g., WO 86 / 05807 and WO 89 / 01036, and U.S. Pat. No. 5,122,464), and antibody variable domains can be cloned into such vectors for expression of the entire heavy chain, the entire light chain, or both the entire heavy and light chains.
[0222] In some embodiments, the expression vector is transferred into a host cell by conventional techniques, and the transfected cells are then cultured by conventional techniques to produce an antibody provided herein. In some embodiments, the host cell contains nucleotides encoding an antibody provided herein, or a heavy or light chain thereof, operably linked to a heterologous promoter. In certain embodiments for expressing double-chain antibodies, vectors encoding both the heavy and light chains can be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as described in more detail below.
[0223] A variety of host-expression vector systems can be utilized to express the fusion proteins provided herein (see, e.g., U.S. Pat. No. 5,807,715). Such host-expression systems represent vehicles in which coding sequences of interest may be produced and subsequently purified, but also cells that, when transformed or transfected with the appropriate nucleotide coding sequences, are capable of expressing the antibody molecules provided herein in situ. In some embodiments, these host-expression systems are microorganisms, such as bacteria (e.g., Escherichia coli and B. subtilis), transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors containing antibody coding sequences. In some embodiments, these host expression systems are yeast (e.g., Saccharomyces) transformed with a recombinant yeast expression vector comprising the antibody coding sequence. In some embodiments, these host expression systems are insect cell systems infected with a recombinant viral expression vector (e.g., baculovirus) comprising the antibody coding sequence, plant cells infected with a recombinant viral expression vector (e.g., cauliflower mosaic virus, CaMV, tobacco mosaic virus, TMV) comprising the antibody coding sequence, or transformed with a recombinant plasmid expression vector (e.g., Ti plasmid) comprising the antibody coding sequence. In some embodiments, these host expression systems are mammalian cell systems (e.g., COS, CHO, BHK, 293, NS0, and 3T3 cells) harboring recombinant expression constructs including promoters derived from the genome of mammalian cells (e.g., metallothionein promoters) or from mammalian viruses (e.g., adenovirus late promoters; cowpox virus 7.5K promoters). In some embodiments, these host expression systems are cells such as E. coli or eukaryotic cells, particularly for expressing complete recombinant antibody molecules, that can be used to express recombinant antibody molecules.In some embodiments, mammalian cells, such as Chinese hamster ovary cells (CHO), in combination with vectors such as the major intermediate-early gene promoter element from human cytomegalovirus, provide an effective expression system for antibodies (Foecking, et al., Gene, 1986, 45:101; and Cockett, et al., Bio / Technology, 1990, 8:2). In some embodiments, the antibodies provided herein are produced in CHO cells. In some embodiments, expression of nucleotide sequences encoding the antibodies provided herein that immunospecifically bind to CD22, GPRC5D, PSMA, or BCMA antigens is regulated by a constitutive promoter, an inducible promoter, or a tissue-specific promoter.
[0224] In bacterial systems, many expression vectors may be advantageously selected depending on the intended use of the antibody molecule being expressed. For example, when producing large quantities of such antibodies, vectors that direct the expression of high levels of fusion protein products that are easily purified to produce pharmaceutical compositions of the antibody molecule may be desirable. Such vectors include, but are not limited to, the E. coli expression vector pUR278 (Ruther, et al., EMBO, 1983, 12:1791) and pIN vectors (Inouye & Inouye, Nucleic Acids Res., 1985, 13:3101-3109; Van Heeke & Schuster, J. Biol. Chem., 1989, 24:5503-9), into which the antibody coding sequence can be ligated separately and in-frame with the lac Z coding region to produce the fusion protein. pGEX vectors can also be used to express foreign polypeptides as fusion proteins with glutathione 5-transferase (GST). In some embodiments, such fusion proteins are soluble and can be easily purified from lysed cells by adsorption and binding to matrix glutathione agarose beads followed by elution in the presence of free glutathione. In some embodiments, pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.
[0225] In some embodiments, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in an insect system. In some embodiments, the virus is grown in Spodoptera frugiperda cells. In some embodiments, the antibody coding sequence may be cloned individually into non-essential regions (e.g., the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (e.g., the polyhedrin promoter).
[0226] In some embodiments, viral vectors, such as those based on tobacco mosaic virus (TMV), are used in plant cells and delivered systematically to multiple parts of the plant by Agrobacterium to express multiple antibodies of interest. (Giritch, A., et al., Proc. Natl. Acad. Sci. USA, 2006, 103(40):14701-6) In some embodiments, the use of plant cells as an expression system results in significantly increased antibody production rate and yield, as well as the ability to synthesize complex mammalian-type N-oligosaccharides. (Loos, A. and Steinkellner, H., Arch Biochem Biophys., 2012, 526-172(2):167-73)
[0227] In mammalian host cells, a number of viral-based expression systems are available. In some embodiments, adenovirus is used as an expression vector, and the antibody coding sequence of interest can be ligated to an adenovirus transcription / translation control complex, e.g., the late promoter and tripartite leader sequence. In some embodiments, this chimeric gene can then be inserted into the adenovirus genome by in vitro or in vivo recombination. In some embodiments, insertion into a non-essential region of the viral genome (e.g., region E1 or E3) results in a recombinant virus that is viable in infected hosts and capable of expressing the antibody molecule (see, e.g., Logan & Shenk, Proc. Natl. Acad. Sci. USA, 1984, 8(1):355-9). In some embodiments, specific initiation signals may be required for efficient translation of inserted antibody coding sequences. In some embodiments, these signals include the ATG initiation codon and adjacent sequences. In some embodiments, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. In some embodiments, these exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. In some embodiments, the efficiency of expression can be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see, e.g., Bittner, et al., Methods in Enzymol., 1987, 153:51-544).
[0228] In some embodiments, a host cell strain can be selected that modulates the expression of inserted sequences, or modifies and processes the gene product in the specific manner desired. Such modifications (including, for example, glycosylation, fucosylation) and processing (e.g., cleavage) of protein products can be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. By selecting an appropriate cell line or host system, the expressed foreign protein can be correctly modified and processed. To this end, eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product can be used. Such mammalian host cells include, but are not limited to, CHO, VERY, BHK, Hela, COS, MDCK, 293, 3T3, W138, BT483, Hs578T, HTB2, BT2O, and T47D, NS0 (a mouse myeloma cell line that does not endogenously produce any immunoglobulin chains), CRL7O3O, and HsS78Bst cells. The fully human monoclonal antibodies provided herein are produced in mammalian cells, such as CHO cells.
[0229] Standard techniques known to those skilled in the art can be used to produce antibodies provided herein having heavy chains that do not contain a fucose residue in their Asn-297-linked N-oligosaccharides. In some embodiments, cells deficient in GMD enzyme (e.g., CHO Lec13 cells) are used to produce antibodies having no fucose residue in the Asn-297-linked N-oligosaccharide on the heavy chain. In some embodiments, cells with reduced α-1,6 fucosyltransferase activity due to a mutated or inactivated FUT8 gene (e.g., rat hybridoma YB2 / 0 cell line) are used to produce antibodies having no fucose residue in the Asn-297-linked N-oligosaccharide on the heavy chain. In some embodiments, cells overexpressing β-1,4-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase (GnT-III) are used to produce antibodies having no fucose residue in the Asn-297-linked N-oligosaccharide on the heavy chain. In some embodiments, cells (e.g., CHO-gmt3 cells) with an inactivated Golgi GDP-fucose transporter (GFT) gene Slc35c1 are used to produce antibodies that do not have a fucose residue in the Asn-297-linked N-oligosaccharide on the heavy chain. In some embodiments, cells heterologously expressing a bacterial RMD are used to produce antibodies that do not have a fucose residue in the Asn-297-linked N-oligosaccharide on the heavy chain. In some embodiments, biochemical inhibitors of fucosylation (e.g., fucose analogs such as 2-fluorofucose and 5-alkynylfucose) are used in the expression system to produce antibodies that do not have a fucose residue in the Asn-297-linked N-oligosaccharide on the heavy chain (Pereira, N.A., et al., supra; Shields, R.L. et al., supra; Kanda Y., supra). In some embodiments, plant cells disrupted in α1,3-fucosyltransferase (FucT) and β1,2-xylosyltransferase (XylT) are used to generate antibodies that lack a fucose residue in the Asn-297-linked N-oligosaccharide on the heavy chain (Pereira, N.A., et al., supra).In some embodiments, chemoenzymatic remodeling is used to generate antibodies that do not have a fucose residue in the Asn-297-linked N-oligosaccharide on the heavy chain (Pereira, N.A., et al., supra). For example, an exoglycosidase such as fucosidase may be used to remove the fucose from the Asn-297-linked N-oligosaccharide on the heavy chain of an antibody (Pereira, N.A., et al., supra).
[0230] Stable expression can be used for long-term, high-yield production of recombinant proteins. For example, cell lines that stably express an antibody molecule can be engineered. Rather than using expression vectors containing viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminator, polyadenylation site, etc.) and a selectable marker. After the introduction of the foreign DNA, engineered cells can be grown for 1-2 days in an enriched medium and then switched to a selective medium. In some embodiments, the selectable marker on the recombinant plasmid confers resistance to the selection, allowing cells to stably integrate the plasmid into their chromosomes and grow to form foci, which can then be cloned and expanded into cell lines. This method can be advantageously used to engineer cell lines that express an antibody molecule. Such engineered cell lines can be particularly useful in screening and evaluation of compositions that interact directly or indirectly with the antibody molecule.
[0231] A number of selection systems can be used, including but not limited to herpes simplex virus thymidine kinase (Wigler, et al., Cell, 1977, 11:223), hypoxanthine guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA, 1992, 48:202), and adenine phosphoribosyltransferase (Lowy, et al., Cell, 1980, 22:8-17), and genes can be utilized in tk-, hgprt-, or aprt- cells, respectively. Antimetabolite resistance can also be used as a selection criterion for the following genes: dhfr, which confers resistance to methotrexate (Wigler, et al., Natl. Acad. Sci. USA, 1980, 77:357; O'Hare, et al., Proc. Natl. Acad. Sci. USA, 1981, 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA, 1981, 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Wu and Wu, Biotherapy, 1991, 3:87-95; Tolstoshev, Ann. Rev. Pharmacol. Toxicol., 1993, 32:573-96; Mulligan, Science, 1993, 260:926-32; and Morgan and Anderson, Ann. Rev. Biochem., 1993, 62:191-217; and hygro, which confers resistance to hygromycin (Santerre, et al., Gene, 1984, 30:147).Methods generally known in the art in the field of recombinant DNA technology can be routinely applied to select the desired recombinant clones, and such methods are described, for example, in Ausubel, et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and Chapters 12 and 13, Dracopoli, et al. (eds.), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin, et al., J. Mol. Biol., 1981, 150:1, which are incorporated herein by reference in their entireties.
[0232] Expression levels of antibody molecules can be increased by vector amplification (for a review, see Bebbington and Hentschel, "The Use of Gene Amplification-Based Vectors for the Expression of Cloned Genes in Mammalian Cells," in DNA Cloning, Vol. 3 (Academic Press, New York, 1987)). In some embodiments, if the marker in the antibody expression vector system is amplifiable, the amplified region will be associated with the antibody gene, and increasing the level of inhibitor present in the host cell culture will increase the copy number of the marker gene and antibody production (Crouse et al., 1983, Mol. Cell. Biol. 3:257).
[0233] Host cells can be cotransfected with two expression vectors provided herein, with the first vector encoding a heavy chain-derived polypeptide and the second vector encoding a light chain-derived polypeptide. The two vectors can contain identical selectable markers that allow for equal expression of heavy and light chain polypeptides. Alternatively, a single vector can be used that encodes and is capable of expressing both heavy and light chain polypeptides. In such a situation, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, Nature, 1986, 322:52; and Kohler, Proc. Natl. Acad. Sci. USA, 1980, 77:2197-9). The coding sequences for the heavy and light chains can comprise cDNA or genomic DNA.
[0234] Once the antibody molecules provided herein are produced by recombinant expression, they can be purified by any method known in the art for purifying immunoglobulin molecules, such as chromatography (e.g., ion exchange chromatography, affinity chromatography, particularly Protein A chromatography followed by affinity chromatography for the specific antigen, and size exclusion column chromatography), centrifugation, differential solubility, or any other standard technique for purifying proteins. Furthermore, the antibodies provided herein can be fused to heterologous polypeptide sequences described herein or otherwise known in the art to facilitate purification. Particular methods for making the antibodies provided herein are described in Section 7, below.
[0235] Pharmaceutical Composition In one aspect, the present disclosure further provides a pharmaceutical composition comprising at least one antibody of the present disclosure. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of an antibody or antigen-binding fragment thereof provided herein and a pharmaceutically acceptable excipient.
[0236] In some embodiments, pharmaceutical compositions comprising antibodies are prepared by mixing the fusion protein of the desired purity with any physiologically acceptable excipient (see, e.g., Remington, Remington's Pharmaceutical Sciences (18th ed. 1980)) in aqueous solution or in lyophilized or other dried form for storage.
[0237] The antibodies of the disclosure may be formulated in any suitable form for delivery to target cells / tissues, for example, as microcapsules or macroemulsions (Remington, supra; Park, et al., Molecules, 2005, 10:146-61; Malik, et al., Curr. Drug. Deliv., 2007, 4:141-51), as sustained-release formulations (Putney and Burke, Nature Biotechnol., 1998, 16:153-57), or in liposomes (Maclean, et al., Int. J. Oncol., 1997, 11:325-32; Kontermann, Curr. Opin. Mol. Ther., 2006, 8:39-45).
[0238] The antibodies provided herein can also be encapsulated in microcapsules, such as hydroxymethylcellulose or gelatin microcapsules and poly-(methyl methacrylate) microcapsules, prepared, for example, by coacervation techniques or by interfacial polymerization, respectively, in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), or in macroemulsions. Such techniques are disclosed, for example, in Remington (supra).
[0239] A variety of compositions and delivery systems are known and can be used with the antibodies described herein, including, but not limited to, in liposomes, in microparticles, encapsulation in microcapsules, recombinant cells capable of expressing the antibody, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem., 1987, 262:4429-32), construction of the nucleic acid as part of a retroviral or other vector, etc. In one embodiment, a pump can be used to achieve controlled or sustained release (see, e.g., Langer, Science, 1990, 249:1527-33; Sefton, Crit. Ref. Biomed. Eng., 1987, 14:201-40; Buchwald, et al., Surgery, 1980, 88:507-16; and Saudek et al., N. Engl. J. Med., 1989, 321:569-74). In another embodiment, polymeric materials can be used to achieve controlled or sustained release of prophylactic or therapeutic agents (e.g., antibodies described herein) or compositions provided herein (see, e.g., Medical Applications of Controlled Release (Langer and Wise, eds., 1974); Controlled Drug Bioavailability, Drug Product Design and Performance (Smolen and Ball, eds., 1984); Ranger and Peppas, J. Macromol. Sci. Rev. Macromol. Chem., 1983, 23:61-126; Levy, et al., Science, 1985, 228:190-92; During, et al., Ann. Neurol., 1989, 25:351-6; Howard, et al., al., J. Neurosurg., 1989, 71:105-12; U.S. Patent Nos. 5,679,377, 5,916,597, 5,912,015, 5,989,463, and 5,128,326; WO 99 / 15154 and WO 99 / 20253).Examples of polymers used in sustained release formulations include, but are not limited to, poly(2-hydroxyethyl methacrylate), poly(methyl methacrylate), poly(acrylic acid), poly(ethylene-co-vinyl acetate), poly(methacrylic acid), polyglycolide (PLG), polyanhydrides, poly(N-vinylpyrrolidone), poly(vinyl alcohol), polyacrylamide, poly(ethylene glycol), polylactide (PLA), poly(lactide-co-glycolide) (PLGA), and polyorthoesters. In one embodiment, the polymers used in the sustained release formulations are inert, free of leachable impurities, stable on storage, sterile, and biodegradable.
[0240] In yet another embodiment, a controlled-release or sustained-release system can be placed in close proximity to a specific target tissue, such as the nasal cavity or lungs, such that only a fraction of the systemic dose is required (see, e.g., Goodson, Medical Applications of Controlled Release Vol. 2, 115-38 (1984)). Controlled-release systems are discussed, for example, by Langer (supra). Any technique known to those of skill in the art can be used to prepare sustained release formulations comprising one or more antibodies described herein (see, e.g., U.S. Pat. No. 4,526,938; WO 91 / 05548 and WO 96 / 20698; Ning, et al., Radiotherapy & Oncology, 1996, 39:179-89; Song, et al., PDA J. of Pharma. Sci. & Tech., 1995, 50:372-97; Cleek, et al., Pro. Int'l. Symp. Control. Rel. Bioact. Mater., 1997, 24:853-4; and Lam, et al., Proc. Int'l. Symp. Control Rel. Bioact. Mater., 1997, 24:759-60).
[0241] Methods of Use, Administration and Dosage In one aspect, provided herein is a method of enhancing the ADCC, CDC and / or ADCP activity of an antibody.
[0242] As another example, C42B and LNCaP cells stably transfected with GFP were seeded at 9,000 cells per well in clear medium (RPMI 1641 + 10% FBS, Thermo Fisher Scientific) in 384-well plates (Perkin Elmer ViewPlate) and allowed to adhere overnight. ADCC assays can be performed using freshly thawed PBMCs (Hemcare, PB009C-3) or NK cells isolated from frozen PBMCs using RoboSep™ Cell Separation Instruments. Isolated NK cells can be used immediately or stimulated overnight with low-dose IL-2 (1 ng / ml, Miltenyi Biotec). The effector to target cell ratio per well can be 34:1 for PBMCs and 5:1 for isolated NK cells. In some embodiments, anti-PSMA antibodies are tested at final concentrations ranging from 100 nM to 0.01 nM. After adding effector cells and antibodies to target cells, real-time imaging can be performed using an Incucyte® S3 instrument (Essen BioScience). The total integrated GPF signal per well can be quantified using Incucyte® software. Data analysis can be performed using Incucyte® software and Prism (GraphPad Software) based on quadruplicate values. The percentage of cell death can be calculated as (1-PSMAmAb / no mAb control) × 100%.
[0243] As another example, C42B and LNCaP cells stably transfected with GFP were seeded at 9,000 cells per well in clear medium (RPMI 1641 + 10% FBS, Thermo Fisher Scientific) in 384-well plates (Perkin Elmer ViewPlate) and allowed to adhere overnight. ADCC assays can be performed using freshly thawed PBMCs (Hemcare, PB009C-3) or NK cells isolated from frozen PBMCs using RoboSep™ Cell Separation Instruments. Isolated NK cells can be used immediately or stimulated overnight with low-dose IL-2 (1 ng / ml, Miltenyi Biotec). The effector to target cell ratio per well can be 34:1 for PBMCs and 5:1 for isolated NK cells. In some embodiments, anti-BCMA antibodies are tested at final concentrations ranging from 100 nM to 0.01 nM. After adding effector cells and antibodies to target cells, real-time imaging can be performed using an Incucyte® S3 instrument (Essen BioScience). The total GFP integrated signal per well can be quantified using Incucyte® software. Data analysis can be performed using Incucyte® software and Prism (GraphPad Software) based on quadruplicate values. The percentage of cell death can be calculated as (1-BCMAmAb / no mAb control) × 100%.
[0244] In some embodiments, the antibodies provided herein cause at least 10% target cell death via ADCC. In some embodiments, the antibodies provided herein cause at least 20% target cell death via ADCC. In some embodiments, the antibodies provided herein cause at least 30% target cell death via ADCC. In some embodiments, the antibodies provided herein cause at least 40% target cell death via ADCC. In some embodiments, the antibodies provided herein cause at least 50% target cell death via ADCC. In some embodiments, the antibodies provided herein cause at least 60% target cell death via ADCC. In some embodiments, the antibodies provided herein cause at least 70% target cell death via ADCC. In some embodiments, the antibodies provided herein cause at least 80% target cell death via ADCC. In some embodiments, the antibodies provided herein cause at least 90% target cell death via ADCC. In some embodiments, the antibodies provided herein cause at least 95% target cell death via ADCC.
[0245] In some embodiments, the CDC activity of an anti-CD22 antibody, anti-GPRC5D antibody, anti-PSMA antibody, or anti-BCMA antibody provided herein is determined by measuring the rate of target cell death. For example, target cells endogenously expressing CD22, GPRC5D, PSMA, or BCMA can be cultured in DMEM medium containing 10% fetal bovine serum (FBS). In some embodiments, the antibody is added to the target cells and incubated at 37°C for 30 minutes, after which baby rabbit serum is added to the target cells to a final concentration of 10% to provide a source of complement components for CDC. In some embodiments, the mixture is incubated at 37°C for 4 hours. 100 μL of CellTiter-Glo reagent (Promega) can be added to the mixture, followed by incubation at room temperature for 10 minutes. Target cell viability can be determined by measuring luminescence with a Tecan SPARK reader. Therefore, target cell death can be determined as the difference between 100% and the viability of the target cells.
[0246] In some embodiments, the antibodies provided herein cause at least 10% target cell death via CDC. In some embodiments, the antibodies provided herein cause at least 20% target cell death via CDC. In some embodiments, the antibodies provided herein cause at least 30% target cell death via CDC. In some embodiments, the antibodies provided herein cause at least 40% target cell death via CDC. In some embodiments, the antibodies provided herein cause at least 50% target cell death via CDC. In some embodiments, the antibodies provided herein cause at least 60% target cell death via CDC. In some embodiments, the antibodies provided herein cause at least 70% target cell death via CDC. In some embodiments, the antibodies provided herein cause at least 80% target cell death via CDC. In some embodiments, the antibodies provided herein cause at least 90% target cell death via CDC. In some embodiments, the antibodies provided herein cause at least 95% target cell death via CDC.
[0247] In some embodiments, the antibodies provided herein enhance ADCC activity by at least about 2-fold. In some embodiments, the antibodies provided herein enhance ADCC activity by at least about 5-fold. In some embodiments, the antibodies provided herein enhance ADCC activity by at least about 10-fold. In some embodiments, the antibodies provided herein enhance ADCC activity by at least about 20-fold. In some embodiments, the antibodies provided herein enhance ADCC activity by at least about 30-fold. In some embodiments, the antibodies provided herein enhance ADCC activity by at least about 40-fold. In some embodiments, the antibodies provided herein enhance ADCC activity by at least about 50-fold. In some embodiments, the antibodies provided herein enhance ADCC activity by at least about 60-fold. In some embodiments, the antibodies provided herein enhance ADCC activity by at least about 70-fold. In some embodiments, the antibodies provided herein enhance ADCC activity by at least about 80-fold. In some embodiments, the antibodies provided herein enhance ADCC activity by at least about 90-fold. In some embodiments, the antibodies provided herein enhance ADCC activity by at least about 100-fold. In some embodiments, the antibodies provided herein enhance ADCC activity by at least about 200-fold. In some embodiments, the antibodies provided herein enhance ADCC activity by at least about 500-fold.
[0248] In some embodiments, the antibodies provided herein enhance CDC activity by at least about 2-fold. In some embodiments, the antibodies provided herein enhance CDC activity by at least about 5-fold. In some embodiments, the antibodies provided herein enhance CDC activity by at least about 10-fold. In some embodiments, the antibodies provided herein enhance CDC activity by at least about 20-fold. In some embodiments, the antibodies provided herein enhance CDC activity by at least about 30-fold. In some embodiments, the antibodies provided herein enhance CDC activity by at least about 40-fold. In some embodiments, the antibodies provided herein enhance CDC activity by at least about 50-fold. In some embodiments, the antibodies provided herein enhance CDC activity by at least about 60-fold. In some embodiments, the antibodies provided herein enhance CDC activity by at least about 70-fold. In some embodiments, the antibodies provided herein enhance CDC activity by at least about 80-fold. In some embodiments, the antibodies provided herein enhance CDC activity by at least about 90-fold. In some embodiments, the antibodies provided herein enhance CDC activity by at least about 100-fold. In some embodiments, the antibodies provided herein enhance CDC activity by at least about 200-fold. In some embodiments, the antibodies provided herein enhance CDC activity by at least about 500-fold.
[0249] In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 2-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 5-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 10-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 20-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 30-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 40-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 50-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 60-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 70-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 80-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 90-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 100-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 200-fold. In some embodiments, the antibodies provided herein enhance both ADCC and CDC activity by at least about 500-fold.
[0250] In some embodiments, the antibodies provided herein have at least about a 2-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 5-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 10-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 20-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 30-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 40-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 50-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 60-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 70-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about an 80-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 90-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 100-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 200-fold increase in cell surface hexamerization ability. In some embodiments, the antibodies provided herein have at least about a 500-fold increase in cell surface hexamerization ability.
[0251] In some embodiments, the antibodies provided herein have at least about a 2-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 5-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 10-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 20-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 30-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 40-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 50-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 60-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 70-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about an 80-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 90-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 100-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 200-fold increase in the ability to engage C1q. In some embodiments, the antibodies provided herein have at least about a 500-fold increase in the ability to engage C1q.
[0252] In another aspect, provided herein is a method for treating a disease or disorder in a subject, comprising administering to the subject an effective amount of an antibody provided herein. In one embodiment, the disease or disorder is a CD22-mediated disease or disorder. In one embodiment, the disease or disorder is a GPRC5D-mediated disease or disorder. In one embodiment, the disease or disorder is a PSMA-mediated disease or disorder. In one embodiment, the disease or disorder is a BCMA-mediated disease or disorder. In some embodiments, the disease or disorder is selected from the group consisting of cancer, autoimmune diseases, inflammatory diseases, cardiovascular diseases, genetic diseases, blood diseases and / or pulmonary diseases affecting the joints, skin, kidneys, liver, intestines, heart, lungs, muscles, stomach, spleen, pancreas, gallbladder, bladder, appendix, thymus, brain, esophagus, eyes or ears, and optionally, the disease or disorder is selected from the group consisting of rheumatoid arthritis, bullous pemphigoid, discoid cutaneous lupus, urticarial vasculitis, Henoch-Schonlein purpura, IgA nephropathy, atopic dermatitis (atopic eczema), psoriasis (plaque psoriasis), seborrheic eczema, asthma, proteinuric kidney disease , liver disease, lupus nephritis, polymyositis, dermatomyositis, calcineurin inhibitor-induced nephrotoxicity, myotonic dystrophy, cardiac dysfunction and insufficiency, Alport syndrome, ulcerative colitis, Crohn's disease, cutaneous vasculitis, cachexia, and inflammatory bowel disease, and optionally the disease or disorder is associated with fibrosis, optionally selected from the group consisting of tissue fibrosis, idiopathic pulmonary fibrosis, interstitial pneumonia, scleroderma (systemic sclerosis), cancer, cancer-associated cachexia, muscle wasting, keloids, inclusion body myositis, and tissue remodeling (see, e.g., Heider, KH, et al. al.,Blood,2011,118(15):4159-68;Carosella,ED,et al.,Adv.Immunol.,2015,127:33-144;Stathis,S.,et al.,Invest New Drugs,2018,36(5):869-76;Stilgenbauer,S.,et al.,Leukemia,2019,33:2531-5;Gomes,RG,et al.,Hum.Immunol.,2018,79(6):477-84;Moroso,V.,et al.,Transplantation,2015,99(12):2514-22;Lazarte,J.,et al.,Hum.Immunol.,2018,79(8):587-93;Rached,MR,et al.,Eur J Obstet Gynecol Reprod Biol.,2019,235:36-41;Koc,A.,et al.,Adv Clin Exp Med.,2018,27(9):1233-7;Ribeyre,C.,et al.,Front Immunol.,2018,9:278;Smith,EL,et al.,Sci Transl Med.,2019,11(485):eaau7746,Kodama,T.,et al.,Mol Cancer Ther.,2019,18(9):1555-64;Cohen,Y.,et al., Hematology, 2013, 18(6):348-51). .
[0253] Also provided herein are methods of treating a disease or disorder, wherein a subject is administered one or more therapeutic agents in combination with an antibody provided herein.
[0254] In another aspect, provided herein is the use of an antibody provided herein in the manufacture of a medicament for treating a disease or disorder in a subject.
[0255] In another aspect, provided herein is the use of a pharmaceutical composition provided herein in the manufacture of a medicament for treating a disease or disorder in a subject.
[0256] In specific embodiments, provided herein are compositions for use in the prevention and / or treatment of a disease or condition, comprising an antibody provided herein. In one embodiment, provided herein are compositions for use in the prevention of a disease or condition, wherein the composition comprises an antibody provided herein. In one embodiment, provided herein are compositions for use in the treatment of a disease or condition, wherein the composition comprises an antibody provided herein. In some embodiments, the disease or condition is a CD22-mediated disease. In some embodiments, the disease or condition is a GPRC5D-mediated disease. In some embodiments, the disease or condition is a PSMA-mediated disease. In some embodiments, the disease or condition is a BCMA-mediated disease. In some embodiments, the disease or disorder is selected from the group consisting of cancer, autoimmune diseases, inflammatory diseases, cardiovascular diseases, genetic diseases, blood diseases and / or pulmonary diseases affecting the joints, skin, kidneys, liver, intestines, heart, lungs, muscles, stomach, spleen, pancreas, gallbladder, bladder, appendix, thymus, brain, esophagus, eyes or ears, and optionally the disease or disorder is selected from the group consisting of rheumatoid arthritis, bullous pemphigoid, discoid cutaneous lupus, urticarial vasculitis, Henoch-Schönlein purpura, IgA nephrophathy, atopic dermatitis (atopic eczema), psoriasis (psoriasis vulgaris), The disease or disorder is selected from the group consisting of seborrheic dermatitis, asthma, proteinuric kidney disease, liver disease, lupus nephritis, polymyositis, dermatomyositis, calcineurin inhibitor-induced nephrotoxicity, myotonic dystrophy, cardiac dysfunction and insufficiency, Alport syndrome, ulcerative colitis, Crohn's disease, cutaneous vasculitis, cachexia, and inflammatory bowel disease, and optionally the disease or disorder is associated with fibrosis, and optionally is selected from the group consisting of tissue fibrosis, idiopathic pulmonary fibrosis, interstitial pneumonia, scleroderma (systemic sclerosis), cancer, cancer-associated cachexia, muscle wasting, keloids, inclusion body myositis, and tissue remodeling.
[0257] In certain embodiments, the subject is a subject in need of treatment thereof. In some embodiments, the subject has a disease or condition. In other embodiments, the subject is at risk of having a disease or condition. In some embodiments, administration results in the prevention, management, treatment, or amelioration of a disease or condition.
[0258] In one embodiment, provided herein is a composition for use in the prevention and / or treatment of symptoms of a disease or condition, the composition comprising an antibody provided herein. In one embodiment, provided herein is a composition for use in the prevention of symptoms of a disease or condition, the composition comprising an antibody provided herein. In one embodiment, provided herein is a composition for use in the treatment of symptoms of a disease or condition, the composition comprising an antibody provided herein. In some embodiments, the disease or condition is a CD22-mediated, GPRC5D-mediated, PSMA-mediated disease, and / or BCMA-mediated disease. In some embodiments, the disease or disorder is selected from the group consisting of cancer, autoimmune diseases, inflammatory diseases, cardiovascular diseases, genetic diseases, blood diseases and / or pulmonary diseases affecting the joints, skin, kidneys, liver, intestines, heart, lungs, muscles, stomach, spleen, pancreas, gallbladder, bladder, appendix, thymus, brain, esophagus, eyes or ears, and optionally the disease or disorder is selected from the group consisting of rheumatoid arthritis, bullous pemphigoid, discoid cutaneous lupus, urticarial vasculitis, Henoch-Schönlein purpura, IgA nephrophathy, atopic dermatitis (atopic eczema), psoriasis (psoriasis vulgaris), The disease or disorder is selected from the group consisting of seborrheic dermatitis, asthma, proteinuric kidney disease, liver disease, lupus nephritis, polymyositis, dermatomyositis, calcineurin inhibitor-induced nephrotoxicity, myotonic dystrophy, cardiac dysfunction and insufficiency, Alport syndrome, ulcerative colitis, Crohn's disease, cutaneous vasculitis, cachexia, and inflammatory bowel disease, and optionally the disease or disorder is associated with fibrosis, and optionally is selected from the group consisting of tissue fibrosis, idiopathic pulmonary fibrosis, interstitial pneumonia, scleroderma (systemic sclerosis), cancer, cancer-associated cachexia, muscle wasting, keloids, inclusion body myositis, and tissue remodeling.
[0259] In certain embodiments, the subject is in need of treatment thereof. In some embodiments, the subject has a disease or condition. In other embodiments, the subject is at risk of having a disease or condition. In some embodiments, administration results in prevention or treatment of a symptom of the disease or condition.
[0260] In another embodiment, provided herein is a method for preventing and / or treating a disease or condition in a subject, comprising administering an effective amount of an antibody provided herein. In one embodiment, provided herein is a method for preventing a disease or condition in a subject, comprising administering an effective amount of an antibody provided herein. In one embodiment, provided herein is a method for treating a disease or condition in a subject, comprising administering an effective amount of an antibody provided herein. In some embodiments, the disease or condition is a CD22-mediated, GPRC5D-mediated, PSMA-mediated disease, and / or BCMA-mediated disease. In some embodiments, the disease or disorder is selected from the group consisting of cancer, autoimmune diseases, inflammatory diseases, cardiovascular diseases, genetic diseases, blood diseases and / or pulmonary diseases affecting the joints, skin, kidneys, liver, intestines, heart, lungs, muscles, stomach, spleen, pancreas, gallbladder, bladder, appendix, thymus, brain, esophagus, eyes or ears, and optionally the disease or disorder is selected from the group consisting of rheumatoid arthritis, bullous pemphigoid, discoid cutaneous lupus, urticarial vasculitis, Henoch-Schönlein purpura, IgA nephrophathy, atopic dermatitis (atopic eczema), psoriasis (psoriasis vulgaris), The disease or disorder is selected from the group consisting of seborrheic dermatitis, asthma, proteinuric kidney disease, liver disease, lupus nephritis, polymyositis, dermatomyositis, calcineurin inhibitor-induced nephrotoxicity, myotonic dystrophy, cardiac dysfunction and insufficiency, Alport syndrome, ulcerative colitis, Crohn's disease, cutaneous vasculitis, cachexia, and inflammatory bowel disease, and optionally the disease or disorder is associated with fibrosis, and optionally is selected from the group consisting of tissue fibrosis, idiopathic pulmonary fibrosis, interstitial pneumonia, scleroderma (systemic sclerosis), cancer, cancer-associated cachexia, muscle wasting, keloids, inclusion body myositis, and tissue remodeling.
[0261] In certain embodiments, the subject is in need of treatment. In some embodiments, the subject has a disease or condition. In other embodiments, the subject is at risk of having a disease or condition. In some embodiments, administration results in prevention or treatment of a disease or condition.
[0262] In another embodiment, provided herein is a method for preventing and / or treating symptoms of a disease or condition in a subject, comprising administering an effective amount of an antibody provided herein. In one embodiment, provided herein is a method for preventing symptoms of a disease or condition in a subject, comprising administering an effective amount of an antibody provided herein. In one embodiment, provided herein is a method for treating symptoms of a disease or condition in a subject, comprising administering an effective amount of an antibody provided herein. In some embodiments, the disease or condition is a CD22-mediated, GPRC5D-mediated, PSMA-mediated disease, and / or BCMA-mediated disease. In some embodiments, the disease or disorder is selected from the group consisting of cancer, autoimmune diseases, inflammatory diseases, cardiovascular diseases, genetic diseases, blood diseases and / or pulmonary diseases affecting the joints, skin, kidneys, liver, intestines, heart, lungs, muscles, stomach, spleen, pancreas, gallbladder, bladder, appendix, thymus, brain, esophagus, eyes or ears, and optionally the disease or disorder is selected from the group consisting of rheumatoid arthritis, bullous pemphigoid, discoid cutaneous lupus, urticarial vasculitis, Henoch-Schönlein purpura, IgA nephropathy, atopic dermatitis (atopic eczema), psoriasis (plaque psoriasis), seborrheic eczema, asthma, rheumatoid arthritis ... and optionally the disease or disorder is associated with fibrosis, and optionally is selected from the group consisting of tissue fibrosis, idiopathic pulmonary fibrosis, interstitial pneumonia, scleroderma (systemic sclerosis), cancer, cancer-associated cachexia, muscle wasting, keloids, inclusion body myositis, and tissue remodeling.
[0263] In certain embodiments, the subject is in need of treatment thereof. In some embodiments, the subject has a disease or condition. In other embodiments, the subject is at risk of having a disease or condition. In some embodiments, administration results in prevention or treatment of a symptom of the disease or condition.
[0264] Also provided herein are methods for preventing and / or treating a disease or condition by administering to a subject an effective amount of an antibody provided herein or a pharmaceutical composition comprising an antibody provided herein. In one aspect, the antibody is substantially purified (i.e., substantially free from substances that limit its effect or cause undesirable side effects). The subject to which the therapy is administered can be a mammal, such as a non-primate (e.g., cow, pig, horse, cat, dog, rat, etc.) or a primate (e.g., monkey, such as macaque (cynomolgus monkey), or human). In one embodiment, the subject is a human. In another embodiment, the subject is a human with a disease or condition.
[0265] In some embodiments, each or any of the above or below embodiments, the binding molecule is used to treat a solid tumor cancer. In other embodiments, the binding molecule is used to treat a hematological cancer. In other embodiments, the disease or disorder is an autoimmune disease or inflammatory disease. In other embodiments, the disease or disorder is an immune disease or disorder.
[0266] In some embodiments of each or any of the above or below embodiments, the disease or disorder is a disease of abnormal cell proliferation and / or dysregulated apoptosis. Examples of such diseases include cancer, mesothelioma, bladder cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, cancer of the fallopian tubes, cancer of the endometrium, cancer of the cervix, cancer of the vagina, cancer of the vulva, bone cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, cancer of the gastrointestinal tract (stomach, colorectum, and / or duodenum), chronic lymphocytic leukemia, acute lymphocytic leukemia, esophageal cancer, small intestine cancer, cancer of the endocrine system, thyroid cancer, parathyroid cancer, adrenal cancer, cancer of the soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular (liver and / or bile duct) cancer, primary or secondary central nervous system tumors, primary or secondary brain tumors, These include, but are not limited to, Hodgkin's disease, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphoma, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, multiple myeloma, oral cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, cancer of the kidney and / or ureter, renal cell carcinoma, cancer of the renal pelvis, neoplasms of the central nervous system, primary central nervous system lymphoma, non-Hodgkin's lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, adrenocortical carcinoma, gallbladder cancer, cancer of the spleen, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblastoma, or a combination thereof.
[0267] In some embodiments of each or any of the above or below embodiments, the disease or disorder is selected from the group consisting of bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, acute lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular carcinoma, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myeloid leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, and splenic cancer.
[0268] In some embodiments of each or any of the above or below embodiments, the disease or disorder is a blood cancer such as leukemia, lymphoma, or myeloma. In some embodiments of each or any of the above or below embodiments, the cancer is Hodgkin's lymphoma, non-Hodgkin's lymphoma (NHL), cutaneous B-cell lymphoma, activated B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicle center lymphoma, transformed lymphoma, lymphocytic lymphoma of intermediate differentiation, intermediate lymphocytic lymphoma (ILL), diffuse poorly differentiated lymphocytic lymphoma (PDL), centrocellular lymphoma, diffuse small cleaved cell lymphoma (DSCCL), peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma. In certain embodiments, the disease or disorder is selected from the group consisting of acute myelodysplastic syndrome (MDS), mantle zone lymphoma, low-grade follicular lymphoma, multiple myeloma (MM), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), myelodysplastic syndrome (MDS), acute T-cell leukemia, acute myelocytic leukemia (AML), acute promyelocytic leukemia, acute myeloblastic leukemia, acute megakaryoblastic leukemia, precursor B acute lymphoblastic leukemia, precursor T acute lymphoblastic leukemia, Burkitt's leukemia (Burkitt's lymphoma), acute biphenotypic leukemia, chronic myelogenous lymphoma, chronic myelogenous leukemia (CML), and chronic monocytic leukemia. In certain embodiments, the disease or disorder is myelodysplastic syndrome (MDS). In another particular embodiment, the disease or disorder is acute myelogenous leukemia (AML). In another particular embodiment, the disease or disorder is chronic lymphocytic leukemia (CLL). In yet another particular embodiment, the disease or disorder is multiple myeloma (MM).
[0269] In other embodiments, the disease or disorder is a solid tumor cancer. In some embodiments of each or any of the above or below embodiments, the solid tumor cancer is selected from the group consisting of carcinoma, adenocarcinoma, adrenocortical tumor, colon adenocarcinoma, colorectal adenocarcinoma, colorectal carcinoma, ductal cell carcinoma, lung cancer, thyroid cancer, nasopharyngeal carcinoma, melanoma, non-melanoma skin cancer, liver cancer, and lung cancer.
[0270] In some embodiments in each or any of the above or below embodiments, the cancer is adrenal cancer. In some embodiments in each or any of the above or below embodiments, the cancer is anal cancer. In some embodiments in each or any of the above or below embodiments, the cancer is appendiceal cancer. In some embodiments in each or any of the above or below embodiments, the cancer is bile duct cancer. In some embodiments in each or any of the above or below embodiments, the cancer is bladder cancer. In some embodiments in each or any of the above or below embodiments, the cancer is bone cancer. In some embodiments in each or any of the above or below embodiments, the cancer is brain cancer. In some embodiments in each or any of the above or below embodiments, the cancer is breast cancer. In some embodiments in each or any of the above or below embodiments, the cancer is cervical cancer. In some embodiments in each or any of the above or below embodiments, the cancer is colorectal cancer. In some embodiments in each or any of the above or below embodiments, the cancer is esophageal cancer. In some embodiments in each or any of the above or below embodiments, the cancer is gallbladder cancer. In some embodiments in each or any of the above or below embodiments, the cancer is gestational choriocarcinoma. In some embodiments in each or any of the above or below embodiments, the cancer is head and neck cancer. In some embodiments in each or any of the above or below embodiments, the cancer is Hodgkin's lymphoma. In some embodiments in each or any of the above or below embodiments, the cancer is intestinal cancer. In some embodiments in each or any of the above or below embodiments, the cancer is renal cancer. In some embodiments in each or any of the above or below embodiments, the cancer is leukemia. In some embodiments in each or any of the above or below embodiments, the cancer is liver cancer. In some embodiments in each or any of the above or below embodiments, the cancer is lung cancer. In some embodiments in each or any of the above or below embodiments, the cancer is melanoma.In some embodiments in each or any of the above or below embodiments, the cancer is mesothelioma. In some embodiments in each or any of the above or below embodiments, the cancer is multiple myeloma (MM). In some embodiments in each or any of the above or below embodiments, the cancer is a neuroendocrine tumor. In some embodiments in each or any of the above or below embodiments, the cancer is non-Hodgkin's lymphoma. In some embodiments in each or any of the above or below embodiments, the cancer is oral cancer. In some embodiments in each or any of the above or below embodiments, the cancer is ovarian cancer. In some embodiments in each or any of the above or below embodiments, the cancer is pancreatic cancer. In some embodiments in each or any of the above or below embodiments, the cancer is prostate cancer. In some embodiments in each or any of the above or below embodiments, the cancer is sinus cancer. In some embodiments in each or any of the above or below embodiments, the cancer is skin cancer. In some embodiments in each or any of the above or below embodiments, the cancer is soft tissue sarcoma spinal cancer. In some embodiments, in each or any of the above or below embodiments, the cancer is gastric cancer. In some embodiments, in each or any of the above or below embodiments, the cancer is testicular cancer. In some embodiments, in each or any of the above or below embodiments, the cancer is throat cancer. In some embodiments, in each or any of the above or below embodiments, the cancer is thyroid cancer. In some embodiments, in each or any of the above or below embodiments, the cancer is uterine cancer, endometrial cancer. In some embodiments, in each or any of the above or below embodiments, the cancer is vaginal cancer. In some embodiments, in each or any of the above or below embodiments, the cancer is vulvar cancer.
[0271] In some embodiments of each or any of the above or below embodiments, the adrenal cancer is an adrenocortical tumor (ACC), adrenocortical carcinoma, pheochromocytoma, or neuroblastoma. In some embodiments of each or any of the above or below embodiments, the anal cancer is squamous cell carcinoma, gross excretory carcinoma, adenocarcinoma, basal cell carcinoma, or melanoma. In some embodiments of each or any of the above or below embodiments, the appendix cancer is a neuroendocrine tumor (NET), mucinous adenocarcinoma, goblet cell carcinoid, intestinal adenocarcinoma, or signet ring cell adenocarcinoma. In some embodiments of each or any of the above or below embodiments, the cholangiocarcinoma is extrahepatic cholangiocarcinoma, adenocarcinoma, perihilar cholangiocarcinoma, perihilar cholangiocarcinoma, distal cholangiocarcinoma, or intrahepatic cholangiocarcinoma. In some embodiments of each or any of the above or below embodiments, the bladder cancer is transitional cell carcinoma (TCC), papillary carcinoma, squamous carcinoma, squamous cell carcinoma, adenocarcinoma, small cell carcinoma, or sarcoma. In some embodiments of each or any of the above or below embodiments, the bladder cancer is primary bone cancer, sarcoma, osteosarcoma, chondrosarcoma, sarcoma, fibrosarcoma, malignant fibrous histiocytoma, giant cell tumor of bone, chordoma, or metastatic bone cancer. In some embodiments of each or any of the above or below embodiments, the brain cancer is astrocytoma, brain stem glioma, glioblastoma, meningioma, ependymoma, oligodendroglioma, mixed glioma, pituitary carcinoma, pituitary adenoma, craniopharyngioma, germ cell tumor, pineal region tumor, medulloblastoma, or primary CNS lymphoma. In some embodiments of each or any of the above or below embodiments, the breast cancer is breast adenocarcinoma, invasive breast cancer, non-invasive breast cancer, breast sarcoma, metaplastic carcinoma, adenocystic carcinoma, phyllodes tumor, angiosarcoma, HER2-positive breast cancer, triple-negative breast cancer, or inflammatory breast cancer. In some embodiments of each or any of the above or below embodiments, the cervical cancer is squamous cell carcinoma or adenocarcinoma. In some embodiments of each or any of the above or below embodiments, the colorectal cancer is colorectal adenocarcinoma, primary colorectal lymphoma, gastrointestinal stromal tumor, leiomyosarcoma, carcinoid tumor, mucinous adenocarcinoma, signet ring cell adenocarcinoma, gastrointestinal carcinoid tumor, or melanoma. In some embodiments of each or any of the above or below embodiments, the esophageal cancer is adenocarcinoma or squamous cell carcinoma.In some embodiments of each or any of the above or below embodiments, the gallbladder cancer is adenocarcinoma, papillary adenocarcinoma, adenosquamous carcinoma, squamous cell carcinoma, small cell carcinoma, or sarcoma. In some embodiments of each or any of the above or below embodiments, the gestational trophoblastic disease (GTD) is hydatidiform mole, gestational trophoblastic neoplasm (GTN), choriocarcinoma, placental site trophoblastic tumor (PSTT), or epithelioid trophoblastic tumor (ETT). In some embodiments of each or any of the above or below embodiments, the head and neck cancer is laryngeal cancer, nasopharyngeal cancer, hypopharyngeal cancer, nasal cavity cancer, paranasal sinus cancer, salivary gland cancer, oral cancer, oropharynx cancer, or tonsillar cancer. In some embodiments of each or any of the above or below embodiments, the Hodgkin lymphoma is classical Hodgkin lymphoma, nodular sclerosing, mixed cytology, lymphocyte-rich, lymphocyte-reduced, or nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). In some embodiments of each or any of the above or below embodiments, the intestinal cancer is small intestine cancer, small bowel cancer, adenocarcinoma, sarcoma, gastrointestinal stromal tumor, carcinoid tumor, or lymphoma. In some embodiments of each or any of the above or below embodiments, the kidney cancer is renal cell carcinoma (RCC), clear cell RCC, papillary RCC, chromophobe RCC, collecting duct RCC, unclassified RCC, transitional cell carcinoma, urothelial carcinoma, renal pelvic carcinoma, or renal sarcoma. In some embodiments of each or any of the above or below embodiments, the leukemia is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), hairy cell leukemia (HCL), or myelodysplastic syndrome (MDS). In certain embodiments, the leukemia is AML. In some embodiments of each or any of the above or below embodiments, the liver cancer is hepatocellular carcinoma (HCC), fibrolamellar HCC, cholangiocarcinoma, angiosarcoma, or liver metastasis.In some embodiments of each or any of the above or below embodiments, the lung cancer is small cell lung cancer, small cell carcinoma, hybrid small cell carcinoma, non-small cell lung cancer, lung adenocarcinoma, squamous cell lung carcinoma, large cell undifferentiated carcinoma, lung nodule, metastatic lung carcinoma, adenosquamous carcinoma, large cell neuroendocrine carcinoma, salivary gland lung carcinoma, lung carcinoid, mesothelioma, sarcomatoid carcinoma of the lung, or malignant granular cell lung tumor. In some embodiments of each or any of the above or below embodiments, the melanoma is superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, lentigo maligna melanoma, amelanotic melanoma, desmoplastic melanoma, ocular melanoma, or metastatic melanoma. In some embodiments of each or any of the above or below embodiments, the mesothelioma is pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma, or testicular mesothelioma. In some embodiments of each or any of the above or below embodiments, the multiple myeloma is active or smoldering myeloma. In some embodiments of each or any of the above or below embodiments, the neuroendocrine tumor is a gastrointestinal neuroendocrine tumor, a pancreatic neuroendocrine tumor, or a pulmonary neuroendocrine tumor.In some embodiments of each or any of the above or below embodiments, the non-Hodgkin's lymphoma is selected from the group consisting of anaplastic large cell lymphoma, lymphoblastic lymphoma, peripheral T-cell lymphoma, follicular lymphoma, cutaneous T-cell lymphoma, lymphoplasmacytic lymphoma, marginal zone B-cell lymphoma, MALT lymphoma, small cell lymphocytic lymphoma, Burkitt's lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), precursor T-lymphoblastic leukemia / lymphoma, acute lymphocytic leukemia (ALL), adult T-cell lymphoma / leukemia (ATLL), hairy cell leukemia, B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, and / or primary idiopathic leukemia. lymphoma, primary central nervous system (CNS) lymphoma, mantle cell lymphoma (MCL), marginal zone lymphoma, mucosa-associated lymphoid tissue (MALT) lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma, lymphoplasmacytic lymphoma, B-cell non-Hodgkin's lymphoma, T-cell non-Hodgkin's lymphoma, natural killer cell lymphoma, cutaneous T-cell lymphoma, Alibert-Bazin syndrome, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), systemic ALCL, enteropathic T-cell lymphoma (EATL), or hepatosplenic gamma / delta T-cell lymphoma. In some embodiments of each or any of the above or below embodiments, the oral cancer is squamous cell carcinoma, verrucous carcinoma, minor salivary gland carcinoma, lymphoma, benign oral tumor, eosinophilic granuloma, fibroma, granular cell tumor, keratoacanthoma, leiomyoma, osteochondroma, lipoma, schwannoma, neurofibroma, papilloma, condyloma acuminata, verrucous xanthomas, pyogenic granuloma, rhabdomyoma, odontogenic tumor, leukoplakia, erythroplakia, squamous cell lip carcinoma, basal cell lip carcinoma, mouth cancer, gum cancer, or tongue cancer.In some embodiments of each or any of the above or below embodiments, the ovarian cancer is ovarian epithelial cancer, mucinous epithelial ovarian cancer, endometrioid epithelial ovarian cancer, clear cell epithelial ovarian cancer, undifferentiated epithelial ovarian cancer, ovarian low malignant potential tumor, primary peritoneal carcinoma, fallopian tube carcinoma, germ cell tumor, teratoma, undifferentiated ovarian germ cell carcinoma, endodermal sinus tumor, sex cord-stromal tumor, sex cord-gonadal stromal tumor, ovarian stromal tumor, granulosa cell tumor, granulosa theca tumor, Sertoli-Leydig tumor, ovarian sarcoma, ovarian carcinosarcoma, ovarian adenosarcoma, ovarian leiomyosarcoma, ovarian fibrosarcoma, Krukenberg tumor, or ovarian cyst. In some embodiments of each or any of the above or below embodiments, the pancreatic cancer is pancreatic exocrine adenocarcinoma, pancreatic endocrine adenocarcinoma, or pancreatic adenocarcinoma, pancreatic islet cell tumor, or neuroendocrine tumor. In some embodiments of each or any of the above or below embodiments, the prostate cancer is prostatic adenocarcinoma, prostatic sarcoma, transitional cell carcinoma, small cell carcinoma, or neuroendocrine tumor. In some embodiments of each or any of the above or below embodiments, the sinus cancer is squamous cell carcinoma, mucosal cell carcinoma, adenoid cystic cell carcinoma, acinic cell carcinoma, undifferentiated carcinoma of the paranasal sinuses, nasal cavity carcinoma, paranasal sinus carcinoma, maxillary sinus carcinoma, ethmoid sinus carcinoma, or nasopharyngeal carcinoma. In some embodiments of each or any of the above or below embodiments, the skin cancer is basal cell carcinoma, squamous cell carcinoma, melanoma, Merkel cell carcinoma, Kaposi's sarcoma (KS), actinic keratosis, cutaneous lymphoma, or keratoacanthoma. In some embodiments of each or any of the above or below embodiments, the soft tissue cancer is angiosarcoma, dermatofibrosarcoma, epithelioid sarcoma, Ewing's sarcoma, fibrosarcoma, gastrointestinal stromal tumor (GIST), Kaposi's sarcoma, leiomyosarcoma, liposarcoma, dedifferentiated liposarcoma (DL), myxoid / round cell liposarcoma (MRCL), well-differentiated liposarcoma (WDL), malignant fibrous histiocytoma, neurofibrosarcoma, rhabdomyosarcoma (RMS), or synovial sarcoma. In some embodiments of each or any of the above or below embodiments, the spinal cancer is a spinal metastatic tumor. In some embodiments of each or any of the above or below embodiments, the gastric cancer is gastric adenocarcinoma, gastric lymphoma, gastrointestinal stromal tumor, carcinoid tumor, gastric carcinoid tumor, type I ECL-cell carcinoid, type II ECL-cell carcinoid, or type III ECL-cell carcinoid.In some embodiments of each or any of the above or below embodiments, the testicular cancer is seminoma, nonseminoma, embryonal carcinoma, yolk sac carcinoma, choriocarcinoma, teratoma, gonadal stromal tumor, Leydig cell tumor, or Sertoli cell tumor. In some embodiments of each or any of the above or below embodiments, the pharyngeal cancer is squamous cell carcinoma, adenocarcinoma, sarcoma, laryngeal carcinoma, pharyngeal carcinoma, nasopharyngeal carcinoma, oropharyngeal carcinoma, hypopharyngeal carcinoma, laryngeal squamous cell carcinoma, laryngeal adenocarcinoma, lymphoepithelioma, spindle cell carcinoma, verrucous carcinoma, undifferentiated carcinoma, or lymph node carcinoma. In some embodiments of each or any of the above or below embodiments, the thyroid cancer is papillary carcinoma, follicular carcinoma, Hurthle cell carcinoma, medullary thyroid carcinoma, or undifferentiated carcinoma. In some embodiments of each or any of the above or below embodiments, the uterine cancer is endometrial carcinoma, endometrial adenocarcinoma, endometrioid carcinoma, serous adenocarcinoma, adenosquamous carcinoma, uterine carcinosarcoma, uterine sarcoma, uterine leiomyosarcoma, endometrial stromal sarcoma, or undifferentiated sarcoma. In some embodiments of each or any of the above or below embodiments, the vaginal cancer is squamous cell carcinoma, adenocarcinoma, melanoma, or sarcoma. In some embodiments of each or any of the above or below embodiments, the vulvar cancer is squamous cell carcinoma or adenocarcinoma.
[0272] In some embodiments of each or any of the above or below embodiments, the disease or disorder is caused by a pathogen. In some embodiments of each or any of the above or below embodiments, the pathogen is acute flaccid myelitis (AFM), anaplasmosis, anthrax, babesiosis, botulism, brucellosis, campylobacteriosis, carbapenem-resistant infections, chancroid, chikungunya virus infection, chlamydia, ciguatera, C. difficile infection, C. perfringens, coccidioidomycosis fungal infection, coronavirus infection, Covid-19 (SARS-CoV-2), Creutzfeldt-Jakob disease / transmissible spongiform encephalopathy, chlamydia, cholera, cholera, flu, flu-like disease ... Lyptosporidiosis (Crypto), Cyclosporiasis, Dengue 1, 2, 3, or 4, Diphtheria, Escherichia coli infection / Shiga toxin-producing (STEC), Eastern equine encephalitis, Hemorrhagic fever (Ebola), Ehrlichiosis, Arbovirus or parainfectious encephalitis, Non-polio enterovirus, D68 enterovirus (EV-D68), Giardiasis, Glanders, Gonococcal infection, Granuloma inguinale, Haemophilus influenzae infection type B (Hib or H-flu), Hantavirus pulmonary syndrome (HPS), Hemolytic uremic syndrome (HUS), Hepatitis A (Hep A), Hepatitis B (Hep B), Hepatitis C (Hep C), Hepatitis D (Hep D), Hepatitis E (Hep E), herpes, herpes zoster (shingles), histoplasmosis, human immunodeficiency virus / AIDS (HIV / AIDS), human papillomavirus (HPV), influenza (Flu), legionnaires' disease, leprosy (hansen's disease), leptospirosis, listeriosis (listeria), Lyme disease, lymphogranuloma venereum infection (LGV), malaria, measles, melioidosis, meningitis (viral), meningococcal disease (meningitis (bacterial)), Middle East respiratory syndrome coronavirus MERS-CoV, Mumps, Norovirus, Pediculosis, Pelvic Infection (PID), Pertussis (Pertussis), Plague (Bubonic, Septicemic, Pneumonic), Pneumococcal Disease (Pneumonia), Poliovirus Infection (Polio), Powassan, Psittacosis, Pediculosis (Pubic Lice), Impetigo Disease (Smallpox, Monkeypox, Cowpox), Q Fever, Rabies, Rickettsiosis (Rocky Mountain Spotted Fever), Rubella (German Measles), Salmonellosis Gastroenteritis (Salmonella), Scabies, ScombroiderySepsis, Severe Acute Respiratory Syndrome (SARS), Shigella gastroenteritis (Shigella), Smallpox, Methicillin-resistant Staphylococcal infections (MRSA), Staphylococcal food poisoning Enterotoxin B poisoning (Staphylococcal food poisoning), Vancomycin-intermediate Staphylococcal infections (VISA), Vancomycin-resistant Staphylococcal infections (VRSA), Group A Streptococcal infections (invasive) (Strep In some embodiments of each or any of the above or below embodiments, the infection is selected from the group consisting of Group A (invasive), Group B Streptococcus infection (Strep-B), Streptococcal toxic shock syndrome (STSS), syphilis (primary, secondary, early latent, late ...
Claims
1. A binding molecule comprising an antigen-binding domain and an Fc region, (i) the antigen-binding domain is monovalent; (ii) the Fc region comprises K248E and T437R mutations (RE mutations), and the numbering of amino acid residues is according to the EU numbering system; the binding molecule has an increased ability to hexamerize on the cell surface and / or an increased ability to engage C1q; A binding molecule comprising an antigen-binding domain and an Fc region.
2. The binding molecule of claim 1 , wherein the antigen-binding domain comprises a VH region and / or a VL region.
3. The binding molecule of claim 2 , wherein the antigen-binding domain comprises a Fab fragment, a scFv, a single VH domain, a single VL domain, or a protein domain specific for the antigen.
4. The binding molecule of any one of claims 1 to 3, wherein the oligosaccharide covalently attached to the Fc region via its N297 residue does not contain a core fucose residue.
5. The binding molecule of any one of claims 1 to 4, wherein the binding molecule is a monovalent antibody or antibody fragment or an engineered antigen-binding protein.
6. The binding molecule of any one of claims 1 to 5, wherein the binding molecule has enhanced antibody-dependent cellular cytotoxicity (ADCC), enhanced complement-dependent cytotoxicity (CDC), and / or enhanced antibody-dependent cellular phagocytosis (ADCP).
7. A binding molecule comprising a first means for enhancing CDC and a second means for enhancing CDC.
8. The binding molecule of claim 7, further comprising a third means for enhancing ADCC.
9. 9. The binding molecule of claim 7 or 8, further comprising a fourth means for enhancing ADCP.
10. The binding molecule of any one of claims 7 to 9, wherein the first means increases hexamerization of the binding molecule on the cell surface and / or increases C1q engagement by the binding molecule.
11. The binding molecule according to any one of claims 7 to 10, wherein the first means enhances CDC, ADCP, and / or ADCC.
12. The binding molecule of any one of claims 7 to 11, wherein the binding molecule is a monovalent antibody or antibody fragment or an engineered antigen-binding protein.
13. A population of binding molecules comprising the binding molecule of any one of claims 1 to 12.
14. A population of binding molecules, each binding molecule comprising an antigen binding domain and an Fc region, wherein (i) the antigen-binding domain is monovalent; (ii) the Fc region comprises K248E and T437R mutations (RE mutations), and the numbering of amino acid residues is according to the EU numbering system; (iii) less than 80% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region contain a core fucose residue. A collection of binding molecules.
15. A population of binding molecules, (i) each binding molecule comprises an antigen-binding domain and an Fc region; (ii) the antigen-binding domains of at least 10% of the binding molecules in the population are monovalent; (iii) the Fc region of each binding molecule comprises a K248E and a T437R mutation (RE mutation), wherein the numbering of amino acid residues is according to the EU numbering system; (iv) less than 80% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region contain a core fucose residue. A collection of binding molecules.
16. (a) the antigen-binding domains of at least 20% of the binding molecules in the population are monovalent; (b) the antigen-binding domains of at least 30% of the binding molecules in the population are monovalent; (c) the antigen-binding domains of at least 40% of the binding molecules in the population are monovalent; (d) the antigen-binding domains of at least 50% of the binding molecules in the population are monovalent. (e) the antigen-binding domains of at least 60% of the binding molecules in the population are monovalent. (f) the antigen-binding domains of at least 70% of the binding molecules in the population are monovalent. (g) the antigen-binding domains of at least 80% of the binding molecules in the population are monovalent; or (h) the antigen-binding domains of at least 90% of the binding molecules in the population are monovalent. A population of binding molecules according to claim 15.
17. (a) less than 70% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region contain a core fucose residue; (b) less than 60% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region contain a core fucose residue. (c) less than 50% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region contain a core fucose residue. (d) less than 40% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region contain a core fucose residue. (e) less than 30% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region contain a core fucose residue. (f) fewer than 20% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region comprise a core fucose residue; or (g) less than 10% of the oligosaccharides covalently attached to the population of binding molecules via the N297 residue of the Fc region contain a core fucose residue. A population of binding molecules according to any one of claims 14 to 16.
18. The population of binding molecules according to any one of claims 14 to 17, wherein the antigen-binding domain comprises a VH region and / or a VL region.
19. 18. The population of binding molecules of any one of claims 14 to 17, wherein the antigen-binding domain comprises a Fab fragment, a scFv, a single VH domain, a single VL domain, or a protein domain specific for the antigen.
20. The population of binding molecules according to any one of claims 14 to 19, wherein the binding molecules are monovalent antibodies or antibody fragments or engineered antigen-binding proteins.
21. 21. The population of binding molecules of any one of claims 14 to 20, wherein the binding molecules are produced by expressing a polynucleotide encoding the binding molecule or a fragment thereof in a host cell that is deficient in the addition of fucose to the oligosaccharides attached to an antibody Fc region.
22. 22. The population of binding molecules of claim 21, wherein the host cell has reduced GDP-mannose 4,6-dehydratase (GMD) activity or reduced α-1,6 fucosyltransferase activity.
23. 23. The population of binding molecules of any one of claims 13 to 22, wherein the population of binding molecules has enhanced ADCC, enhanced CDC, and / or enhanced ADCP.
24. A nucleic acid encoding a binding molecule according to any one of claims 1 to 12.
25. A vector comprising the nucleic acid of claim 24.
26. 24. A method of making a binding molecule of any one of claims 1 to 12 or a population of binding molecules of any one of claims 13 to 23 comprising expressing a polynucleotide encoding said binding molecule or one or more of its fragments in a host cell which is defective in the addition of a fucose residue to the oligosaccharide attached to the antibody via the N297 residue.
27. (a) the host cell has reduced α-1,6 fucosyltransferase activity; (b) the host cell has reduced GDP-mannose 4,6-dehydratase activity. (c) the gene encoding the α-1,6 fucosyltransferase is mutated, expressed at lower than normal levels, or knocked out in the host cell; or (d) the gene encoding the GDP-mannose 4,6-dehydratase is mutated, expressed at a lower than normal level, or knocked out in the host cell.
27. The method of claim 26.
28. 1. A method of making a population of binding molecules, each of which comprises a monovalent antigen binding domain and an Fc region, comprising: (i) introducing K248E and T437R mutations (RE mutations) into the Fc region of the binding molecule; (ii) generating a population of binding molecules having reduced amounts of core fucose in the oligosaccharides attached to the binding molecule via the N297 residue of the Fc region; A method for producing a population of binding molecules, each of which comprises a monovalent antigen-binding domain and an Fc region, comprising:
29. A population of binding molecules produced according to the method of any one of claims 26 to 28.
30. 30. A pharmaceutical composition comprising a binding molecule according to any one of claims 1 to 12 or a population of binding molecules according to any one of claims 13 to 23 or 29, and a pharma- ceutically acceptable excipient.
31. 1. A method for enhancing CDC, ADCP, and / or ADCC in a system, comprising: (a) contacting said system with a binding molecule according to any one of claims 1 to 12, or (b) contacting said system with said population of binding molecules according to any one of claims 13 to 23 or 29; A method for enhancing CDC, ADCP, and / or ADCC in a system, comprising:
32. 1. A method for modulating immunity in a host, comprising: (a) administering a binding molecule according to any one of claims 1 to 12, or (b) administering a population of binding molecules according to any one of claims 13 to 23 or 29; The method of claim 1, further comprising:
33. 1. A method of treating a disease or disorder in a subject, comprising: (a) administering a binding molecule according to any one of claims 1 to 12, or (b) administering a population of binding molecules according to any one of claims 13 to 23 or 29; A method of treating a disease or disorder in a subject, comprising:
